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RESUMO  
A leucemia é um tipo de cancro que se inicia na medula óssea e resulta na produção desregulada de 
glóbulos brancos imaturos (células leucémicas). A leucemia mieloide crónica (LMC) é o seu subgrupo 
mais homogéneo, afetando aproximadamente 1.5 milhões de pacientes no mundo. Praticamente todos 
os casos apresentam a translocação t(9;22)(q34.1;q11.2) e a consequente fusão genética BCR-ABL1, 
que codifica a tirosina cinase BCR-ABL1. O sucesso do tratamento da LMC advém do seu diagnóstico 
precoce e do desenvolvimento de inibidores de tirosina cinase eficazes. 
A nanotecnologia apresenta um enorme potencial para suprimir as lacunas dos procedimentos 
convencionais usados no combate à LMC. As nanopartículas de ouro (AuNPs), em particular, possuem 
propriedades óticas relevantes para deteção ex vivo de biomarcadores, mas podem funcionar também in 
vivo numa estratégia de teranóstico, combinando tratamento e diagnóstico de acordo com o perfil 
molecular do paciente. 
Neste estudo, foi otimizado um ensaio colorimétrico, usando nanossondas de ouro, para a deteção 
da isoforma mais frequente de BCR-ABL1 (e14a2), tendo sido posteriormente validado em amostras 
clínicas. Este método simples e direto permitiu a deteção de amostras de RNA que expressam e14a2, 
com precisão e especificidade. O ensaio foi ainda incorporado num chip de microfluídica, traduzindo-
se em resultados mais rápidos recorrendo a volumes mais baixos de amostra, devido à escala e estrutura 
do dispositivo. 
Adicionalmente, foi desenhada uma nova estratégia terapêutica para combater os mecanismos de 
resistência ao tratamento de primeira linha para LMC: imatinib (IM). O silenciamento in vitro de BCR-
ABL1 foi eficaz, usando AuNPs funcionalizadas com polietilenoglicol e oligonucleotídos de DNA em 
cadeia simples, antisense e em formato hairpin. A nanoformulação permitiu redução da dose de IM, 
numa estratégia combinada, e potenciou um decréscimo da viabilidade de células K562 resistentes a 
IM. 
Os resultados desta tese demonstram a adequação e flexibilidade das AuNPs como ferramentas para 
nanoteranóstico, diagnóstico e tratamento personalizado de LMC.  
 
 
Termos chave:  
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ABSTRACT 
Leukemia is a type of cancer that initiates in the bone marrow and results in the unregulated 
production of immature white blood cells (leukemic cells). The most homogenous subgroup of the 
disease is chronic myeloid leukemia (CML) accounting for nearly 1.5 million patients worldwide. 
Virtually all cases harbor the genetic translocation t(9;22)(q34.1;q11.2) resulting in the BCR-ABL1 gene 
fusion, that encodes for BCR-ABL1 tyrosine kinase. CML treatment success relies on an early diagnosis 
and the intense research towards developing effective tyrosine kinase inhibitors (TKI).  
Nanotechnology offers unprecedent advantages to tackle the shortcomings of conventional 
procedures for the management of CML. Gold nanoparticles (AuNPs) have unique optical properties 
suitable for ex vivo biosensing applications, but can also function in vivo as nanocarriers in a theranostic 
approach that links treatment with diagnosis according to patient’s molecular profile.  
A gold nanoprobe (Au-nanoprobe) colorimetric assay was optimized for the detection of the most 
frequent BCR-ABL1 isoform (e14a2) and was validated on fully characterized clinical samples. This 
simple and cheap method enabled the direct detection of e14a2-expressing RNA samples, with accuracy 
and high specificity. The Au-nanoprobe assay was translated onto a microfluidics chip, resulting in a 
faster outcome with smaller sample volumes, due to the scale and design of the device.   
Additionally, a new therapeutic strategy was designed to overcome CML resistance to first line 
therapy, such as imatinib (IM). BCR-ABL1 gene silencing was effectively achieved in vitro, using 
AuNPs functionalized with polyethylene glycol and a hairpin-shaped antisense single stranded DNA 
(ssDNA) oligonucleotide. Furthermore, the nanoconstruct allowed to reduce the dose of IM, when 
tested in a combined approach, and potentiated a viability decrease of K562 cells resistant to IM. 
The results of this thesis strongly suggest that AuNPs are a suitable and flexible tool for CML 
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"Well I can ease your pain 
Get you on your feet again 
Relax 
I'll need some information first 
Just the basic facts." 
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1.1 Leukemia 
Hematologic malignancies are the most common type of cancer among children and young adults, 
and comprise diseases such as leukemia, lymphoma and myeloma, which affect the bone marrow, 
lymphatic system and blood cells.1 The sequential stages of hematopoietic differentiation provide 
multiple occasions for the occurrence of mutations and other disruptive events that lead to distinct tumor 
subtypes and clinical presentations.2 In fact, the heterogeneity of tumors of the hematopoietic system 
presents unique challenges for current diagnosis and treatment.3–6 
Leukemia is a clonal disorder originated in the bone marrow during hematopoiesis and is 
characterized by the unregulated proliferation of poorly differentiated white blood cells. Prognosis and 
treatment of the disease depend highly on the type of leukemia, the extent of the disease, age and patient 
history. Most patients are treated with chemotherapy/targeted therapy, although a small portion 
ultimately undergoes radiation therapy and/or bone marrow transplantation.7 
Though hematological malignancies constitute no more than 10 % of all cancers worldwide, 
leukemia research has attracted considerable attention. This is believed to result from the combination 
of several factors: 1) the blood-borne nature of the disease and accessibility of relevant tissues; 2) the 
fact that hematopoiesis has been thoroughly dissected, thus prompting modelling of leukemogenesis; 
3) the emotional impact of a lethal cancer of childhood, since acute leukemia is the most common 
pediatric cancer in developed societies, which engrossed massive funding opportunities; and 4) the early 
identification of chromosomal translocations and fusion genes in leukemia karyotypes.7 
 
1.1.1 Classification 
Classification of leukemia is based on the type of cell affected (myeloid or lymphoid) and the degree 
of cell proliferation (acute or chronic), resulting in four main categories.2 Acute myeloid leukemia 
(AML) is the most common type in adults and acute lymphocytic leukemia (ALL) is more prevalent 
among pediatric patients.1 Chronic myeloid leukemia (CML) is a myeloproliferative disorder with an 
annual incidence of 1-2 cases per 100 000 adults, accounting for 15-20 % of newly diagnosed cases of 
leukemia in adults.1,8 
The distinction between lymphomas and lymphoid leukemias (both included in lymphoid-derived 
neoplasms) should be carefully addressed since they are closely related. In fact, chronic lymphocytic 
leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially the same disease, where the 
only difference is the location of the primarily occurrence of cancer. In CLL, a significant number of 
the anomalous lymphocytes are found in the blood, bone marrow and lymphoid tissue; in SLL, the bulk 
of the disease is in the lymph nodes, bone marrow, and other lymphoid tissues, but is rarely detected in 
peripheral blood. Both conditions are tackled the same way, using immunomodulating agents, 
monoclonal antibodies or kinase inhibitors.9 
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Following clinical, morphological and immunophenotypic diagnosis,10 genetics plays an important 
role in the classification of these diseases and commonly assist risk stratification, from poor to favorable 
prognosis (Table 1.1).11,12  
AML is the most clinically and biologically heterogeneous group of leukemias. Many of the 
variations that underlie the pathogenesis of the disease include chromosomal additions, deletions, and 
translocations, as well as small-scale mutations in oncogenes (Table 1.1). Since disease progression and 
treatment response are largely dependent on these genetic events, proper cytogenetic and molecular 
testing is imperative for patient evaluation and provide insights into critical pathways involved in AML 
pathogenesis. Small-scale mutations on genes encoding for nucleophosmin 1 (NMP1), fms-related 
tyrosine kinase 3 (FLT3) and CCAAT/enhancer-binding protein  (CEBPA) are in fact used to define 
AML sub-classes according to World Health Organization (WHO) guidelines. CEBPA encodes for a 
transcription factor that is critical for myeloid differentiation. Point mutations on this gene confer a 
relatively good prognosis for AML patients, but this seems only true for cases with biallelic 
variations.13–16 
CML is a good example of how hematological diseases have greatly benefited from the advance of 
cytogenetic and molecular methodologies. It was the first cancer in which a unique chromosomal 
abnormality was identified, t(9;22)(q34.1;q11.2) – Philadelphia chromosome (Ph) - and the associated 
BCR-ABL1 gene, providing a specific target for disease treatment (Table 1.1).17 Tyrosine kinase 
inhibitors (TKIs) target the dysregulated kinase activity of the fusion protein encoded by BCR-
ABL1.18,19 
 
Table 1.1 Common genetic abnormalities associated to leukemia.11,20 
Subtype Frequent genetic biomarkers 
AML - t(8;21)(q22;q22); RUNX1-RUNX1T1 
- inv(16)(p13q22) or t(16;16)(p13;q22); CBFB-MYH11 
- t(15;17)(q22;q12); PML-RARA 
- t(9;11)(p21;q23); MLLT3-KMT2A 
- t(6;9)(p23;q34); DEK-NUP214 
- inv(3)(q21q26) or t(3;3)(q21;q26); RPN-EVI1, GATA2, MECOM 
- t(1;22)(p13;q13); RBM15-MKL1 
- t(9;22)(q34;q11); BCR-ABL1 
- CEBPA, NPM1, and FLT3 mutations predict response to 
chemotherapy for cytogenetically normal AML patients 
CML - t(9;22)(q34;q11); BCR-ABL1 
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B-cell ALL - t(9;22)(q34;q11); BCR-ABL1 
- t(v;11q23); KMT2A 
- t(12;21)(p13;q22); ETV6-RUNX1 
- t(5;14)(q31;q32); IL3-IGH 
- t(1;19)(q23;p13); TCF3-PBX1 
- Hyperdiploidy 
- Hypodiploidy 
T-cell ALL - TAL1 gene rearrangements (1p32) 
- TLX1 gene rearrangements (10q24) 
- LMO2 gene rearrangements (11p13) 
- t(5;14)(q35;q32); TLX3- BCL11B 
- t(10;11)(p12;q14); PICALM- MLLT10 
- NUP214- ABL1 fusion and amplification 
- KMT2A gene rearrangements (11q23) 
CLL (or SLL) - del(13q) 
- trisomy 12 
- del(11q); ATM  
- del(17p); TP53  
ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, 
chronic myeloid leukemia; SLL, small lymphocytic leukemia.  
Genes: ABL1, Abelson murine leukemia 1; ATM, ataxia-telangiectasia mutated; BCL11B, B-cell 
lymphoma/leukemia 11B; BCR, breakpoint cluster region; CBFB, core-binding factor ß; CEBPA, 
CCAAT/enhancer-binding protein ; DEK, DEK proto-oncogene; ETV6, erythroblast transformation-specific 
translocation variant 6; EVI1, ecotropic virus integration site 1; FLT3,  fms-related tyrosine kinase 3; GATA2, 
GATA-binding factor 2; IGH, Immunoglobulin heavy-chain; IL3, interleukin-3; KMT2A, lysine methyltransferase 
2A; LMO2, LIM-domain only 2; MECOM, MDS1 and EVI1 complex locus; MKL1, megakaryoblastic leukemia 
1; MLLT10, histone lysine methyltransferase DOT1L cofactor; MLLT3, super elongation complex subunit; 
MYH11, myosin heavy chain 11; NPM1, nucleophosmin 1; NUP214, nucleoporin 214; PBX1, pre B cell leukemia 
homeobox 1; PICALM, phosphatidylinositol binding clathrin assembly protein; PML, promyelocytic leukemia; 
RARA, retinoic acid receptor ; RBM15, RNA binding motif protein 15; RPN, ribophorin I; RUNX1, runt related 
transcription factor 1; RUNX1T1, RUNX1 translocation partner 1; TAL1, TAL bHLH transcription factor 1, 
erythroid differentiation factor; TCF3, transcription factor 3; TLX1/3, T-cell leukemia homeobox 1 or 3; TP53, 
tumor protein p53. 
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1.1.2 Chronic myeloid leukemia 
Originally named chronic granulocyte leukemia, the first documented cases of CML are believed 
to date back to 1840s.21,22 Since then, there has been a solid evolution in the strategies for laboratorial 
diagnostics of the disease, from cytogenetics to molecular characterization that support therapeutic 
decisions, which ought to be tailored so as to enhance therapy success. CML is also paradigmatic in the 
straightforward relation between early and accurate hematologic, cytogenetic and molecular 
characterization, and patients’ prognosis.17 
 
1.1.2.1 Molecular biology and disease progression 
The molecular hallmark of CML is the Ph chromosome - a shortened and truncated version of 
chromosome 22 present in at least 95 % of patients.23 This abnormality occurs in the myeloid lineage 
of hematopoiesis and results in the reciprocal translocation of genetic material between the long arms 
of chromosomes 9 and 22 - t(9;22)(q34.1;q11.2). The subsequent fusion of the Abelson murine 
leukemia (ABL1) gene on chromosome 9 (region q34) with the breakpoint cluster region (BCR) gene 
on chromosome 22 (region q11), results in the BCR-ABL1 oncogene.23,24 This chimeric version of ABL1 
has unregulated activity and triggers a cascade of events that culminate in malignant cell transformation. 
The constitutive expression of the active protein kinase leads to the phosphorylation of a series of 
intracellular substrates, perturbing multiple signaling pathways, including the Ras/mitogen-activated 
protein kinases (Ras/MAPK), phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), and Janus 
kinase 2/signal transducer and activator of transcription 5 (Jak2/Stat5) pathways. This phosphorylation 
cascade promotes cell growth, survival advantage, cytokine independence, protection against apoptosis 
and causes the clonal expansion of fully differentiated myeloid cells.25–27 
Although CML molecular hallmarks have been deeply studied, chromosome instability originates 
a range of BCR-ABL1 variants. Due to three well-defined breakpoint regions in the BCR gene (m-BCR, 
M-BCR and µ-BCR), the product of the BCR-ABL1 fusion oncogene may exist in three principal forms 
of molecular weight: 190, 210, and 230 kDa, containing the same region of the ABL1 tyrosine kinase 
at the C-terminal but including different portions of BCR sequence at the N-terminal.28,29 This reciprocal 
translocation during hematopoiesis combined with alternative splicing events may result in multiple 
BCR-ABL1 transcripts, all encoding proteins with high tyrosine kinase activity (Figure 1.1).30 
Nevertheless, the majority of Ph-positive (Ph+) CML patients (~95 % harbor the 210 kDa protein 
(P210BCR-ABL1) translated from either the e13a2 (b2a2) or e14a2 (b3a2) fusion transcripts. Less frequent 
in CML is the 190 kDa fusion protein (P190BCR-ABL1) translated from an e1a2 junction (<5 %). ABL1 
breakpoints can occur anywhere over a larger area at its 5’ end but occur invariably between exon 1a 
and exon 2 (Figure 1.1).29 Additional rare BCR–ABL1 fusion transcripts (<1 %) characterized by 
particular phenotypes have been described, such as e14a3 (P210), e13a3 (P210), e1a3 (P190), e19a3 
(P230), e6a2 (P195), e8a2 (P200) and e18a2 (P225) (Figure 1.1).30–32 
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There is a high controversy between the various published studies concerning the type of fusion 
transcript (e.g., e13a2 vs e14a2) and its influence in CML phenotype.29,33–35 Balatzenko et al 
demonstrated that CML patients with high levels of expression of the multidrug resistance 1 gene 
(MDR1) and presenting the e14a2 transcript had a significantly higher platelets count and a lower white 
blood cell count compared to e13a2 patients.33 More recently, Hanfstein et al stated that e13a2 and 
e14a2 CML might represent distinct biological entities but the clinical outcome under treatment was 




Figure 1.1 Structure of BCR-ABL1 isoforms. P210BCR-ABL1 isoforms represent 95 % of Ph+ CML cases 
and may derive from two transcript types (e14a2 or e13a2) due to alternative splicing events.  
Alternative splicing may also occur to ABL1 exons 2 or 3, thus originating additional (rare) isoforms of 




CML onset comprises three distinct phases: chronic (CP), accelerated (AP) and blast crisis (BC).36 
The disease is usually diagnosed in CP (85 % of newly diagnosed cases), which is relatively long-lasting 
(three to five years, without treatment) and is characterized by the accumulation of myeloid progenitors 
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(blast cells) in the blood, bone marrow and spleen.36 Despite being generally asymptomatic, there are 
common symptoms in this stage, such as fatigue, weight loss, illness and general pain, due to anemia 
and splenomegaly (enlarged spleen - detected in 50-60 % of cases).37 Over the years it may progress 
into AP with a rapid expansion of circulating myeloid elements. Ultimately, CML may evolve to BC, 
which is characterized by differentiation retention in the myeloid or lymphoid lineage, resembling an 
acute leukemia with a predominant myeloid phenotype (~70 %).38,39 BC occurs when over 30 % 
immature blasts, myeloid or lymphoid, are present in blood or bone marrow, resulting in the increase 
of BCR-ABL1 mRNA and protein levels.38 This terminal phase usually leads to metastasis, organ failure 
and death, presenting a poor prognosis and worsening symptoms, bleeding, fever and infections.37 The 
median survival of patients with BC without treatment is 3 months.40  
The mechanisms underlying CML triphasic model of progression can be partially explained by the 
genetic instability characteristic of blast cells, resulting in the acquisition of additional genomic 
alterations, such as trisomy 8, isochromosome 17, double Ph+, c-MYC amplification and activation of 
pathways that block myeloid differentiation and inactivation of tumor suppressor genes such as 
phosphoprotein 53 gene (p53) and retinoblastoma gene (RB). These molecular events extend leukemic 
stem cells (LSCs) replicative lifespan.24, 26,41 Therefore, LSCs and related pathways may serve as key 
targets for curing CML.26 
 
1.1.2.2 Diagnostics and disease follow-up 
Clinical manifestations of CML are often non-specific, and many patients diagnosed with CML are 
asymptomatic (30-50 % in the US alone). CML is frequently detected when an elevated white blood 
cell count is revealed by a routine blood test or when splenomegaly is detected on a general physical 
examination.37 After hematological characterization, bone marrow biopsy is mandatory to confirm 
diagnosis. In a case of persistent unexplained leukocytosis, CML diagnosis consists of probing for the 
presence of the Ph chromosome by routine cytogenetics (karyotype); or the Ph-related molecular BCR-
ABL1 abnormalities by fluorescence in situ hybridization (FISH); or by molecular biology screening.8,38 
The Ph chromosome is present in 95 % of CML patients (typical t(9;22) from chromosome banding 
analysis of at least 20 marrow cells metaphases) as the sole chromosomal abnormality. The remaining 
patients show additional chromosomal alterations (clonal evolution), such as trisomy 8, isochromosome 
17, deletions in the 22q, or other Ph-variants (involving chromosome 22 or 9 or involving other 
chromosomes in addition to chromosomes 9 and 22). These are treated as standard Ph+ patients since 
Ph-variant patients present similar responses to therapy and prognosis.8,38 
FISH analysis relies on analyzing at least 200 nuclei for the co-localization of DNA probes designed 
to hybridize specifically to the BCR and ABL1 genes.38 FISH may be performed in bone marrow and/or 
blood samples with high concordance (false positive range of 1–10 % depending on the probes used).8 
CML characterization at diagnostic is imperative but CML patients must be monitored continuously to 
assess their response to therapy (Table 1.2) to achieve an optimal response and a deeper, stable, 
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treatment-free remission.38 For disease follow up, peripheral blood samples should be used in place of 
bone marrow.42 
The success of precise therapy for CML depends greatly on its diagnosis, but also on disease follow-
up. Three key parameters should be considered when monitoring CML patients’ response to 
therapeutics: hematologic response or normalization of blood counts; cytogenetic response, which 
relates to the percentage of Ph+ cells in the bone marrow; and molecular response, defined by the 
expression level of BCR-ABL1 transcript in a bone marrow or blood sample. The European 
LeukemiaNet (ELN) established milestones for hematologic, cytogenetic, and molecular responses to 
be achieved at specific time-points after therapy initiation for improved clinical outcome (Table 1.2). 
Beginning treatment with imatinib (IM), the first TKI for CML treatment released after the interferon 
era (additional information in section 1.1.2.3 – CML therapeutics), the following events are expected: 
complete hematologic response (CHR) with major cytogenetic response (MCyR) after 3 months; 
complete cytogenetic response (CCyR) after 6 months; and major molecular response (MMR) after 12 
months of therapy. Therefore, follow-up is crucial for disease monitoring. It is recommended that these 
patients perform a peripheral blood collection and analysis every 3 months after starting TKI treatment. 
Patients who do not achieve these milestones should be immediately considered for an alternative 
TKI/therapy (Tables 1.2 and 1.3).38,42,43  
 
 
Table 1.2 Expected levels of CML patients response after TKI therapy initiation (ELN guidelines).38,42 
Additional information on different TKIs can be accessed in section 1.1.2.3 – CML therapeutics. 
Time point for IM 








n/a 3 months CHR ≤ 65 % ≤ 10 % 
3 months 6 months CHR, MCyR ≤ 35 % ≤ 10 % 
6 months 12 months CCyR 0 % ≤ 1 % 
12 months >12 months MMR 0 % ≤ 0.1 % 
>12 months n/a DMR 0 % ≤ 0.01 %* 
*Expected result in two consecutive blood samples (assay sensitivity > 10-4) 
CCyR, complete cytogenetic response; CHR, complete cytogenetic response; CML, chronic myeloid leukemia; 
DMR, deep molecular response; ELN, European LeukemiaNet; IM, imatinib; IS, international scale; MCyR, 
major cytogenetic response; MMR, major molecular response; n/a, not applicable; Ph+, Philadelphia 




CML molecular monitoring 
BCR-ABL1 mRNA transcripts typically remain detectable after CCyR. Reverse transcriptase 
polymerase chain reaction (RT-PCR) is thus far the only tool capable of monitoring responses after 
patients reach CCyR.43 This methodology has become an integral part of CML management since 1999 
due to its sensitivity levels.44 The low levels of minimal residual disease (MRD) normally achieved 
during therapy call for a sensitive monitoring assay for reliable detection and quantitation.8,43 Currently, 
two PCR-based modalities can be performed to detect the BCR-ABL1 transcript in CML patient 
samples: RT-nested PCR, a qualitative approach; or reverse transcriptase quantitative polymerase chain 
reaction (RT-qPCR), a quantifiable assay.  
Nested PCR is a modification of PCR that was designed to improve its sensitivity and specificity. 
Basically, two pairs of primers target the same region: the first pair (outer primers) amplifies a fragment 
in a conventional PCR reaction; the second set (inner primers) anneals to sites within the first amplicon.  
In CML, RT-nested PCR provides characterization of the transcript allowing the identification of the 
more frequent transcripts: e13a2 or e14a2. This approach also allows for identification of one of the 
atypical fusion transcripts that are not amplified by the standard primer sets.44 As previously mentioned, 
there is a high controversy among the various published studies concerning the type of fusion transcript 
and its influence in CML phenotype and/or response to therapy.29,33–35 Recently, the ELN expert panel 
acknowledged that the transcript type (e13a2 vs e14a2 or other more atypical variants) may influence 
response to therapy and disease outcome, which demonstrates the relevance of performing this 
molecular screening.38  
RT-qPCR provides data on the actual percentage of BCR-ABL1 mRNA transcripts in peripheral 
blood or bone marrow, and is capable to detect one CML cell in a background of 100 000 normal 
cells.43,45 It also provides a strong correlation between the results obtained from peripheral blood and  
bone marrow, allowing molecular monitoring without the necessity of obtaining bone marrow 
aspirations.38,43 RT-qPCR is definitely the current method of choice for CML molecular detection and 
quantification, and should be performed before initiation of specific TKI therapy to establish a baseline 
for BCR-ABL1 mRNA levels for each individual patient.38 As such, several efforts have been made to 
optimize and standardize this methodology to reduce the heterogeneity of BCR-ABL1 expression results 
amongst different clinical laboratories.42,46,47 According to guidelines from the National Comprehensive 
Cancer Network (NCCN) and the ELN, results are now conveyed as the ratio of BCR-ABL1 transcript 
numbers to the number of control gene transcripts (typically, ABL1 gene).42 This value is then compared 
to a standardized baseline representing 100 % IS (International Scale, defined by the median value of 
BCR-ABL1 mRNA at the time of diagnosis in 30 patients with CML as established in the Study of 
Interferon and STI571 - IRIS), that is independent of individual patient-specific BCR-ABL1 baseline 
values.48  
Deep molecular response (DMR) is defined as the 4-log reduction or more from the standardized 
baseline (BCR-ABL1 transcripts = 0.01 % IS). A MMR corresponds to a 3-log reduction in the BCR-
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ABL1 transcripts from the baseline and is fixed at 0.1 % IS. These correlate to minimal risk of 
transformation to advanced phases of disease with 100 % probability of remaining progression-free at 
24 months. Generally, a 2-log reduction (BCR-ABL1 transcripts = 1 % IS) and 1-log reduction (BCR-
ABL1 transcripts = 10 % IS) correlate with CCyR (defined as absence of Ph+ chromosomes) and MCyR, 
respectively (Table 1.2).38,42 
Another integral part of molecular diagnosis and therapy management in CML is the assessment of 
the chimeric gene mutational status. Kinase domain mutation profile plays a minor role in selecting an 
initial TKI, but becomes highly relevant for patients where no ab initio response to the TKI is obtained, 
or in relapsed cases. Indeed, BCR-ABL1 mutations range from 25 % to 30 % of early CP patients on 
first-line IM to approximately 70 % to 80 % of BC patients.38,49 Due to the clonal diversity of BCR-
ABL1-expressing cells, mutational screening is conventionally performed via Sanger sequencing that is 
capable to detect a point mutation if the clone accounts for more than 15 % of all Ph+ cells.49  
 
1.1.2.3 Therapeutics 
Treatment depends on the type of leukemia, the disease stage, prior history of treatment, age and 
health of the patient, as well as the genetic profile. Most patients are treated with chemotherapy, while 
some may also undergo radiation therapy, stem cell transplantation or targeted therapy.37,39,40  
Up until the 1990s, the best nontransplant options for CML-CP management were nonspecific 
agents such as busulfan, hydroxyurea and interferon-alfa, which provide for temporary disease control. 
In fact, IFN-α is capable of reducing the proportion of the Ph chromosome but with multiple side 
effects.50,51 From the 1990s onwards, the treatment of choice resulting in curatives interventions, was 
the allogeneic stem cell transplantation (AlloSCT). However, AlloSCT not only carries high risks of 
morbidity and mortality, but also requires relatively young patients and an appropriate stem cell 
donor.52,53 CML treatment strategies and outcomes boosted with the design and development of small 
molecules capable of interfering and inhibiting the kinase activity of the BCR-ABL1 protein – TKIs.54–
57 TKI therapy is considered the standard first-line treatment for patients with newly diagnosed CML-
CP. As shown in table 1.3, five TKIs are available and recommended in the management of CML 
patients: IM (first generation), dasatinib, nilotinib (second generation), bosutinib (second/third 
generation) and ponatinib (third generation).57–62 
IM is usually well tolerated and constitutes the preferable option due to its high efficacy with 
durable hematological and cytogenetic responses.64,65 It retains the BCR-ABL1 protein in its inactive 
conformation, via competitive inhibition at the ATP-binding site and consequently blocking the 
downstream signal transduction pathways, preventing the phosphorylation of substrates.64 Although this 
first generation TKI demonstrates the ability to induce complete hematologic response in CML-CP 
patients, IM monotherapy is not curative for several patients. Early relapse, primary and acquired TKI 
resistance remain an important concern mainly due to the incomplete eradication of BCR-ABL1 
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expressing leukemic cells.27, 57,66–68 Besides IM, dasatinib and nilotinib have indication for first-line 
therapy in CML. The choice of the most appropriate TKI is based on several factors such as blood 
counts at diagnosis, patient age, drug cost, comorbidities and drug toxicity profile. This ensures that the 
treatment is the most adequate, target-oriented and well tolerated by each patient, with minimal impact 
on quality of life.57,69,70 These molecules (dasatinib and nilotinib) are more potent inhibitors than IM (in 
vitro) and have demonstrated the ability to induce more rapid and deeper responses in newly diagnosed 
patients. However, their impact on long-term overall survival remains undetermined.71–74  
 
 





First line therapy for CML-CP 




For patients resistant or intolerant to prior therapy (at any CML phase) 




For patients resistant or intolerant to prior therapy (CML-CP and AP) 




For patients resistant or intolerant to prior therapy (CML-CP and AP), 




As second-line therapy or beyond when no other TKI is indicated, or 
when a T315I mutation in BCR-ABL1 is identified 
3/2013 
AP, advanced phase; BC, blast crisis; CML, chronic myeloid leukemia; CP, chronic phase; IM, imatinib; TKI, 
tyrosine kinase inhibitor 
 
 
Overcoming TKI resistance 
It is known that 15 % to 40 % of CML patients will develop resistance or intolerance to first-line 
TKI treatment, with a need for a second-line TKI.57,75 This limited therapeutic potential is mainly due 
to TKIs resistance mechanisms that can be BCR-ABL1 dependent or independent. BCR-ABL1 
dependent TKIs resistance mechanisms rely mostly on the overexpression of the BCR-ABL1 oncogene 
and mutational events.76 The most studied ones are the mutations occurring on the kinase domain of 
BCR-ABL1, generally point mutations, impairing TKIs activity, mainly by preventing the fusion 
protein from adopting the inactive conformation. It has been demonstrated that the majority of these 
IM-resistant mutations are related to substitutions of amino acids that play a crucial role on specific IM 
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binding. The most recurrent alterations can occur at three different regions and seven specific residues: 
in the docking site for phosphate moieties of ATP named P-loop (M244V, G250E, Y253F/H and 
E255K/V); in the contact site related to selective BCR-ABL1 inhibition by IM (T315I); and in the 
catalytic domain (M351T and F359V).77,78 
Generally, second generation TKIs are active against most of the IM-resistant mutations, however, 
CML patients harboring T315I, F317L or V299L mutations usually do not respond to dasatinib, whereas 
patients harboring the E255K/V, T315I, F359C/V or Y253H mutations have a lower response to 
nilotinib.79,80 More recently, bosutinib appeared as the newest second-generation TKI, and have been 
proved to be highly effective in CML patients with BCR-ABL1 kinase mutations that lead to IM failure 
(exceptions are the V299L and T315I mutations).81–85 The T315I mutation displays resistance to all 
current available TKIs, except for ponatinib, a third generation TKI that was recently approved for 
patients resistant or intolerant to prior TKI therapy (Table 1.3).83,86 Therefore, mutational screening 
could lead to a better and informed selection of second and third line TKI therapy to be applied in 
patients who failed first or second line treatment, providing clinical benefit for those involved.49, 85,87 
Upon resistance to a first-line TKI, BCR-ABL1 mutation analysis is then recommended according to 
the NCCN and ELN guidelines.58 Patients that fail all current TKIs regimens are eligible for 
AlloSCT.38,88  
BCR-ABL1 independent TKIs resistance mechanisms have been reported. These include patient 
compliance and drug metabolism.89,90 Other mechanisms are linked to drug transport and its intracellular 
influx. IM cell uptake is mediated by the human organic cation transporter 1 (OCT1). When its activity 
is high there is an improvement on overall survival and response rates 91. Conversely, patients with 
lower OCT1 activity are associated with sub-optimal responses and they are more likely to undergo 
leukemic transformation.91,92  
IM exposure can also lead to a multidrug resistance (MDR) phenomenon, known as a recurrent 
cause of chemotherapy failure.93,94 This BCR-ABL1 independent resistance process is multifactorial 
and may comprise repair, drug detoxification and apoptotic resistance mechanisms. The MDR 
mechanism involving the expression and activity of ATP-binding-cassette (ABC) transporters, which 
modulates efflux transport, is the most studied one. These ABC transporters are transmembrane proteins 
that usually provide protections against xenobiotics. MDR1, for example, is overexpressed in 
hematopoietic cells and encodes for  the drug efflux pump P-glycoprotein, forcing substances out of 
cells and preventing drugs, such as TKIs, from achieving an effective intracellular concentration.95–99  
 
1.1.2.4 Current trends 
Diagnostics 
Diagnostic testing plays a key role in the management of CML and, for that purpose, has been 
rapidly changing over the years with the introduction of novel sensitive diagnostic tests. RT-qPCR is 
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probably the most sensitive technique available for detection of BCR-ABL1 transcripts. However, 
detection of BCR-ABL1 through RT-qPCR strongly depends on the quality and efficiency of RNA 
extraction and/or reverse transcription. False negatives may arise from RNA degradation or from 
repression of the BCR-ABL1 transcript. Specific concerns include optimization of RNA extraction and 
real-time amplification protocols, to ensure the detection of minimal BCR-ABL1 copies and maximal 
integrity of control gene; use of suitable control genes (e.g. ABL1, BCR and GUSB) for correct 
normalization of results; control RT-qPCR fluctuations over time due to technical issues; and, the 
stochasticity of reverse transcription and PCR amplification processes, especially when analyzing 
samples with low copy number.42 Other downsides include complexity, sensitivity to contamination, 
lack of portability, limitations in terms of multiplexing and reporting standardization issues. These make 
it very difficult to shift CML molecular monitoring towards point-of-care (POC).100  
The tight follow up of a CML patient after diagnosis increases the costs on the healthcare system, 
thus requiring the optimization of faster, cheaper and effective CML diagnostics methods. This is 
particularly important in countries in which molecular surveillance is not readily available to assist 
patient care. Note that the incidence of cancer is a worldwide issue, particularly impacting low-and 
middle-income countries, due to the increase of the population life expectancy and the lack of effective 
diagnostics and treatment capacity. In fact, the percentage of newly reported CML cases occurring in 
low-to-middle income countries has more than tripled over the past 40 years and only about 5 % of the 
global resources spent on cancer are deployed in these countries.101,102 
Research on CML molecular diagnostics focuses on four key issues: i) increase detection sensitivity 
through robust nucleic acid amplification strategies; ii) increase the amount of information on leukemic 
cells status, such as type of fusion transcript, occurrence of mutations and kinase activity; iii) 
miniaturization towards decreasing sample volume requirements; and iv) fast and cost-effective 
methods for POC suitable for preliminary screening. Currently, CML diagnostics may be performed on 
a single microfluidic platform that uses a small volume of blood and incorporates RNA extraction, 
reverse transcription, qPCR and result calculation to detect the fusion transcript.103 Though this 
automated microfluidic device improves sensitivity, standardization and reduces the variability from 
test to test, a specialized instrument is required, as well as reference material calibrated to IS and 
validated by the WHO.104 
As discussed previously, detection of the t(9;22) can be performed at chromosome level through 
karyotyping or FISH, or at the mRNA level through reverse transcriptase coupled to nested PCR and/or 
qPCR. Each one of these approaches has its advantages and disadvantages, and the safest option for 
CML monitoring is to integrate several strategies, at different levels (Figure 1.2; Table 1.4). Due to the 
reported persistence of leukemic DNA even with undetectable levels of chimeric transcript, detection 
of BCR-ABL1 genomic DNA using a DNA-based marker of the translocation will facilitate patient 
management by confirming absence/presence of the fusion gene.105 The information on the type of 
transcript and its expression levels can only be provided at mRNA level, due to alternative splicing 
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events and consequent genetic heterogeneity. Compared with cytogenetic testing, PCR-based molecular 
monitoring offers an analytical sensitivity 100 to 1000 times greater than FISH or bone marrow 
cytogenetic analysis.43 However, nanoparticle (NP)-related assays offer unprecedent versatility for 
CML diagnosis, due to their size- and shape-dependent optical properties, and their ability to be loaded 
with a wide range of ligands at nanoscale. These features enabled the design of novel diagnostic systems 
that offer significant advantages in terms of sensitivity, selectivity, reliability and practicality, which 
will be further discussed on sections 1.2 (Nanomedicine) and 1.3 (Nanotechnology towards leukemia 
management). 
For BCR-ABL1 kinase domain mutation analysis, the primary technique tool to monitor patients 
with TKI resistance, has been Sanger sequencing. However, the presence of mutations may be identified 
with more sensitive techniques, such as mass spectrometry or ultra-deep sequencing. Indeed, mass 
spectrometry can improve the sensitivity of mutation detection by 1-log compared to standard direct 
sequencing.106 A cohort study showed that next generation sequencing (NGS) detected emerging 
mutations, in both diagnostic and follow-up samples, earlier than Sanger sequencing in cases of therapy 
failure. Moreover, NGS enabled accurate identification of mutations in patients whose BCR-ABL1 
transcript level fluctuated around 0.1 % IS (MMR) or deeper molecular response. However, further 
studies are needed to understand the benefit of ultra-sensitive mutation screening after MMR is 
achieved.107 NGS has also been applied to BCR-ABL1-independent gene mutations.108 The large panel 
of 25 genes that was analyzed combined with the high sensitivity of NGS based sequencing improved 
mutation detection and provided novel genetic information regarding CML biology, however routine 
NGS data in cancer genomics is still far from implementation in all clinical settings due to its cost and 
computational tools requirements.109 
 Though available, other techniques for the identification of mutations are still far from routine labs: 
pyrosequencing, denaturing high-performance liquid chromatography (D-HPLC), double-gradient 
denaturing electrophoresis, multiplex-PCR and allele-specific oligonucleotide PCR.42,110,111 These 
technologies may increase the level of detection for BCR-ABL1 subclones that might be 
underrepresented in the pool of blast cells, and consequently reduce the probability of unresponsiveness 
to therapy.112 
There is still plenty of discussion among clinicians and molecular biologists on whether a negative 
result by karyotype analysis, FISH or RT-qPCR means that the patient is truly free of the disease. 
Discontinuation of IM in CML patients who have maintained DMR for at least 2 years have been subject 
of investigation and the first large clinical trial - the French STIM study - reported sustained treatment-
free remission in 40 % of patients.113 More recently another trial - the TWISTER study, performed by 
the Australasian Leukemia & Lymphoma Group (Australian New Zealand Clinical Trials Registry: 
ACTRN 12606000118505) - has shown that treatment-free remission may be achieved in patients 
testing negative by RNA-based qPCR but positive by DNA-based real-time PCR.42 For these reasons, 
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there has been a continuous demand for methodologies capable to probe DNA, RNA and protein levels 




Figure 1.2 Conventional vs innovative methodologies for cytogenetic and molecular screening of CML, 
via genomic DNA, mRNA and protein. The disease-causing translocation results in a shortened 
chromosome 9, the Philadelphia chromosome (Ph). The two most frequent BCR-ABL1 splicing variants 
(accounting for 95 % of Ph+ cases) are represented, as well as the encoded enzyme. ChromPET, 
chromosomal paired-end tags; ELISA, enzyme-linked immunosorbent assay; FISH, fluorescence in situ 
hybridization; HRP, horseradish peroxidase; LDI-TOF, laser desorption ionization-time of flight; 
MRM, multiple reaction monitoring; mut, mutations; PNA, peptide nucleic acid; RT-PCR, reverse 
transcription-polymerase chain reaction; TMA-HPA, transcription-mediated amplification-
hybridization protection assay.
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Table 1.4 Advantages and disadvantages of new approaches in CML molecular characterization. 
Method Advantages Disadvantages Sensitivity Ref. 
Anchored 
ChromPET 
Analysis of multiple samples in a single assay 
Higher sensitivity than karyotyping, FISH or 
PCR 







Detection of multiple chromosomal 
translocations/breakpoints in a single reaction 
Suitable for minimal residual disease 
monitoring 





Digital PCR Lower limit of detection than RT-PCR 
Less prone to erroneous quantification 
(absolute copy number determination; no need 
for calibrators) 
Expensive 
Requires a rough estimate of target copy 







Does not require amplification step 
Cheaper than RT-PCR 
May be extended to fluorescence/luminescent 
assays  
Lack of standard protocol for high-purity 
carbon nanotubes in large scale applications  
(b) 120 
Molecular Beacon Does not require amplification step  
May be used for sequence specific RT-PCR 
Lower sensitivity than RT-PCR (b) 121,122 
Au-nanoprobe 
colorimetric assay 
Cheap, fast and single tube 
Does not require amplification step 
Enables quantification of transcripts 
Requires standardization protocol to be 




PNA-FISH Analyze clonal evolution 
Detection at single cell level 
Less information than Sanger sequencing 
(probes designed for specific mutations) 





Fast and cheap 
Detection of mutations at single cell level 
Highly sensitive 
Less information than Sanger sequencing 
(probes designed for specific mutation) 
0.5 %  
(c)  
126 
TMA-HPA Single tube method 
Enables quantification 
Reduces risk of carryover contamination and 
false positives 
Complex design 




AuNPs-LDI-TOF Does not require purification steps 
Low background signals  
Time consuming 
Requires internal standards  
(b) 128 
Immuno-beads Detection of all isoforms of chimeric protein 
Higher sensitivity than karyotyping or FISH.  
Does not require purification step 





Allows determination of chimeric BCR-ABL1 
activity 
Requires concentration step (b) 129 
ChromPET, chromosomal paired-end tags; FISH, fluorescence in situ hybridization; HRP, horseradish peroxidase; LDI-TOF, laser desorption ionization-time of flight; MRM, 
multiple reaction monitoring; PNA, peptide nucleic acid; TMA-HPA, transcription-mediated amplification-hybridization protection assay 
(a) Sensitivity values expressed as the number of BCR-ABL1 expressing cells in a background of BCR-ABL1 negative cells (e.g., successful detection of one K562 cell in a 
background of 10 000 HL60 cells corresponds to a sensitivity value of 10-4). Sensitivity of gold standard methodologies: RT-nested PCR = 10-6; RTq-PCR = 10-5 
(b) Information not available or different scoring units were used. 
(c) Sensitivity values expressed as the percentage of mutated cells/template in a wild-type background. Sensitivity of Sanger sequencing: 10-20 % 
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In myeloid neoplasms, conventional diagnostics consist of blood counts and biomarker evaluation 
on peripheral blood cells, complemented by morphologic examination of tumor tissues, which includes 
a collection of a substantial core biopsy of the bone marrow using a fine needle. Follow-up relies on 
peripheral blood assessment every 3 months for morphological, cytogenetic or molecular marker 
evaluation. Since there is a good correlation between blood and core biopsies in hematological 
disorders, a current debate focuses on whether bone marrow biopsies are still necessary.130,131 
Liquid biopsies allow for non-invasive disease monitoring techniques and have been associated 
with circulating material originated from solid tumors, mainly circulation tumor cells (CTCs), 
circulating cell free DNA (cfDNA), microRNAs (miRNAs) and exosomes, that provide valuable 
information before and during treatment.132–134 However, this is even more so in liquid tumors, since a 
direct sample of tumor cells may be retrieved from a peripheral blood collection. As a result, besides 
the usual counting of leukocytes, hemoglobin, lymphocytes, and platelet levels, new prognostic markers 
should be addressed as far as disease outcome and clinical decision-making are concerned.135 For 
example, exosomes (vesicles of 30-100 nm that transport proteins, mRNAs and miRNAs) play an 
important role in cell communication, being able to induce some sort of transformation in receptor cells, 
including activation, proliferation, differentiation, or apoptosis 136,137. In CML-derived exosomes, a 
specific expression pattern of miRNAs was unveiled, which might be further explored for future use as 
disease biomarkers.138 In fact, higher concentrations of exosomes are found in sera of AML, CML and 
CLL patients with an abundant expression of surface proteins according to their cell of origin, which is 
rarely observed in exosomes of healthy individuals. Together, this supports the use of exosomes and 
miRNAs as leukemia biomarkers. 
 
Therapeutics 
Current treatment of CML patients has converted a fatal cancer into a manageable chronic disease. 
In fact, the 8-year survival rate of a CML patient is 87 % since 2001 and, since the advent of second-
generation TKIs, the life expectancy of CML patients is now close to that observed for the general 
population.139,140 The majority of patients respond very well to chemotherapy, however it is still 
challenging for clinicians to know when it is safe to discontinue a successful treatment and why, in 
some patients, leukemia recurs.141 The recommendation is to continue medication permanently but this 
raises other problems, such as the development of resistance, non-compliance with treatment, fertility 
and pregnancy issues, and the economic burden of long-term medication. Hence, treatment cessation is 
currently one of the major discussion points regarding CML.106, 113,142 
As for many other types of cancer, the way forward seems to be precision medicine, where a more 
specific chemotherapy strategy is conveyed to a given patient following the accurate genetic and 
biochemical profiling. As such, the selective delivery of a drug solely to those patients that will respond 
effectively to the chemotherapeutics will greatly improve the outcome. These approaches shall be made 
possible via the more sensitive and easy to operate detection strategies described previously which, in 
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conjunction with the novel molecules targeting specific subtypes of CML causing aberrations, will 
enable personalization of CML management. 
It has been reported that transfection of siRNA against BCR-ABL1 significantly reduced levels of 
corresponding mRNA and oncoprotein, with induction of apoptotic cell death in human leukemia K562 
cells.143 This approach was successfully applied using BCR-ABL1 siRNA in a female patient with 
recurrent Ph+ CML, resistant to IM (Y253F mutation) and to chemotherapy with AlloSCT.144 BCR-
ABL1 mRNA levels decreased dramatically and led to the reduction of circulating CML cells without 
side effects, suggesting that siRNA targeting of this gene has great potential for treatment of IM resistant 
CML.145 Kim et al developed a DNAzyme-based strategy to specifically target and cleave both the 
junction sequence and the site of the T315I point mutation that confers IM resistance. The designed 
molecules induced apoptosis and proliferation arrest in both wild-type and T315I-mutant CML cells, in 
a selective manner. Moreover, in vitro co-treatment with the DNAzyme targeting the T315I mutation 
and IM resulted in enhanced inhibition of proliferation and induction of apoptosis in T315I leukemic 
cells as compared with IM alone, thereby abrogating IM resistance in CML cells. DNAzyme combined 
with IM treatment may be an alternative approach to overcome TKIs resistance in leukemic cells.146 
Due to the genetic heterogeneity of BCR-ABL1 and sub-optimal response to chemotherapy by some 
patients, one can take advantage of a personalized approach. Coupling the benefits of nanotechnology, 
it is possible to integrate imaging, targeting and therapeutic agents in a single vehicle – 
nanotheranostics, allowing real-time monitoring of disease progression/remission, minimization of off-
target accumulation and side-effects, treatment specificity, reduction of therapeutic doses and repeated 
administrations. Linking diagnostics with targeted treatments at an early stage of the disease will benefit 
both patients and the economics of healthcare.147–149 This trend will be further discussed in the following 
sections - 1.2 (Nanomedicine) and 1.3 (Nanotechnology towards leukemia management). 
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1.2 Nanomedicine 
Traditional approaches for cancer management depend on centralized diagnostic platforms that can 
be complex, time-consuming and are set for the wide spectrum of patients and malignancies.150 These 
approaches have been developed to identify suitable biomarkers and profiles, for which standard 
chemotherapeutics protocols are designed.151 This has been the grounds for the development of 
precision oncology, in which profile data of the cancer cells enable a tailored treatment for individual 
patients. 
Nanoscale particles have played a central role in the detection of cancer biomarkers, which is 
essential for the personalized assessment at the basis of precision therapeutics. These NPs versatile 
structural and functional properties offer the possibility for the development of rapid, specific and 
sensitive diagnostics, opening the door for decentralized assessment and/or ambulatory follow-up.17 In 
what therapeutics are concerned, nanoconstructs’ size and their ability to be tailored with specific 
ligands for precise delivery to the focus of disease allow for more effective strategies to cross biological 
barriers. Moreover, NPs can work as therapeutic/imaging agents on their own or as carriers of multiple 
molecules that serve a specific function: tumor targeting, cancer cells ablation (via drug or gene 
silencing) and real-time monitoring of cancer cells expansion or decay. This flexibility is of particular 
interest for theranostics strategies, offering the possibility of simultaneous cancer detection and 
therapy.148  
NPs are synthesized in the range of 1-100 nm from diverse materials that, when at nanoscale, 
usually feature unique electronic, optical and catalytic properties, different than those of bulk 
materials.152–154 There is a wide variety of NPs, including liposomes, polymers, dendrimers, carbon, 
metal (e.g. magnetic, gold, silver, iron oxide) and quantum dots (QDs).155 Overall, their size is optimal 
for intracellular uptake and their large surface ratio permits a functionalization with different 
biomolecules for diagnostics and therapeutic purposes.152–156 Among the plethora of different nanoscale 
devices applied to cancer diagnostics and therapeutics, this section will be focused on gold nanoparticles 
(AuNPs) and its advantages over the remaining NPs in cancer management. 
 
1.2.1 Focus on gold 
Nanomaterials, such as noble metal NPs, brought a fresh perspective with new possibilities to create 
and improve setups for biodetection of clinically relevant biomarkers157 or genomic sequences of 
interest.158,159 AuNPs, in particular, have been immensely researched for their colorimetric properties, 
that is, intense colors and tunable localized surface plasmon resonance (SPR), chiefly for biomolecular 
assays involving a colorimetric result.158,160 SPR has been shown to be dependent on NP composition, 
size and shape.161–163 A colloidal gold solution containing spherical AuNPs (<40 nm) typically presents 
a localized SPR absorption band with a maximum centered at approximately 520 nm, presenting a bright 
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red color. This localized SPR absorption band is also influenced by interparticle distance, which 
constitutes the foundations for most AuNP-based colorimetric assays.164 
The chemical synthesis of AuNPs can be achieved through the reduction of gold salts to zero 
valence atoms, usually Au3+ to Au0. The final NP size is dependent on the reaction conditions, such as 
nature and quantity of reducing agents, temperature, reaction time and capping agent.165 The capping 
agent controls the NP growth in terms of rate, final size and morphology, and is required to increase the 
colloidal stability of the synthesized AuNP, either by electrostatic stabilization or by steric hindrance.166 
Electrostatic stabilization is attained through coulombic repulsion between particles possessing a layer 
of ions adsorbed to their surface and a second layer of counterions,167 whereas steric hindrance 
stabilization relies on the use of organic molecules that restrict interactions between two independent 
metallic cores, preventing aggregation of the colloidal suspension.168 Both the reduction agent as well 
as the capping agent should be carefully chosen to be consistent with the final application, as they may 
limit the solubility and subsequent derivatization of the NP. Considering a subsequent functionalization 
with thiolated ssDNA,123, 160,169 these AuNPs should be hydrophilic. 
One of the most common methods for the production of spherical NPs with a narrow distribution 
of size in aqueous medium is the citrate reduction method employed by Turkevich et al.170 and later 
optimized by Frens171 and Lee and Meisel.172 This method produces hydrophilic spherical AuNPs (10–
30 nm) compatible with subsequent functionalization steps. Here, the citrate molecule acts as both a 
reducer and a capping agent. The diameter of the produced AuNPs may be tailored, to an extent, by 
varying the relative ratio of citrate to gold salts. Higher concentrations of citrate yield smaller particles, 
while lower concentrations of citrate tend to favor the formation of larger particles.173,174 This method 
yields rather stable particles with negative charge due to the weak electrostatic adsorption of citrate on 
the surface of the NP, which constitutes an advantage for subsequent surface modification. Other 
procedures can be implemented to synthesize AuNPs in a variety of sizes,175–177 however, as explained 
above, the citrate reduction method is a simpler and straightforward approach for the synthesis of 
hydrophilic AuNPs in large quantities, with relatively low size dispersion, for subsequent modification 
and detection methods. For additional reading on AuNP synthesis and modifications please refer to 
Conde et al, 2015.178 
 
1.2.2 Gold nanoparticle-based diagnostics 
Molecular diagnostics based on screening of genomic sequences constitutes a powerful and 
promising way to identify genetic variations and ultimately evaluate their consequences at phenotypic 
level. This is particularly relevant as individual genetic variability has been associated with different 
multifactorial diseases179–182 and a differential response to therapeutic agents.183,184 To cope with this, 
molecular diagnostic has undergone sequential miniaturization and adaptation to medium-to-high 
throughput,159,185 which has greatly benefited from the emergence of nanotechnology.160,186 
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In 1996, oligonucleotide probes were functionalized to the surface AuNPs for the first time by 
Mirkin and co-workers.187 This concept utilized two different probes and generated a AuNP–DNA 
network, where the AuNP:oligonucleotide conjugates (Au-nanoprobes) were brought together, upon 
hybridization to a target complementary to both probes. In close vicinity, the Au-nanoprobe solution 
turns from red to blue, presenting a clear colorimetric identification of the target.188 This crosslinking 
assay made a significant contribution and revealed an immense potential for colorimetric detection, 
when applied to clinical diagnostics.189 For this reason, a wide number of crosslinking-like approaches 
have been developed for the molecular detection of nucleotide sequences, single nucleotide 
polymorphisms (SNPs) and other analytes.188–190 Crosslinking systems present some drawbacks, such 
as the need to use two nanoprobes, a strict control of temperature to yield a successful result, and a 
constant need for optimization of hybridization conditions, especially when detecting long nucleotide 
targets (RNA or DNA), due to steric hindrance. 
With this in mind, Sato and co-workers arranged a different detection scheme, relying on a single 
Au-nanoprobe, where aggregation was achieved by destabilizing nanoprobes in solution through an 
increase in ionic strength.186 In this case, the oligonucleotide probes at the AuNP surface are required 
to be precisely the same length as the target aimed to detect; so, when a complementary target is present, 
it will fully hybridize with the Au-nanoprobe, resulting in blunt-end heteroduplexes. This phenomenon, 
conjugated with salt addition, is responsible for AuNPs’ aggregation and, in the same way as in the 
crosslinking detection, the colloidal solution’s color changes from red to blue. Conversely, the same 
ionic strength is not sufficient to destabilize Au-nanoprobes hybridized to a mismatched target; so, 
aggregation does not occur, and the solution retains its red color. This non-crosslinking (NCL) setup 
possesses some limitations, since real biological targets are usually longer than nanoprobes and cannot 
always confer the blunt-end heteroduplexes mandatory for aggregation, and so, for analysis of real 
samples, this method would always require a previous single-base extension step.191 
Considering these limitations, Baptista and co-workers took the NCL assay one step further and 
designed an approach where hybridization between Au-nanoprobes and complementary targets resulted 
in heteroduplex formation at the nanoprobe surface, stabilizing it against salt-induced aggregation.160 
The presence of a non-complementary or mismatched target in solution would not sufficiently stabilize 
Au-nanoprobes, and aggregation would occur, accompanied by color change from red to blue (Figure 
1.3). This design was rather simpler that the previous ones, in terms of detection. Also, it did not demand 
the strict temperature control required by the crosslinking assay187,188 or present the target length 
limitation verified in the first NCL assay.191 Conceptually, this method proved suitable for identification 
of specific nucleotide sequences in longer targets, for example, PCR products, genomic DNA, and for 
different applications such as detection of pathogen agents,159,192 discrimination of single-base 





Figure 1.3 Au-nanoprobe non-crosslinking assay developed by Baptista et al.160 When a 
complementary target is present in solution and is fully hybridized with the Au-nanoprobe, preventing 
aggregation upon salt induction, the colloidal solution maintains its red color. The formation of 
heteroduplexes resulting from hybridization between probe and complementary target bears a protective 
effect due to their negatively charged backbones and steric hindrance. This way, both the electrostatic 
repulsions and the interparticle distance between nanoprobes increase, promoting further stabilization. 
Conversely, the presence of non-complementary or mismatched targets does not effectively stabilize 
the nanoprobes, and they aggregate after salt addition with concomitant color change in the solution 
from red to blue/purple. AuNP, gold nanoparticle; NP, nanoparticle. 
 
 
1.2.2.1 Non-cosslinking assay optimization 
NCL approaches using DNA-modified AuNPs for molecular detection constitute powerful tools 
with potential implications in clinical diagnostics and tailored medicine. From detection of pathogenic 
agents to identification of specific point mutations associated with health conditions, these methods 
have shown remarkable versatility and simplicity. 
In NCL hybridization assays, the colorimetric result is achieved by a differential aggregation of 
nanoprobes in solution, according to hybridization to different targets or in the absence of target. After 
the hybridization step, this aggregation usually occurs in response to an increase in ionic strength 
provided by salt addition. However, some authors have described NCL assays using pH-induced 
aggregation.194,195 Functionalization of NPs with thiol-modified oligonucleotides confers a higher 
stability (proportional to the oligonucleotide density) against aggregation, since the electrostatic charges 
of the ssDNA bases increase the repulsion forces among nanoprobes in solution.159,160,187 NaCl and 
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MgCl2 are commonly used electrolytes for developing this colorimetric result. Divalent salts are capable 
of inducing aggregation at lower concentrations than monovalent salts; nevertheless, it is important to 
consider that divalent cations could also lead to a semi-crosslinked aggregation by coordinating 
phosphate groups in the nanoprobes.196,197 Aside from this, nanoprobe concentration can also affect 
stability assays, for it is directly related to the interparticle distance in solution. Lower concentrations 
reflect larger interparticle distances and limit the probability for nanoprobes to interact with each other. 
So, an optimal concentration is required for extensive aggregation to occur.198  
Strick control of pH should be considered for the development of NCL methods, namely, during 
DNA hybridization, since an optimal hybridization occurs in the 6.5–8 pH range. pH value directly 
influences hybridization efficiency and target:probe specificity: a pH of 8.0 permits discrimination 
between a complementary and a single-base mismatched target, since it considerably decreases non-
specific bindings.199 However, this is somewhat dependent on the setup, as some NCL hybridization 
approaches have shown the capability to effectively discriminate SNPs at a pH 7.186,191 Moreover, this 
discrimination is improved if the mismatch is located at the 3’ end of the Au-nanoprobe, as nucleotide 
bases near the 5’ end become less available for base pairing interaction, due to stronger electrostatic 
interactions.199,200 
A different feature that influences hybridization efficiency is oligonucleotide density at the Au-
nanoprobe surface. By tuning the optimal conditions for stability and hybridization, differential integrity 
of nanoprobe:target complexes for different target complementarities (100 % complementary, 
noncomplementary or mismatched) may be optimized, which would be translated into distinct 
aggregation profiles and enhanced discrimination. 
The colorimetric result, visible to the naked eye, constitutes one of the great advantages of the 
method. Besides this, the color change can be followed up in a ultraviolet–visible (UV-Vis) 
spectrophotometer in a relatively short time period after salt addition (usually 15 min is enough to reveal 
a colorimetric result).159,160,193 The ratio between the absorbance at 525 nm (Abs525nm) and at 600 nm 
(Abs600nm) has been found to be a powerful analytical tool to evaluate surface plasmon resonance 
variations. Abs525nm and Abs600nm represent the typical absorbance maxima for the dispersed and 
aggregated Au-nanoprobes, respectively.192 This ratio may not be accurate when different aggregation 
levels are not so pronounced (e.g., in case of mismatch target discrimination), since the noise level in 
the spectra increases. This can be countered by using the trapezoidal rule to calculate the area under the 
curve (AUC) corresponding to the disperse and aggregated fractions, and conjuring an adequate ratio 
between them, indicative of differential aggregation.123,201  
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1.2.2.2 Non-crosslinking assay application to biomolecular detection 
Development of highly sensitive, selective and inexpensive approaches for biodetection is of great 
importance for clinical diagnostics of infectious diseases, genetic disorders and monitoring toxicity at 
both clinical and environmental levels. PCR is still considered the gold-standard technique for 
molecular detection associated with clinical diagnostics.202,203 However, PCR-based techniques are 
generally more expensive due to reagents and enzymes, specialized personnel and equipment.202 
Colorimetric assays that use Au-nanoprobes combine several advantages in the development of new 
biosensors with potential implications in nanodiagnostics,204 exhibiting rapid, simple and visible to 
naked eye results, with high specificity and PCR-comparable sensitivity (10–100 ng of DNA/RNA), at 
significantly lower costs.123,160 The fact that Au-nanoprobe assays permit the detection of biomarkers 
directly on RNA samples is a major advantage, since it eliminates the stochasticity of reverse 
transcription and amplification processes, and enables fast and simple gene expression studies with a 
direct correspondence between output and biological targets.123,124, 160,203 
Additionally, this methodology reduces carry-over contamination, since the reaction is performed 
in a single tube, does not require heavy implementation and is a suitable alternative to fluorescence- or 
radioactivity-based assays. With significant impact on cost, time, specificity and sensitivity, this 
detection technique is able to multi-target gene detection, is well suited for miniaturization and can be 
easily adapted to automated high-throughput screening.165,204,205 As described in table 1.5, the NCL 
design has been applied in the detection of specific nucleotide sequences, mutations or SNPs. 
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fto gene Single-base mismatch AuNPs 212 




Alkylating agents DNA adducts Glycidamide-guanine 
adducts 
Secondary structure between 
analyte and aptamer 
AuNPs 201 
Household paints Metal ion  Pb2+ Secondary structure between 
analyte and aptamer 
AuNPs 214 
Fish Metal ion Hg2+ T-Hg2+-T coordination AuNPs 215 
General mercury 
toxicity 
Metal ion Hg2+ T-Hg2+-T coordination AuNPs 216 
AuAg-alloy-NPs, gold/silver alloy nanoparticles; AuNPs, gold nanoparticles; CML, chronic myeloid leukemia; LAMP, loop-mediated isothermal amplification; NASBA, 
nucleic acid sequence based amplification.  
Genes: c-MYC, avian myelocytomatosis viral oncogene homolog; dnaK, chaperone; FSY1, fructose symporter 1; fto, -ketoglutarate-dependent dioxygenase; gyrB, DNA 
gyrase, subunit B; inhA, enoyl-[acyl-carrier-protein] reductase; KRAS, Kirsten rat sarcoma viral oncogene homolog; rpoB, DNA-directed RNA polymerase, subunit B; TP53, 
tumor protein 53. 
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1.2.2.3 Point-of-need devices 
These NCL-based biomolecular strategies are beginning to leave the test tube to integrate more 
complete platforms for detection, with a focus on miniaturization, portability and even envisioning a 
translation to the clinical setting, with a direct impact on society. The development of point-of-need 
devices for molecular diagnostics faces some challenges when integrating biochemical or analytical 
assays onto miniaturized systems, mainly in terms of automation, amount of information, 
reproducibility and throughput.217,218 The NCL colorimetric assay shows great potential towards 
miniaturization and integration into medical diagnostic systems.169,204 The simple principle of detection 
in NCL assays can readily be integrated into systems with a previous sample preparation step, for 
example, microfluidics, constituting rapid, inexpensive alternatives, with medium-to-high throughput 
capabilities, without the need for specialized personnel. 
NCL Au-nanoprobe–based DNA analysis was demonstrated on a microfluidic device with a slight 
variation: instead of aggregating, AuNPs deposited onto the substrate made of polydimethylsiloxane 
(PDMS).219 Even though this remarkable platform requires further optimization and insights into the 
mechanism of deposition, the outcome is very promising. The reaction on the PDMS microchip required 
only a small sample volume (3 µl) and discrimination of the target DNA was possible within five 
minutes with high sensitivity values. In a separate study, a PDMS chip has also been successfully 
applied for the detection of Mycobacterium tuberculosis using only 3 µl of DNA solution.220 A gold-
on-paper platform was developed to combine the colorimetric changes of the NCL Au-nanoprobe assay 
with inexpensive paper-based platforms and digital image. The wax-printed plate is impregnated with 
MgCl2 to induce Au-nanoprobe aggregation, yielding a colorimetric discrimination dependent on the 
absence/presence of the complementary target. With the help of a smartphone and a simple data analysis 
tool, unequivocal and fast identification is possible.221 
In a near future, routine laboratory diagnostics will be revolutionized by means of nanoscale-
enabled technology. These nanoscale devices shall substitute the cumbersome equipment and 
biochemical reactions required for assessing genomic and transcriptomic biomarkers. One of the main 
impacts will be in sensitivity, where it is expected that the current limits of detection will be surpassed, 
and molecular diagnostics will focus on two main approaches: miniaturization of devices and platforms 
to assist clinicians at POC and patients in ambulatory medicine; and increase in sensitivity for low 
sampling and wide-ranging analytical output. These approaches will be instrumental for effective 
precision medicine. AuNPs, will play a key role in setting up standards in biosensing taking full 





1.2.3 Gold nanoparticle-based theranostics 
Significant efforts have been made in the past years towards understanding the genetic and 
pathophysiological processes contributing to malignant transformation and tumorigenesis. The 
overwhelming amount of information thus retrieved is now being translated into the field of biomarker 
discovery and foster cancer therapy by selective interference with cancer hallmarks. Despite these 
efforts, conventional cancer therapy, including surgery, chemotherapy and radiation, lack target cell 
specificity and are often disconnected from individual diagnosis. Also, the efficacy of conventional 
therapeutic strategies is often limited by the acquisition of multidrug resistance by tumor cells and by 
poor drug penetration into the tumor 222. This is why several molecular targeted therapeutics have been 
designed to selectively target tumor cells, thus improving efficacy and decreasing toxicity.223 These 
novel targeted therapeutics may be engineered to simultaneously provide information about delivery, 
biodistribution and diagnostics, e.g., as imaging agents allowing disease detection at its early and 
asymptomatic stages.149 
Integration of diagnosis and therapy in a single platform has been termed theranostics, which has 
promised to significantly increase the precision and effectiveness of treatment, shifting the current 
clinical standard from generalized procedures to a personalized or precise approach.224–227 
Consequently, theranostics shows particular impact in heterogeneous diseases that require 
individualized and tailored methods of treatment and monitoring, such as cancer,147, 149,228 rheumatoid 
arthritis,229 infectious and cardiovascular diseases.230,231 Nanotechnology has proven its capability to 
engineer solutions to enhance theranostics – nanotheranostics – to simultaneously diagnose a disease 
and monitor therapeutic efficacy noninvasively and in real-time. This tailored approach enables 
physicians to customize treatment based on each patient’s responses and needs, thereby preventing 
unwanted deleterious side-effects or sub-optimal dosage that might lead to drug resistance, incomplete 
remission and relapse.232,233 
Nanostructures’ primary advantage is their size and their augmented surface area-to-volume ratio. 
They can be loaded with a plethora of (bio)molecules, such as imaging moieties (e.g., fluorophores), 
targeting (e.g., antibodies, peptides), therapeutic agents (e.g., chemicals/drugs, siRNA, therapeutic 
oligonucleotides, etc.) and stabilizers (e.g., polyethylene glycol (PEG)), which greatly favor solubility, 
bioavailability, and circulation half-life. These nanocarriers provide a platform for vectorization of these 
(bio)molecules, at high density; a protective effect upon the cargo, preventing degradation before 
reaching the biological target; enhancement of delivery, cancer cell uptake and deep tissue penetration, 
ensuring time and spatial control over imaging and/or therapeutics.149 
Amongst the nanosized dependent properties, the optical properties of these nanocarriers have been 
widely explored in nanotheranostics’ application. In fact, SPR resulting from photon confinement to 
the small particle size is a remarkable property of noble metal NPs, such as gold, which has found a 
multitude of biological and medical applications.147,234,235 Indeed, these multifunctional platforms allow 
monitoring the route taken by the formulation, its delivery kinetics, intra-organ and/or intra-tumor 
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distribution, which ultimately allow evaluation of strategy and tuning of efficacy. Nevertheless, there 
are still some drawbacks, such as (i) the overwhelming relevance attributed to the enhanced and 
permeability retention (EPR) effect; (ii) the poor tumor/tissue penetration of nanoformulations that 
render them ineffective due to stromal modifications; (iii) the need for a more effective targeting of 
metastasis; and (iv) the toxicological impact on the whole organism.222 
Despite these drawbacks, AuNPs have led the world of nanotheranostics with their unique physical 
and chemical properties. They can be synthesized in different shapes such as spheres, hollow, rods, 
diamonds, prisms, cages, either as single solid bodies or in a core shell format.236,237 Each combination 
of size and shape shows slightly different properties that may be explored for theranostic purposes, such 
as optical properties from intense bright colors, contrast agents and photothermal capability in the 
infrared (IR), near infrared (NIR) and visible range, biofunctionalization potential and low 
toxicity.238,239 What is more, hollow NPs and nanocages show the advantage of simultaneously acting 
as encapsulating vectors, allowing a higher load of agents per particle.240  
Despite the divisive studies about AuNPs’ toxicological impact in vitro and in vivo, spherical 
AuNPs between 10 and 60 nm in diameter are generally considered as non-toxic.241–243 In fact, toxicity 
may vary with administration route, concentration and surface coverage but also with the NPs’ sizes 
and shapes. The difficulty in standardization of the nanoconjugates, their characterization and the effect 
of monitorization, has strained the definition for nanosafe AuNPs.244,245 For example, larger particles, 
45 nm in size, have been demonstrated to exhibit higher cytotoxicity at a lower concentration (10 
μg/mL) than those 13 nm in size (75 μg/mL).242 Oral and intraperitoneal administration routes showed 
higher toxicity than tail vein injection on mice.246 Sharp-edged NPs tend to have higher cytotoxicity 
than rounded ones, with several studies showing that lower concentrations are needed for stars and 
flowers to induce toxicity, compared to nanospheres.247,248 On the other hand, sharp-edged 
conformations are more prone to endosomal escape favoring drug delivery.249 These factors have been 
extensively debated in several studies.250–253 
 
1.2.3.1 Targeting and delivery 
AuNPs can be functionalized with molecules to provide for targeting and to enhance stability and 
biocompatibility in vivo.243 There is a wide range of stabilizers available that may also act as therapeutic 
agents (e.g., miRNA, siRNA, DNA, peptides and antibodies) or to reduce NPs’ immunogenicity (e.g., 
PEG). In fact, PEG of different molecular weights is one of the most frequently used biomolecules to 
increase NPs’ circulation half-life and improve cellular uptake.254,255 When referring to PEG grafting to 
AuNPs’ surfaces, bi-functional PEGs (with a thiol group in one extremity and another group at the other 
end - amine, carboxylic, biotin, azide) have been widely used for direct coupling to another molecule 
of interest via straightforward chemistry with high yield.256 AuNPs can be further engineered to trick 
the immune system, avoid removal from circulation or to cross biological barriers (e.g., blood-brain 
barrier), in order to increase therapeutic efficacy and allow systemic tracking.257  
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Passive targeting takes advantage of the fact that vessels surrounding solid tumors are leaky, due to 
incomplete endothelial linings, allowing nanomedicines to reach the tumor through the EPR effect 
alone. Generally, particles between 10 and 60 nm in diameter tend to passively accumulate in tumor 
tissues enabling, for instance, higher drug payload at the tumor site and circulating half-lives about 100 
times longer than that of free anticancer drugs, with reduced systemic toxicity.258,259 However, this 
strategy depends greatly on the degree of tumor vascularization and angiogenesis and on heterogeneous 
blood flow, which limit drug uptake and homogenous distribution within the tumor. Several approaches 
may overcome these limitations, for instance, using vasoconstrictive drugs. These agents cause normal 
vessels to constrict and blood pressure to increase, while tumor vessels do not respond to this effect 
because of insufficient muscular structure, thus leading to a relative increase in the input function of 
tumor tissues.260 Although the EPR effect might be useful when treating confined tumor sites, it is not 
a factor when treating cancer cells on the bloodstream. 
Another valuable strategy to increase NPs efficacy and specificity relies on attaching targeting 
moieties to their surface. Typically, NPs reach target cells through ligand-receptor interactions that 
induce receptor-mediated endocytosis and drug release inside the cell.259 Peptide conjugation to AuNPs 
is one method by which active and specific targeting may be used for enhanced tumor 
accumulation/delivery. Chanda and collaborators used bombesin peptide-functionalized AuNPs to 
target the gastrin-releasing peptide (GRP) receptor which is overexpressed in breast, prostate, and 
small-lung carcinomas.261 Bombesin peptide-functionalized AuNPs exhibited GRP-enhanced tumor 
accumulation and decreased liver uptake compared with nonspecific protein-conjugated AuNPs. In 
three other studies, it was possible to actively target endothelial cells of the tumor vasculature, through 
αvβ3 integrin, using an arginylglycylaspartic acid (RGD)-peptide conjugated to an AuNP. These RGD-
functionalized AuNPs showed an increased tumor accumulation in mice xenograft studies.262–264  
Successful targeting has also been achieved via functionalizing AuNPs with antibodies that 
recognize specific receptors overexpressed by cancer cells: transferrin,265 epidermal growth factor 
(EGF)243,266–271 and folate receptors.272–275 Fernandes et al designed a multifunctional AuNP system 
composed of a monoclonal antibody against EGFR and a compound (TS265) with proven 
antiproliferative activity towards cancer cells. In vivo, the nanoformulation efficiently delivered TS265 
in a controlled selective manner, boosting tumor cytotoxicity, when compared to the nontargeted 
counterpart or to the free compound.243 Lu et al demonstrated that folate functionalized NPs were 4.7 
times more directed to tumor cells and internalized by endocytosis into lysosomes when compared to 
non-functionalized NPs.276 Targeting has been crucial for the development of vectorization systems 
capable of site specific accumulation/retention enabling NPs to deliver their cargo on site for improved 
therapeutic effect.258  
Some authors have been focusing their attention on developing nanovectorization systems that 
mediate cargo delivery upon a particular stimulus, such as pH, increased heat, ultrasound, light and 
magnetic field. Tumor cells usually become hypoxic and exhibit high glycolytic activity, thus producing 
  33 
 
carbonic and lactic acids.277 Coating NPs with pH Low Insertion Peptides (pHLIPs) increase efficiency 
of targeting acidic diseased tissues. pHLIP, being a membrane peptide, has affinity to cellular 
membranes and targets extracellular acidity. In contrast to other pH-sensitive systems, it tracks acidity 
at the surface of cancer cells.278 Antosh and collaborators reported a 34 % increase in pHLIP decorated 
NPs in contrast with AuNPs alone, on human lung carcinoma cell lines at pH 6.0.279 Photothermal 
conversion of light into heat can increase target cells’ temperature, enough to directly kill cells.239,280 
but also to release therapeutic moieties at the tumor site.281 In a similar manner, ultrasounds and 
magnetic fields can locally increase temperature and precisely deliver cargo.282 Despite the broad range 
of targeting approaches, there is still much more to explore in this field with many groups still looking 
for new effective targeting moieties that allow tumor specific accumulation and retention for improving 
drug release and therapeutic efficacy.258,277 
 
1.2.3.2 Therapeutic agents 
Drug discovery coupled with pre-clinical studies strongly focus on overcoming general issues that 
hamper the efficacy of drugs, such as limited solubility, high toxicity, high dosage, nonspecific delivery 
and short circulating half-lives.283 Due to the advances in nanotechnology based drug delivery, the 
current idea has been to repackage classic drugs using targeted delivery systems to increase patient 
compliance, extend the product life cycle and reduce healthcare costs. Beside small drugs, these agents 
might be a peptide/antibody, a ribozyme, a siRNA or an antisense oligonucleotide.256 Probably the most 
studied and used concept has been Doxil® (Janssen Products, Horsham, PA, USA), where doxorubicin 
(approved by FDA in 1974 to treat a broad range of cancer types) has shown improved efficacy when 
encapsulated into PEGylated liposomes. In fact, traditional chemotherapy drugs (e.g. vincristine, 
paclitaxel, cisplatin, etc)284–287 and other potential anti-tumor metal compounds288 have followed suit 
and been encapsulated and delivered in similar engineered vesicles.  
AuNP/doxorubicin nanoformulations attempted to mimic their liposome counterpart and showed 
promising advantages, such as increased targeting and functionalization as well as the possibility to 
couple with phototherapy and to act as imaging/contrast agents.289 Various AuNPs shapes have been 
functionalized with doxorubicin – stars,262 clusters,290 shells,291 hollow spheres,292 etc - showing the 
versatility of the nanoconstructs and their ease of functionalization. All previous examples were tested 
in vivo and have shown increased efficiency when compared with doxorubicin alone, as well as lower 
levels of cytotoxicity. 
AuNPs have been also applied in therapeutic approaches in combination with anti-tumor drugs 
(e.g., platinum prodrugs,293 5-fluorouracil,294 irinotecan,276 camptothecin295,296, Co(II) coordination 
compound243). All nanoformulations showed remarkable anticancer activity when compared with the 
free drug. For instance, Shi and collaborators described the use of gold hollow and nanocage shells 
layered with mesoporous silica and a thermosensitive polymer loaded with camptothecin. The drug is 
tightly packed inside the nanoconstruct with a “leakage” of only 6.8 % to the medium after 14 h in in 
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vitro conditions. NIR triggered release of the drug leading to increased tumor cell death, compared with 
only NIR or nanocarrier exposure.295 
Gene therapy has been receiving increasing attention in tumor suppression due to the possibility to 
downregulate specific oncogene expression or to sensitize cells in an intra-cellular targeting process. In 
particular, small interfering RNA (siRNA) has shown potential to downregulate specific gene 
expression in cancer cells.178 Since naked siRNAs show extremely short half-lives due to cellular 
RNases activity and poor chemical stability, the development of efficient delivery vehicles for in vivo 
applications remains a major obstacle in translating siRNA into effective therapeutics. AuNPs have 
been widely used as nanovectorization for gene silencing strategies.297–300 Almost all the different 
shapes and sizes of AuNPs reported above have been used to vectorize gene silencing elements into 
cancer cells.301,302  
Feng Yin reported the use of a light-triggered therapy using gold nanorods as nanocarriers for dual-
delivery of doxorubicin and KRAS gene siRNA. The synergistic effect of the chemo- and gene-therapy 
allowed the reduction of the tumor volume rate by 90 % in vivo.303 Gold spheres were described for 
siRNA targeting and delivery using models of increasing complexity (cells, hydra and mice), achieving 
effective silencing of c-MYC gene (~65 % reduction in expression). It was also shown that covalently 
bounded siRNAs were more effective silencers than siRNAs adsorbed on the surface of the NPs.304 
Different molecular concepts for gene silencing rather than siRNA have also been used to block a 
particular gene. Baptista’s group was pioneer in the use of hairpin ssDNA structures vectorized via 
AuNPs to particularly silence any possible RNA mediated pathway inside the cell.300,305,306 In fact, the 
molecular actuator thus developed - gold nanobeacon (Au-nanobeacon) - is one of the most effective 
molecular nanotheranostics platforms, since the hairpin may be further functionalized with a 
fluorophore, whose fluorescence is triggered once the silencing event occurs. The potential of this 
system has been further characterized in vitro and in vivo with low toxicity.241, 304,305,307 Furthermore, 
this system was shown to be effective in vivo in a promising approach to combat multidrug resistant 
tumors, combining in the same particle an antitumor agent (5-fluorouracil) with silencing of MRP1, a 
gene associated with acquired resistance in several tumors. In vivo results showed a remarkable tumor 
size reduction, from the synergic effect of the two agents.294 Using gold nanobeacons, Bao et al were 
able to silence KRAS gene and reduce gastric tumor size in mice by 60 %, tumor vascularization by 90 
% and lung metastasis by 80 %.297 
 
1.2.3.3 Phototherapy 
Photothermal therapy (PTT) is based on the selective sensitization of cells to thermal damage, or 
hyperthermia, near 45 °C. What is more, traditional PTT may be coupled to AuNPs and profit two ways: 
(i) the possibility to vectorize additional cargo and use the NP as scaffold for selective targeting; and 
(ii) enhance PTT by the AuNPs’ ability to convert absorbed photons into thermal energy. By modulating 
the AuNPs’ shape and/or shell thickness, it is possible to shift the localized SPR peak of AuNPs toward 
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the near-infrared (NIR), allowing deeper light penetration into tissues. Moreover, the laser energy 
required to achieve this transformation is far below that stipulated in medical safety standards. AuNP-
mediated PTT is predominantly associated with nanorods, nanoshells and nanocages.308,309 For example, 
hollow gold nanospheres (44 nm-diameter), one of the first nanotheranostics systems to be evaluated in 
vivo, have shown comparable photothermal capacity using 100 times lower concentrations to that of 
superparamagnetic iron oxide silica coated counterparts.310 
Wei Lu et al reported in 2009 the use of hollow gold nanospheres carrying siRNA in vivo. After 
intravenous injection of the nanoconstruct and NIR laser (800 nm) irradiation, significant 
downregulation of the target oncogene was observed, when compared to non-exposed tumors on the 
same mice. Moreover, the authors proved that the escape of the NPs from the lysosomes and siRNA 
release in the cytosol was irradiation-dependent, coining this method as “photothermal transfection”.310 
Due to their NIR band, gold rods have also been used for photothermal transfection311 coupled to NP 
imaging,312 hyperthermia,313 or co-delivery.303,314 
A recent study has also focused on smaller spherical AuNPs that show improved photoconversion 
capability from irradiation in the visible range using standard green lasers. Efficient light-to-heat 
conversion of AuNPs irradiated in the visible region (at the SPR peak: 530 nm) resulted in the in vitro 
elimination of laser-exposed breast cancer cells. A synergistic interaction between heat and 
conventional breast cancer drug doxorubicin was also observed.239 
Another strategy that can be coupled to nanosized structures is photodynamic therapy (PTD), which 
involves the administration of a nontoxic agent that acts as a photosensitizer (PS) and a laser source. 
Photoexcitation of the photosensitizer leads to the generation of free radicals, which destroy tumor 
tissue.315 Combining PDT with AuNPs has proven to be a good strategy to overcome two of its major 
limitations: the dark toxicity of the PS and the poor selectivity of the cellular uptake of PS between the 
target cells and normal tissues.316,317 
 
1.2.3.4 Multimodal Imaging 
The implementation of imaging techniques for diagnostic purposes enables the non-invasive 
assessment of anatomical, functional and molecular information, with image-guided drug delivery 
gaining much attention nowadays.318 The imaging modalities most often used in the clinics are 
computed tomography (CT), ultrasound (US), magnetic resonance imaging (MRI), positron emission 
tomography (PET), single-photon emission computed tomography (SPECT), photoacoustic 
tomography (PAT) and fluorescence imaging.319 When choosing an imaging technique, one should take 
into consideration several parameters: target tissue, resolution, sensitivity, contrast and 
implementation.320–323 
AuNPs are optimal contrast agents for CT, due to the relatively high X-ray attenuation of gold and 
the stability of gold colloids. Since gold has higher absorption than iodine, AuNPs can achieve better 
contrast with lower X-ray dose.228 On the contrary, AuNPs do not possess intrinsic properties that enable 
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their visualization through MRI; hence, they are usually combined with super-paramagnetic iron oxide 
(SPIO), gadolinium or manganese, demonstrating significant contrast enhancement in tumor models.324 
Furthermore, in vivo studies with gold nanorods labelled with radioactive iodine enabled photothermal 
therapy towards ovarian cancer and monitoring of NPs’ distribution via SPECT/CT imaging. Tumor 
sites were clearly visualized from the SPECT images even at 24 h post-injection.325 
Fluorescence imaging is highly suitable for high-throughput screening with high sensitivity, 
providing detailed molecular profiling with subcellular resolution, enabling multicolor imaging and 
being relatively inexpensive, but has low tissue penetration and spatial resolution, thus limiting its 
applications in clinical settings. Using the NIR part of the spectrum for fluorescence-based imaging, 
spatial resolution is improved and autofluorescence is highly reduced making the technique much more 
attractive for clinical applications.272,326 
Owing to their underlying physical principles and distinct benefits/drawbacks, one can take 
advantage of combining two or more techniques in a single nanocarrier, avoiding a repeated challenge 
to the patient’s immune system and providing more accurate and dependable data on the patient’s 
condition than using a single imaging moiety.327,328 Liu et al report the use of gold nanostars for 
multimodal imaging. Combining CT, surface-enhanced Raman scattering (SERS, of molecules 
adsorbing on a noble metal surface) and thermal imaging, authors could accurately detect gold stars 
located in the tumor and further confirm photothermal effectiveness with a thermal camera.329 Other 
successful examples of combined imaging modalities using AuNPs include: a multicomponent 
nanocapsule used for real-time US and high-resolution MRI for image guided photothermal tumor 
ablation.330 
Since the challenges of efficient tumor treatment include accurately identifying the location and 
size of tumors and monitoring the effectiveness of therapy after treatment, integration of contrast-
enhanced diagnostic imaging capability with photothermal therapy is a winning bet in the fight against 
cancer. 
 
1.2.3.5 From research lab to the clinic 
The use of gold in medicine dates back to 2500 BC when Chinese and Arabic physicians used gold 
preparations in their practice. Medieval physicians used mixtures of colloidal gold for various ulcerative 
skin conditions. In the 20th century, several formulations of gold salts were used to treat tuberculosis, 
Lupus vulgaris, syphilis and rheumatism. In 1997, Guy Abraham and Peter Himmel reported the use of 
20 nm AuNPs for rheumatism treatment in 10 patients.331 Their results showed a “rapid and dramatic” 
positive effect on the tenderness and swelling of joints with no evidence of toxicity in any of the patients. 
Since then, there have been no follow-up studies on AuNPs for rheumatism in clinical settings. 
Recombinant human tumor necrosis factor alpha (rhTNF) was applied in the 80s with remarkable 
antitumor effects in mice, inducing apoptosis, cytolysis or cytostasis of tumor cells. However, multiple 
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phase II studies, with more than 156 patients, resulted in only one complete and one partial response at 
the maximum tolerated dose, which may correlate to a low therapeutic dose at disease site. CYT-
6091(Aurimune®) from CytImmune (Rockville, MD, USA) was the first product on clinical trial using 
AuNPs for patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT00356980, 
NCT00436410). The nanoformulation is composed of PEGylated 27 nm AuNPs functionalized with 
rhTNF. It was administered systemically to 30 patients at doses of rhTNF that were previously shown 
to be toxic, without detectable side effects.332 In addition, gold was found in breast tumor tissue but not 
in healthy breast tissue showing the potential of this approach. Phase II clinical trials are ongoing, 
aiming at understanding if this nanotechnology approach induces greater vascular leak by dynamic 
contrast-enhanced MRI and to evaluate the safety and efficacy of CYT-6091. 
AuroLase® (Nanospectra Biosciences, Houston, TX, USA) is an FDA-approved pilot study that 
uses silica-gold nanoshells with a NIR laser for photothermal therapy (ClinicalTrials.gov Identifier: 
NCT00848042, NCT01679470). NPs called AuroShells are injected intravenously in the patient’s blood 
stream and accumulate passively in the tumor. This clinical trial was designed to evaluate the approach’s 
effectiveness for the treatment of advanced lung tumors resulting from either primary lung cancer or 
metastatic tumors in the lung. Although the trials are complete, the results have not yet been 
disseminated. 
 
1.2.4 Nanotechnology commercial impact 
Nanotechnology R&D continues to grow in importance both in terms of public and private funding. 
Indeed, global demand for nanotechnology medical products grew by 17 % from 2009 to 2014. The 
USA National Nanotechnology Initiative (NNI) investment in nanotechnology R&D, policy and 
regulation since 2001 now totals a staggering $22 billion, with the 2016 USA federal budget providing 
more than $1.5 billion for the NNI. The European Union (EU) and Japan are investing substantial 
resources in nanotechnology, with a comparable level to the USA. The returns are expected to surpass 
the investment, and the medical field appears to be a front runner in nanotechnology innovations.148  
NP-based drug delivery is one of the major areas, providing a wide range of formulations that are 
now beginning pre-clinical or clinical trials. Besides the traditional hurdles conventional therapeutics 
face to enter the clinics, nanomedicines also face a lack (or the deficiency) of protocols for the 
characterization of these products in terms of absorption, distribution, metabolism, excretion, and 
toxicity. However, the FDA, in collaboration with the Nanotechnology Characterization Laboratory, 
has released guidelines describing how it defines a nanoscale product - specifically, as having at least 
one dimension between 1 and 100 nm, or as being less than a micron in size, and demonstrating size-
dependent behavior. These agencies are now drafting protocols to address nanomedicines’ regulatory 
and safety gap. The European Commission has also established several goals in terms of 
nanotechnology regulation, patenting and business creation, with international cooperation being a key 
asset to improving R&D. Bringing the EU together with countries who are active in nanotechnology 
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research (USA, Japan, Switzerland and Russia) could pave the way for standardized protocols and 
further initiatives. The fact that nanotechnology is one of the sections included in the Horizon 2020, the 
biggest EU Research and Innovation Program, shows the commitment to this subject and its importance 
in increasing Europe’s competitiveness. Its main objectives include: scaling up laboratory experience 
to industrial settings; ensuring the safe development and application of nanotechnologies in health and 
the environment; and proving the significant long-term benefits provided by nanotechnology-based 
systems, in terms of health care and quality of life.148 
Nanomedicines are still at an early development stage and, thus, their impact on health spending 
and cost effectiveness is still difficult to predict. Can these formulations compete with conventional 
products in the medical sector? For example, examining the cost-effectiveness of chemotherapy 
(gemcitabine) versus nanotherapy (PEGylated liposomal doxorubicin) for ovarian cancer showed that 
the chemotherapy pre-treatment costs were cheaper by €1285. Nonetheless, these costs were more than 
offset by administration and hospitalization costs, which were €2670 in favor of nanotherapy. The 
clinical benefit associated with nanotherapy was proven, yielding not only positive cost-effectiveness 
results, but also significant financial savings.333 
Nanotheranostics innovations, specifically, can have a significant impact on health costs by 
reducing the number of diagnostic tests and increasing therapy efficacy. Additional savings are expected 
due to the overall reduction of the number of days in hospital for each patient. Hence, the global market 
for nanomaterials used in theranostics is anticipated to be more than $187 billion.148 Despite these 
figures and expectations, those relating to AuNPs alone are just the tip of the iceberg. Another good 
indicator of AuNPs’ increasing impact on the medical sector is the number of companies that are 
devoted to R&D in this area alone. Due to high competition among market players and low yield 
coupled with high expenditures in R&D, most companies choose to invest in specific end-use 
applications: diagnostic tests for the point-of-care market, biomedical imaging or photothermal therapy. 
Successful examples include Nanospectra (Aurolase®) and Cytimmune (Aurimune®) whose flagship 
products are now facing clinical trials. Although the market for gold nanomaterials is still developing, 
their clinical and financial benefits are undeniable. In the future, efforts should be made to improve the 
bridge between academia, R&D companies, regulatory agencies and the pharmaceutical industry.  
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1.3 Nanotechnology towards leukemia management 
Nanodiagnostics 
An effective treatment depends heavily on the accuracy and sensitivity of diagnosis. Traditionally, 
leukemia cells are detected through morphological, cytogenetic and molecular analysis of cells, that 
relies on the detection via fluorescent markers, FISH, PCR and/or DNA sequencing. Several 
nanocarriers have been researched for leukemia biosensing,225 but for the purpose of this study and for 
all the reasons disclosed in section 1.2.2 (Gold nanoparticle-based diagnostics), this segment will focus 
on AuNP-based platforms. 
For acute leukemia diagnostics, an anti-leukemia thiolated aptamer (sgc8c) was used to specifically 
recognize protein tyrosine kinase 7 (PTK7), an overexpressed transmembrane receptor in human T-cell 
acute lymphocytic leukemia cells. Aptamers feature a high affinity and selectivity towards their targets, 
and can be modified to allow the functionalization into NPs, for example, using a thiol group which 
permits their loading in gold surfaces through strong Au-S linkage.334  
Since CML is associated to a unique chromosomal abnormality - BCR-ABL1 gene - this specific 
target was used as a diagnostic approach using Au-nanoprobes on a NCL colorimetric assay,123,124 and 
via spectral coding using Au-nanobeacons (Table 1.4).122  Both systems enabled the distinction between 
the two major isoforms of BCR-ABL1 (e14a2 vs e13a2), but their accuracy is yet to be tested in clinical 
samples.  
The remaining targets for leukemia diagnostics are antigens, such as CD20, CD45 and CD19 that 
are overexpressed by malignant B-cells, particularly in ALL.335 Hence, CD20 antibody (rituximab) can 




Current treatment strategies for leukemia involve chemotherapy and radiation, which often induce 
long-term side-effects and multidrug resistance, or more invasive strategies like stem cell transplant 
that require a matching donor. Nanotechnology provides the possibility to selectively deliver a high 
payload of anticancer agents to malignant cells without damaging healthy cells or systemic toxicity.337 
In addition, some tissue compartments, such the bone marrow, may be inaccessible for otherwise 
effective drugs. Indeed, multiple studies using different types of NPs and conjugation strategies confirm 
this trend also for hematological diseases.338–344 
In a 2016 study, AuNPs were functionalized with dsDNA oligonucleotides with a sequence 
corresponding to a gene that is overexpressed in CML cell lines (BIRC5), where only the antisense 
strand of the DNA duplex is covalently attached to the AuNP. Dasatinib, a potent TKI frequently used 
against CML, was conjugated to the non-covalently linked DNA strand. Targeted RNA binds to the 
antisense oligonucleotide and displaces the drug-conjugated DNA oligonucleotide proportionally to 
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BIRC5 mRNA in cells.345 Other studies examined the efficacy of drug-coated AuNPs on AML treatment 
improvement, using different TKIs or fludarabine.346–348 One of these took additional advantage of the 
fact that folate receptors are highly overexpressed on the surface of many tumor types and used folic 
acid to target AML cells.348 
 
Nanotheranostics 
When designing a nanotheranostics vector for hematological malignancies, one should take into 
consideration the following parameters: (1) choice of most suitable nanocarrier for effective delivery 
and cell internalization; (2) the effector molecule, usually conventional drugs or nucleic acids; (3) 
ensure controlled release of effector molecule; (4) an imaging component that allows for the real time 
monitoring of the nanoconjugate location and effect on targeted aberrant cells; (5) an active targeting 
agent, typically a cell-surface marker or an oligonucleotide, that maximizes specificity of the vector and 
minimizes damages to healthy cells, whether in peripheral blood or when targeting the bone marrow 
(Figure 1.4). Note that passive targeting also occurs via the EPR effect characteristic of confined tumor 
sites, such as the bone marrow, due to leaky vasculature, hypervascularization and lack of lymphatic 
drainage. This is the first and necessary step for therapeutic nanoconjugates or free drugs to accumulate 
in these locations, then active targeting could be achieved.222  
The only pre-clinical study of a nanotheranostics approach used for leukemia management was 
done on a CML in vivo model, but using magnetic NPs. These were functionalized with an 
antineoplastic drug, paclitaxel (pac-MNP). Paclitaxel formulations can augment the anti-leukemia 
activity by coordinating different apoptotic signaling cascades. Pac-MNPs, acting as both drug delivery 
and magnetic resonance imaging contrast agent, were further functionalized with lectin glycoprotein 
which resulted in higher cellular uptake and lower IC50 value suggesting the efficacy of targeted delivery 
of paclitaxel. Moreover, these nanoformulations showed prolonged circulation time in serum suggesting 
increased bioavailability and therapeutic effect of the drug in vivo. The nanocarrier acted as theranostic 
mediator, helping in early diagnosis and monitoring of leukemia, during and after treatment.349 
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Figure 1.4 Precision nanomedicine for the management of hematological disorders. Nanodiagnostics 
based on liquid biopsies to assess multiple leukemia biomarkers using nanoparticles (ex vivo analysis). 
Nanotherapeutics according to the patient’s molecular profile (in vivo). Nanotheranostics combines 
diagnostics and therapeutics onto a single nanomaterial. Therapeutic efficacy may be improved for 
standard chemotherapeutics by efficient delivery to the target that can be monitored in real-time. CTCs, 
circulating tumor cells; ctDNA, circulating tumor DNA; D, conventional drug; F, fluorophore; NP, 
nanoparticle; O, oligonucleotide; PEG, polyethylene glycol; p-MBA, p-mercaptobenzoic acid (Raman 






1.3.1 Clinical trials 
The described pre-clinical studies show great potential of nanomedicines in the fight against 
hematological malignancies but, thus far, only but a few have reached the clinical trial stage. Of these, 
liposomal nanoformulations seem to have some impact in blood malignancies, and recently three 
liposomal formulations for the treatment of leukemia have reached this milestone. In 2012, liposomal 
vincristine sulfate (Marqibo, Talon Therapeutics Inc, San Francisco, CA, USA) was the first 
nanoformulation to get approval by the FDA to treat Ph+ ALL in adults that relapse or that do not 
respond to at least two anti-leukemia drugs. Vincristine inhibits microtubule formation in mitotic 
spindle, resulting in an arrest of dividing cells at the metaphase stage and is a standard component of 
chemotherapy regimens used to treat ALL and other lymphoid malignancies for over 50 years. 
Nevertheless, the free version of drug induces major side effects thus limiting the administered dose. 
Its encapsulation in a sphingomyelin/cholesterol-based liposome changed vincristine pharmacokinetics 
dramatically. It is now slowly released from the liposome and delivered to tissues more efficiently 
allowing a higher dose (ClinicalTrials.gov Identifier: NCT01439347).350 Marqibo has also completed 
phase I clinical trials for the treatment of pediatric ALL (ClinicalTrials.gov Identifier 
NCT01222780).351  
CPX-351, a liposomal formulation of cytarabine and daunorubicin, has produced interesting results 
in phase III clinical trials for the treatment of high-risk AML. CPX-351 significantly improved overall 
survival, event-free survival, and response rates in comparison with the standard regimen of cytarabine 
and daunorubicin (ClinicalTrials.gov Identifier: NCT02286726). Annamycin, an anthracycline 
intended for the treatment of relapsed or refractory leukemia, has also been encapsulated in a liposome 
and submitted to phase I/II multi-center clinical trials. The drug was well-tolerated and showed 
encouraging anti-leukemic activities against ALL (ClinicalTrials.gov Identifier: NCT00271063).352 
Future studies should focus on the combination of these nanoformulations with other anti-leukemic 
drugs, namely TKIs, and incorporate new classes of therapeutic agents, such as, siRNA, miRs, ssDNA 
and gene editing. 
 
  
  43 
 
1.4 Scope of the Thesis 
Conventional chemotherapy of hematological cancers is challenged by its poor selectivity, resulting 
in low therapeutic efficacy and pronounced adverse side effects, which may be overturned by innovative 
nanomedicine approaches. Leukemia unique features have provided for the possibility of developing 
innovative approaches, simple and non-invasive methodologies for diagnosis and treatment using NPs. 
The molecular basis of each subgroup of patients is very well defined by common chromosomal 
translocations, shared mutations in oncogenes, gene expression profiles and immune-phenotype, which 
can be used as target for diagnostic testing and therapy (nanotheranostics). Moreover, a simple blood 
sample (liquid biopsy) provides access to the patient’s full tumor profile that can support more focused 
therapeutic regimens. Unlike solid tumors, that require NPs to reach the site of action, liquid tumors 
burden is spread throughout the bloodstream. In fact, most of the barriers that NPs face to reach solid 
tumors are not applied in liquid tumors since circulating tumor cells are freely exposed to these agents. 
However, while in circulation, NPs can also be opsonized by blood proteins followed by recognition by 
the mononuclear phagocyte system.353 As such, liquid tumors require slightly different diagnostic, 
treatment and targeting strategies. 
Nanomedicine, particularly AuNP-based technology, provides several advantages for leukemia 
management. Concerning its therapeutic application, most studies are primarily focused on solid 
cancers due to the possibility to take advantage from the EPR effect experienced by tissues in the close 
vicinity of tumors, which enhance nanomedicine accumulation and, consequently, improve efficacy. 
Leukemia is addressed differently from solid tumors when nanomedicines are concerned since EPR 
effect is not a factor when treating bloodstream cells.  
In this study, focus was given to AuNP-based nanotechnology that supports CML biomarker 
detection and targeted treatment. CML is a key model of leukemic hematopoiesis associated with a 
chromosomal translocation between the BCR and the ABL1 genes. Differences in disease phenotype, 
prognosis and treatment are related to the qualitative and quantitative variations of the BCR-ABL1 
fusion products, thus making current CML molecular diagnostic methodologies essential to obtain the 
best possible outcome when it comes to treatment response. However, routine methodologies are time-
consuming, expensive and some display low sensitivity. Considering the benefits of AuNPs as carriers 
in biological detections, the goal of this PhD project is to develop a simple method based on Au-
nanoprobes able to identify a specific BCR-ABL1 transcript type, directly in RNA samples. After 
validation of the assay in clinical samples, a point-of-care diagnostic device will be designed, as well 







This PhD thesis will be structured around the following main stages: 
 
i) Molecular characterization of leukemia clinical samples (Chapter 2) 
Human bone marrow and peripheral blood samples were provided by Hospital dos Capuchos 
(Centro Hospitalar de Lisboa Central, CHLC, Lisboa). Samples were collected from Ph+ leukemia 
patients at different time points of treatment (at diagnostic and during follow-up) and from control 
individuals (Ph-negative leukemia patients) for posterior Au-nanoprobe assay validation in clinical 
samples. Particular attention was given to patients in molecular remission for sensitivity assessment.  
All clinical samples (from AML, Ph+ ALL and CML patients) were routinely characterized at 
Hospital dos Capuchos (CHLC, Lisboa) which includes morphological, cytogenetic (karyotype analysis 
and FISH) and molecular analysis (RT-qPCR). At our laboratory, samples were further characterized 
at molecular level, including identification of transcript type and assessment of point mutations using 
routine methodology: RT-nested PCR44 and Sanger sequencing. The large biological information 
contained in all these samples can bring new information for diagnosis, monitoring and treatment of 
leukemia patients and is crucial for the validation of a new nanodiagnostic system.  
 
ii) Detection of BCR-ABL1 transcripts in clinical samples via Au-nanoprobe assay (Chapter 
3) 
In this chapter, optimization and validation of the Au-nanoprobe colorimetric assay123 in RNA 
extracted from clinical samples, not requiring retrotranscription or amplification steps, was performed. 
First, AuNPs were functionalized with ssDNA capable of specifically hybridizing to the most 
predominant BCR-ABL1 isoform, e14a2, in biological samples. Then, the method was optimized using 
synthetic oligonucleotides and RNA from leukemia cell lines (HL60 or THP1, negative from BCR-
ABL1; K562, positive for e14a2 BCR-ABL1 transcript; BV173, positive for e13a2 BCR-ABL1 
transcript). This step allows the assessment and optimization of several features in the Au-nanoprobe 
assay, before moving on to clinical samples, namely probe density, selectivity, and sensitivity. Finally, 
the Au-nanoprobe assay was tested using fully characterized clinical samples. Comparison of the 
colorimetric assay outcome to the gold-standard methodology results (RT-nested PCR) should be a 
good indicator of the robustness of the Au-nanoprobe diagnostic assay. 
 
iii) Development of a point-of-care device for BCR-ABL1 RNA detection via Au-nanoprobe 
(Chapter 4) 
Highly sensitive and specific biosensors based on AuNPs have opened the possibility of creating 
new diagnostic platforms for disease markers, especially in cancer. Based on the previous task and 
considering the current clinical need for a sensitive, cost-effective and fast way to diagnose CML, we 
intended to design a microfluidics platform for BCR-ABL1 detection. This task was performed in 
collaboration with the Center of Excellence in Microelectronics Optoelectronics and Processes 
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(CEMOP, Universidade Nova de Lisboa), due to their expertise in the development of miniaturized 
biosensors. 
 
iv) Development of a nanotheranostics approach for CML via BCR-ABL1 gene silencing 
using Au-nanoconjugates (Chapter 5) 
Based on the knowledge acquired from the previous tasks in terms of selectivity and specificity for 
target recognition, the aim was to develop an approach suitable for both CML nanotheranostics 
(diagnosis and therapy), which could lead to an effective monitoring and reduction of abnormal 
leukemic cells. 
To achieve this goal, PEGylated AuNPs were functionalized with the same ssDNA sequence 
optimized in task ii), but in a hairpin conformation to potentiate the probe’s selectivity to BCR-ABL1 
gene silencing, particularly the e14a2 isoform. Several parameters were assessed upon exposure of 
K562 cells to the Au-nanoconjugate: target and downstream gene silencing, protein expression levels, 
cell proliferation and apoptosis. Attention was given to the effect of the Au-nanoconjugate when 
combined to TKIs therapy and its efficacy on IM resistant K562 cells. Although, this Au-nanoconjugate 
was only tested as a nanotherapeutics approach for CML via BCR-ABL1 gene silencing, this is the first 































CHAPTER 2 – MOLECULAR CHARACTERIZATION OF LEUKEMIA CLINICAL 
SAMPLES 
 
Clinical samples were kindly provided by Hospital dos Capuchos (Centro Hospitalar de Lisboa Central, 
CHLC, Lisbon). Hematological evaluation, cytogenetic characterization, BCR-ABL1 gene 
quantification, NMP1 and FLT3 molecular characterization were performed at their Hematology 
Department, as part of their routine procedures. R. Vinhas performed BCR-ABL1 and CEBPA molecular 
characterization, at the Research Unit on Applied Molecular Biosciences (UCIBIO, Universidade Nova 
de Lisboa), under the supervision of P.V. Baptista and A.R. Fernandes. Data enclosed in this chapter 
were originally published in the following issues: 
 
• Vinhas R, Tolmatcheva A, Canto R, Ribeiro P, Lourenço A, Sousa AB, Baptista PV, Fernandes 
AR. 2016. A novel mutation in CEBPA gene in a patient with acute myeloid leukemia. Leukemia 
& Lymphoma. 57(3):711-713. 
• Vinhas R, Lourenço A, Santos S, Ribeiro P, Silva M, Sousa AB, Baptista PV, Fernandes AR. A 
double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing 
P210BCR-ABL1 and P195BCR-ABL1 isoforms. [Submitted to Haematologica] 
• Vinhas R, Lourenço A, Santos S, Lemos M, Ribeiro P, Sousa AB, Baptista PV, Fernandes AR. A 
novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute 
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2.1 Abstract 
Leukemia is a biologically diverse disease with a range of different chromosomal and genetic 
abnormalities that define subsets of the disease with prognostic relevance. Ph+ leukemia research, 
particularly regarding CML, was groundbreaking at several stages: it was associated to a specific 
chromosome abnormality, providing evidence of a genetic link to cancer for the first time; its effective 
genetic diagnostics allowed for an improvement on patient’s overall survival; and enabled the rational 
drug design of the most effective agents against BCR-ABL1 expressing cells so far (TKIs).  
Diagnosis of the disease plays an essential role, starting from patient’s physical examination to bone 
marrow and peripheral blood tests that comprise hematological, cytogenetic and molecular analysis. In 
this chapter, focus is given to standard diagnostic procedures at molecular level: BCR-ABL1 transcript 
identification, quantification and mutational analysis. A complete molecular analysis of CML, ALL and 
AML samples is presented.  
 
2.2 Introduction 
The Ph translocation is found in the majority of CML patients, in 25 % of patients with acute 
lymphoblastic leukemia (ALL), and in 1 % of newly diagnosed adults with acute myeloid leukemia 
(AML).354,355 Although most CML patients present themselves in CP at diagnostics, a small but not 
irrelevant proportion of CML patients present in AP or even in BC when a proliferation of BCR-ABL1 
positive blasts is found, making the distinction between CML, Ph+ ALL and Ph+ AML not always 
straightforward.38,356 As such, full molecular characterization of chromosomal breakpoints, gene 
rearrangements and variations, coupled to extensive biochemical and clinical evaluation should be taken 
together for accurate diagnosis and treatment success. 
Molecular monitoring of Ph+ hematological diseases has become an integral part of the clinical 
management of these patients, from diagnosis to follow-up surveillance. This is valid for transcript 
identification and quantification (this last is critical for monitoring minimal disease), but also for 
mutational analysis of the ABL1 domain of the chimeric transcript. The latter screening is essential since 
it is one of the mechanisms that leads to TKI resistance, whether due to pre-existent mutations (primary 
resistance accounts for one third of patients) or mutations that arise from TKI treatment pressure 
(acquired resistance). Patients that fail to respond to IM (first generation TKI),  dasatinib, nilotinib, 
bosutinib and ponatinib (second- and third-generation TKIs) should be administered according to results 
of the mutational analysis.17 More than 100 mutations have been reported in the ABL1 kinase domain 
and are frequently positioned in the following regions: phosphate-binding loop (P-loop), ATP/IM 





Figure 2.1 Map of the most recurrent amino acid substitutions in the BCR-ABL1 kinase domain in Ph+ 
clinical samples, usually associated to imatinib (IM) resistance. Highlighted mutations are the most 
frequent. Numbering of residues is according to normal ABL1 protein. Key structural motifs within the 
kinase domain are indicated: P-loop, phosphate binding loop; IM binding, ATP/IM binding region; C-




BCR-ABL1 chimeric gene is remarkably homogenous in CML, as nearly all patients express the 
P210BCRABL1 protein originated by the e14a2 or e13a2 fusion transcripts. Nevertheless, rarer isoforms 
of the transcript can be found in 5 % of CML cases: P190 (e1a2); P195 (e6a2); P200 (e8a2); P225 
(e18a2); P230 (e19a2).29–31 All BCR-ABL1 isoforms encode for a constitutively active tyrosine kinase 
that disturbs cells proliferation, differentiation and survival, and is therefore the target for the most 
effective therapy against CML so far.30,139 After the introduction of TKIs, such as IM, the annual 
mortality of CML has been reduced significantly, to less than 3 % per year.139 
Several reports state that different isoforms might be associated to different prognosis, response to 
treatment and/or survival. Although both e13a2 and e14a2 transcripts originate the P210BCR-ABL1 variant, 
they seem to represent distinct biological entities since patients with the e13a2 transcript have a slower 
molecular response with inferior response rates to IM and a poorer long-term outcome.35,357,358 
Moreover, P190BCR-ABL1 results in a greater potential to induce a malignant change than P210BCR-
ABL1.359,360 The P195BCR-ABL1 has been described in very few CML patients and has been linked to a poor 
clinical outcome due to the aggressive progression of the disease.31,361–364 This enhanced oncogenic 
potential of the P190/P195 isoforms is believed to result from the partial loss of BCR domains, namely, 
the guanine exchange factor/dbl-like domain which mediates the communication with several Ras-
proteins crucial for the regulation of signaling pathways and processes such as cell proliferation, 
differentiation, adhesion, apoptosis, and migration.31, 361,364,365 More recently, Reckel and collaborators 
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(2017) demonstrated the existence of strong differences in the interactome and tyrosine 
phosphoproteome between P190 and P210 signaling pathways. P190 interacts particularly with the AP2 
adaptor complex involved in the regulation of clathrin-mediated endocytosis, whereas P210 interacts 
mostly with phosphatase Sts1. Indeed, the authors showed a stronger activation of the Stat5 transcription 
factor and the Erk1/2 kinases in the presence of P210, whereas P190 activates the Lyn kinase.366 
The genetic instability of BCR-ABL1 expressing blast cells may lead to additional cytogenetic 
aberrations (ACAs), such as, double Ph, trisomy 8, and isochromosome 17. These are known to reduce 
the response to IM, the first line TKI, and are detected in less than 5 % of CML patients at diagnosis.367 
Furthermore, cytogenetic monitoring for the detection of ACAs during TKI treatment is mandatory due 
to the clonal evolution of the disease. It is hypothesized that the presence of a double BCR-ABL1 
chimeric gene induces stronger kinase activity and a more active blast cells proliferation.368,369 
 
Ph+ ALL 
ALL is very heterogenous, comprising several hematological, cytogenetic and molecular groups. 
The Ph chromosome is the most frequent genetic abnormality in adult ALL (Ph+ ALL), representing 
20-30 % of B-lineage adult cases (B-ALL), but only 5 % of pediatric cases.370,371 Ph+ ALL frequency 
increases with age representing approximately 50 % of all cases in the elderly.371  
In Ph+ ALL, the most frequent expressed isoform of BCR-ABL1 is the P190 in which the exon 1 of 
BCR is fused to exon 2 of ABL1 (e1a2), accounting for 70 % of the patients.372,373 The remaining Ph+ 
ALL cases (approximately 30 %) are associated with the presence of P210BCR-ABL1. As stated for CML 
cases, P190BCR-ABL1 exhibits a higher transforming potential than P210BCR-ABL1 and is usually linked to a 
higher risk of relapse.359,360,373  
Alike CML, TKI therapy revolutionized Ph+ ALL prognosis. Complete remission can be achieved 
in 95 % of the cases,373 however IM resistant Ph+ ALL patients frequently harbor the T315I mutation 
(ATP/IM binding site) and will only respond to ponatinib.374,375 Several studies report the impact of 
ABL1 mutational screening in Ph+ ALL patients.374,376,377 
 
AML 
AML accounts for the majority of acute leukemia cases in adults, despite the high level of cell and 
molecular heterogeneity.378 Karyotyping at diagnosis provides for the most important prognosis 
information in AML. Only a small percentage (~1 %) harbor the Ph chromosome and approximately 
40–50 % of AML patients do not show any clonal chromosomal aberration and the most prominent sign 
of the disease is a blockage in granulocytic blasts differentiation. Cytogenetically normal AML patients 
are now classified into molecularly defined subgroups with distinct clinical outcomes. Indeed, CEBPA, 
NPM1, and FLT3 mutations predict response to chemotherapy for those individuals.379 FLT3 and NMP1 
mutational screening is well implemented in AML diagnostics routine, however CEBPA molecular 
analysis has several technical issues and requires further optimization. CEBPA PCR amplification and 
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sequencing is difficult due to its high GC content, frequently correlating with the presence of 
background or sequencing artifacts. The entire gene sequencing detects all mutations, but is labor-
intensive and requires expertise with unusual variants.380  
The role of CEBPA in AML has gained clinical significance over recent years and is underlined by 
the discovery that the gene is mutated in around 11 % of patients.381 Located on chromosome 19q13.1, 
CEBPA is a member of the basic region leucine zipper family of transcription factors. The gene encodes 
a 42-kDa protein with a C-terminal region (bZIP), consisting of a leucine zipper domain and an adjacent 
basic region, which modulates C/EBP dimerization and DNA binding, and triggers the two 
transactivation domains (TAD) in the N-terminal region.378 In hematopoiesis, C/EBP plays a central 
role during granulocyte differentiation, where a diminishing activity is associated to the reduction of 
myeloid progenitors’ differentiation potential, thus deregulating proliferation of hematopoietic cells.378 
CEBPA mutations affect mostly bZIP and/or TAD domains.380 
AML patients usually exhibit biallelic CEBPA mutations, comprising an N-terminal and a C-
terminal mutation, which result in complete abrogation of wild-type C/EBP expression and is 
associated to a favorable clinical outcome.382 Single CEBPA mutations also occur, in which expression 
of the wild-type product is retained.383 This subgroup of patients could not be distinguished from wild-
type cases as regards clinical outcome.384 These results demonstrate significant heterogeneity within 
CEBPA mutation-positive AML with prognostic relevance.  
 
Molecular characterization of leukemia samples (gene isoform identification and gene mutational 
screening) constitutes a useful tool for disease diagnostics and follow-up monitoring, particularly to 
detect molecular relapse and contribute to a more direct and personalized treatment. Hence, a complete 
molecular analysis was performed for all clinical samples provided by Hospital dos Capuchos (CHLC, 
Lisbon).  
 
2.3 Patients and Methods 
Patients informed consent and study approval 
Patients were sent to the Hematology Department of Hospital dos Capuchos (CHLC, Lisbon, 
Portugal) for leukemia diagnosis. Written informed consent was obtained from all participants and the 
study was approved by Hospital dos Capuchos Ethics Committee. All approved ethical requirements 
for sample collection and assortment, processing, and analysis required by Hospital dos Capuchos 
Ethics Committee have been strictly followed. 
 
Clinical samples 
The presence of the Ph chromosome was confirmed by karyotype analysis and FISH. Levels of 
BCR-ABL1 were assessed using RT-qPCR, according to the 2015 ELN guidelines.38 Treatment with 
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TKIs was initiated immediately after diagnostics confirmation and clinical, hematological, and 
molecular remission was evaluated. Fresh bone marrow and peripheral blood patient samples were used 
immediately, or collected in RNAlater® (ThermoFisher Scientific, Waltham, MA, USA) for maximum 
RNA stabilization, and used directly for RNA extraction without any culture expansion and/or any cell 
culture method. 
 
Karyotype banding and FISH analysis 
This analysis was performed by the Hematology Department, at Hospital dos Capuchos (CHLC, 
Lisboa). Chromosome analysis was performed according to G-banding standard procedures on 
overnight cultured bone marrow cells. A total of 20 metaphases were analyzed. FISH analysis was 
performed in interphase cells using the LSI BCR/ABL1 Dual Color, Dual Fusion translocation probe 
(Abbott Molecular, Des Plaines, IL, USA), according to the manufacturer’s instructions. A total of 100 
and 500 nucleus were scored at diagnosis and follow-up, respectively. This analysis was carried out 
using a fluorescence microscope (Eclipse Ci, Nikon, Tokyo, Japan) and image capture was performed 
using Isis FISH Imaging System V 5.7.1 (MetaSystems, Altlussheim, Germany). 
 
Cell culture of leukemia cell lines 
Immortalized cell lines derived from CML patients in blast crisis, K562 (BCR-ABL1 e14a2 fusion 
transcript positive cell line) and BV173 (BCR-ABL1 e13a2 fusion transcript positive cell line) were 
cultured, respectively, in DMEM and RPMI with 10 % fetal bovine serum (FBS), at 37 °C with 5 % 
(v/v) CO2. Human acute promyelocytic leukemia cell line (HL60), negative for BCR-ABL1, was 
cultured in RPMI with 10 % FBS, at 37 °C with 5 % (v/v) CO2. These cell lines were used as positive 
and negative controls for the presence or absence of BCR-ABL1 transcript. 
 
Total RNA extraction and cDNA synthesis 
Total RNA was extracted from clinical samples white cells. Briefly, 5 mL of bone marrow or 
peripheral blood were mixed with 10 mL of red blood cells lysis solution (5 mM MgCL2, 10 mM NaCl, 
10 mM Tris-HCl pH 7) and centrifuged at 400 x g for 5 min. The procedure was repeated to lyse any 
residual red blood cells. Total RNA extraction of white blood cells pellet was performed using the 
guanidine thiocyanate procedure (SV Total RNA Isolation System, Promega, Madison, WI, USA). Cell 
pellets were lysed in a solution containing 4 M guanidine thiocyanate, 0.1 M Tris-HCl pH 7.5, and 1 % 
(v/v) β-mercaptoethanol and were subsequently centrifuged at 13 000 x g for 10 min to clear the lysate 
of precipitated proteins and cellular debris. Nucleic acids were selectively precipitated with 30 % (v/v) 
ethanol; bound to the silica surface of glass fibers; and washed with 60 mM potassium acetate, 10 mM 
Tris-HCl pH 7.5, and 60 % (v/v) ethanol. On-column DNase I treatment lasted for 15 min at room 
temperature to remove genomic DNA. After several washing steps, RNA was resuspended in DEPC-
treated water and stored at −80 °C until use. RNA concentration and purity (Abs260nm/Abs230nm and 
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Abs260nm/Abs280nm) were determined by ultraviolet (UV) spectrophotometry. As control, total RNA was 
also extracted from leukemia cell lines, using the same procedure. 
Total RNA extracted (100 ng) was reverse transcribed into cDNA, using the NZY M-MuLV First-
Strand cDNA Synthesis kit (Nzytech, Lisbon, Portugal). 
 
Primer design 
The following sequences were used to design all PCR primers described in this study: BCR-ABL1 
e14a2 (GenBank AJ131466.1); BCR-ABL1 e13a2 (GenBank AJ131467.1); BCR-ABL1 e1a2 (GenBank 
AF113911.1); BCR-ABL1 e6a2 (GenBank AM491362.1); BCR (GenBank NM_004327.3); ABL1 
(GenBank NM_005157.5); CEBPA (GenBank NM_004364.4); NMP1 (GenBank NM_002520.6) and 
FLT3 (GenBank NM_004119.2). 
 
BCR-ABL1 molecular analysis – Transcript identification 
Nested-PCR amplification of BCR-ABL1 from cDNA samples was performed in two separate 
setups: one that identifies the P210 isoforms of BCR-ABL1 (e14a2 or e13a2) and one that identifies 
rarer isoforms, such as the P200 (e8a2), P195 (e6a2), P190 (e1a2).44 Used primers are depicted in Table 
2.1. PCR mixture components included 1x NH4 reaction buffer (Bioline, Taunton, MA, USA), 2.5 mM 
MgCl2, 0.15x Hi-Spec additive (Bioline), 200 µM dNTPs, 400 nM primers, and 0.02 U/µL BIOTAQ 
DNA polymerase (Bioline). Outer PCR was performed using 3 µL of cDNA in a 50 µL-reaction, under 
the following conditions: initial denaturation at 95 °C for 5 min; 30 cycles of 94 °C for 30 s, 55 °C for 
30 s, 72 °C for 1 min; and a final extension step at 72 °C for 10 min. Inner PCR was performed using 1 
µL of outer PCR product in a 50 µL-reaction, under the following conditions: initial denaturation at 95 
°C for 5 min; 30 cycles of 94 °C for 15 s, 55 °C for 30 s, 72 °C for 1 min; and a final extension step at 
72 °C for 10 min. A control PCR, for the amplification of ABL1, was performed using primers also 
depicted in Table 2.1 and the same conditions described for the outer PCR.  
 
BCR-ABL1 molecular analysis – Mutational screening 
Nested-PCR amplification of BCR-ABL1 for mutation analysis was done using primers depicted in 
Table 2.2. PCR mixture components included 1x NH4 reaction buffer (Bioline, Taunton, MA, USA), 
2.5 mM MgCl2, 0.15x Hi-Spec additive (Bioline), 200 µM dNTPs, 400 nM primers, and 0.02 U/µL 
BIOTAQ DNA polymerase (Bioline). Outer PCR was performed using 3 µL of cDNA in a 50 µL-
reaction, under the following conditions: initial denaturation at 95 °C for 5 min; 30 cycles of 94 °C for 
30 s, 55 °C for 30 s, 72 °C for 1.5 min; and a final extension step at 72 °C for 10 min. Inner PCR was 
performed using 1 µL of outer PCR product in a 50 µL-reaction, under the following conditions: initial 
denaturation at 95 °C for 5 min; 30 cycles of 94 °C for 15 s, 55 °C for 30 s, 72 °C for 1 min; and a final 
extension step at 72 °C for 10 min.  
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BCR-ABL1 molecular analysis – BCR-ABL1 levels quantification 
This analysis was performed by the Hematology Department, at Hospital dos Capuchos (CHLC, 
Lisboa). Quantitative monitoring of BCR-ABL1 (P210 transcript) was performed in 200 µL 
ethylenediaminetetraacetic acid (EDTA) peripheral blood samples using the 4-module GeneXpert 
platform and Xpert BCR-ABL Monitor IS G2(V1) system (Cepheid, Sunnyvale, CA, USA), according 
to the manufacturer’s recommendations. 
 
Mutational analysis of ABL1 on patient’s genomic DNA from non-leukemic cells 
Buccal epithelial cells were collected from patient 54 (Table 2.3) by twirling a swab on the inner 
cheeks for 1 min. The swab was separated from the stick and inserted in a microtube containing 440 µL 
of lysis buffer (50 mM Tris; 1 % (m/v) SDS). The tube was vortexed for several minutes to promote 
the release of most epithelial cells. The swab was removed, 20 µL of proteinase K (100 mg/mL 
dissolved in Tris-EDTA (TE) buffer: 10 mM Tris-HCl; 0.1 mM EDTA pH 8) were mixed with the cell 
suspension and incubated for 10 min at 50 °C. After adding 40 µL of 5 M NaCl, 500 µL of isopropanol 
were gently mixed with the DNA containing solution and allowed to stand for 5 min at room 
temperature. Sample was centrifuged for 5 min at 12 000 x g, the supernatant was removed and the dry 
pellet was resuspended in 100 µL of TE buffer. DNA concentration and purity (Abs260nm/Abs230nm and 
Abs260nm/Abs280nm) were determined by UV spectrophotometry. DNA was stored at 4 °C until use. 
PCR amplification of ABL1 exon 8 of patient’s epithelial cells was performed using the following 
primers: forward 5’CTCAAATAATCCTCCCACTTCA and reverse 
5’CCTGGAATGCCCACATATAC. PCR mixture components included 1x NH4 reaction buffer 
(Bioline, Taunton, MA, USA), 2.5 mM MgCl2, 0.15x Hi-Spec additive (Bioline), 200 µM dNTPs, 400 
nM primers, 0.02 U/µL BIOTAQ DNA polymerase (Bioline) and 20 ng of gDNA. PCR conditions 
included an initial denaturation at 95 °C for 5 min; 30 cycles of 94 °C for 15 s, 55 °C for 30 s, 72 °C 
for 1 min; and a final extension step at 72 °C for 10 min.  
 
NMP1 and FLT3-ITD molecular analysis 
This analysis was performed by the Hematology Department, at Hospital dos Capuchos (CHLC, 
Lisboa). NPM1 primers were the following: NPM1-F 5´GCGCCAGTGAAGAAATCTAT; NPM1-R 
5’ACAGCCAGATATCAACTGTTAC; NPM1-Fwt 5´ATCTCTGGCAGTGGAGGAAG; NPM1-
RmtA 5´CTCCACTGCCAGACAGAGA; NPM1-RmtB 5’ACTTCCTCCACTGCCATGC. PCR 
amplification was performed as follows: initial denaturation at 95 ˚C for 15 min; 36 cycles of 94 ˚C for 
1 min, 56 ˚C for 1 min, 72 ˚C for 1 min; and a final extension step at 72 ˚C for 10 min. The amplified 
products were separated using electrophoresis in agarose gel. FLT3-ITD was performed as described 





CEBPA molecular analysis – Mutational screening 
PCR amplification of CEBPA was performed in three fragments, each one comprising a different 
domain of the encoded protein: TAD-1; TAD-2 and bZIP. PCR mixture components included 1x 
NZYLong reaction buffer (Nzytech, Lisbon, Portugal), 200 µM dNTPs, 100 nM primers and 0.05 U/µL 
NZYLong DNA polymerase (Nzytech). PCR was performed using 3 µL of cDNA in 25 µL-reactions. 
CEBPA primers for TAD-1 and TAD-2 regions were the following: CEBPA-1F 
5´TCGCCATGCCGGGAGAACTCTAAC; CEBPA-1R 5’AGCTGCTTGGCTTCATCCTCCTC; 
CEBPA-2F 5’CCGCTGGTGATCAAGCAGGA; CEBPA-2R 5’CCGGTACTCGTTGCTGTTCT. 
PCR amplification was performed as follows: initial denaturation at 95 ˚C for 5 min; 40 cycles of 95 ˚C 
for 1 min, 53 ˚C for 40 s, 68 ˚C for 1 min; and a final extension step at 68 ˚C for 10 min. The C-terminal 
bZIP coding region of the gene was amplified using primers CEBPA-3F 
5’CAAGGCCAAGAAGTCGGTGGACA and CEBPA-3R 
5’CACGGCTCGGGCAAGCCTCGAGAT, and the following conditions: initial denaturation at 95 °C 
for 10 min; 40 cycles of 95 °C for 1 min, 61 °C for 40 s, 68 °C for 1 min; and a final extension step at 
68 °C for 10 min.  
 
PCR amplification of CEBPA in non-leukemic cells genomic DNA 
The stroma of the bone marrow contains not only hematopoietic tissue, but also the yellow marrow 
that consists of all tissues that are not related to hematopoiesis. This fraction includes adipocytes, 
osteoblasts and connective fibroblasts, and are usually extracted along with hematopoietic cells during 
the bone marrow aspiration procedure. Hence, due to lack of additional samples (patient death; family 
members in the islands) and to obtain non-leukemic cells from the AML subject (patient 7; Table 2.3), 
the yellow marrow present in the aspirate of the AML subject was isolated and washed several times in 
phosphate-buffered saline (PBS) solution.  Genomic DNA was extracted from these cells using the High 
Pure PCR Template Preparation Kit from Roche (Amadora, Portugal), according to the manufacturer’s 
instructions. Briefly, 200 µL of cells diluted in PBS were mixed with 200 µL of binding buffer (6 M 
guanidine-HCL, 10 mM urea, 10 mM Tris-HCL, 20 % (v/v) Triton X-100, pH 4.4) and treated with 
proteinase K. The solution was mixed with 30 % (v/v) isopropanol, applied to a High Pure filter tube 
(polypropylene tube with two layers of glass fiber fleece), and centrifuged at 8 000 x g for 1 min. Then, 
500 µL of inhibitor removal buffer (38 % (v/v) ethanol, 5 M guanidine-HCL, 20 mM Tris-HCL, pH 
6.6) were added to the High Pure filter tube and centrifuged. After two washes (80 % (v/v) ethanol, 20 
mM NaCL, 2 mM Tris-HCL, pH 5.5) and centrifugation steps, DNA was eluted with 100 µL of 10 mM 
Tris-HCL, pH 8.5 (pre-heated at 70 °C). 
The bZIP coding region of the gene was amplified using primers CEBPA-3F and CEBPA-3R, 
described in the previous item, and the following components: 1x NZYLong reaction buffer (Nzytech, 
Lisbon, Portugal), 200 µM dNTPs, 100 nM primers, 0.05 U/µL NZYLong DNA polymerase (Nzytech) 
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and 20 ng of gDNA. PCR conditions include: initial denaturation at 95 ˚C for 10 min; 40 cycles of 95 
˚C for 15 s, 61 ˚C for 10 s, 68 ˚C for 15 s; and a final extension step at 68 ˚C for 10 min.  
 
Sequencing and sequence alignments 
PCR products were visualized via 1-2 % agarose gel electrophoresis, and subsequently analyzed by 
Sanger sequencing at STABVIDA (Caparica, Portugal). The Basic Local Alignment Search Tool 
(BLAST), from the National Center for Biotechnology Information (NCBI), was used to align all 
obtained sequences, via Sanger sequencing, with reference sequences specified in the Primer design 
segment of this section. Mutations are described according to the guidelines of the Human Genome 
Variation Society.386 
 
Bioinformatics for mutation analysis 
All novel gene mutations identified in this study were analyzed using three different softwares to 
predict their effect on the stability and structure of the encoded protein. MutationTaster predicts changes 
in the transcript splice sites, as well as alterations to protein features.387 Support Vector Machine infers 




Table 2.1 Nested-PCR primers for ABL1 and BCR-ABL1 molecular analysis of P210 and rare isoforms (P190, P195 and P200) in Ph+ hematologic 
malignancies.44  




 ABL1 – Control P210 (e14a2 or e13a2) P200 (e8a2), P195 (e6a2) or P190 (e1a2) 
Outer PCR 
For 5’ GGCCAGTAGCATCTGACTTTG 
(ABL1 exon 2) 
Rev 5’ ATGGTACCAGGAGTGTTTCTCC 
(ABL1 exon 3) 
For 5' GAAGTGTTTCAGAAGCTTCTCC 
(BCR exon 12) 
Rev 5’ GTTTGGGCTTCACACCATTCC 
(ABL1 exon 3) 
For 5' GACTGCAGCTCCAATGAGAAC 
(BCR exon 1) 
Rev 5’ GTTTGGGCTTCACACCATTC 
(ABL1 exon 3) 
Inner PCR N/A 
For 5’ CAGATGCTGACCAACTCGTGT 
(BCR exon 13) 
Rev 5’ TTCCCCATTGTGATTATAGCCTA 
(ABL1 exon 3) 
For 5’ CAGAACTCGCAACAGTCCTTC 
(BCR exon 1) 
Rev 5’ TTCCCCATTGTGATTATAGCCTA 




e14a2 - 360 bp 
e13a2 - 285 bp 
e8a2 - 1284 bp 
e6a2 - 1023 bp 
e1a2 - 381 bp 
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Table 2.2 Primers for BCR-ABL1 nested-PCR amplification and subsequent analysis of ABL1 mutational status of fusion genes encoding P210 and rare BCR-

















For, forward; Rev, reverse
 P210 (e14a2 or e13a2) P200 (e8a2), P195 (e6a2) or P190 (e1a2) 
Outer PCR 
BCR-ABL1 fusion 
For 5’ TGCTGACCAACTCGTGTGTGA     
(BCR exon 13) 
Rev 5’ CTTCGTCTGAGATACTGGATTCCT 
(ABL1 exon 9) 
For 5’ CAGAACTCGCAACAGTCCTTC 
(BCR exon 1) 
Rev 5’ CTTCGTCTGAGATACTGGATTCCT 
(ABL1 exon 9) 
Inner PCR 
ABL1 exons 4-7 
For 5’ GCAACAAGCCCACTGTCTAT 
(ABL1 exon 4) 
Rev 5’ TGTTGTAGGCCAGGCTCTC 
(ABL1 exon 7) 
Inner PCR 
ABL1 exons 7-9 
For 5’ TGAGCAGGTTGATGACAGG 
(ABL1 exon 7) 
Rev 5’ TGAGATACTGGATTCCTGGAAC 
(ABL1 exon 9) 
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2.4 Results and Discussion 
CML diagnosis, as well as disease follow-up and treatment monitoring, is routinely assessed at the 
hematologic, cytogenetic and molecular level. In the current era of highly sensitive molecular assays, 
CML clinical samples should be submitted to the following tests: RT-nested PCR to identify the specific 
isoform of BCR-ABL1; RT-qPCR to quantify transcript levels; and transcript sequencing for mutational 
screening.17 Table 2.3 summarizes the outcome for each collected sample regarding: FISH or qPCR 
analysis (information provided by Hospital dos Capuchos); transcript identification (BCR-ABL1); point 
mutations that are associated to disease relapse or a specific prognosis (BCR-ABL1 and CEBPA, in the 
context of Ph+ leukemias and cytogenetically normal AML, respectively); and ACAs.  
RT-nested PCR allows for the distinction of the two major isoforms of the gene due to their 
amplicons size difference (e14a2 vs e13a2) (Table 2.1). Other PCR set-ups have been designed that 
enable the detection of rarer isoforms, as described in Table 2.1, which was the case for samples 44 
(e6a2) and 54 (e1a2) (Table 2.3). Out of 37 CML samples (collected at diagnosis and follow-up): 20 
harbored the e14a2 variant (54 %); 11 harbored the e13a2 isoform (30 %); 3 co-expressed two different 
transcripts (8 %); and 3 follow-up samples were inconclusive (8 %). These statistics are in accordance 
with several studies that report the incidence of BCR-ABL1 transcripts over several populations. Most 
studies describe that more than half of CML patients express the e14a2 variant and that approximately 
95 % cases are associated to e14a2 and/or e13a2 BCR-ABL1 variants.32, 34,390–392 
Nested-PCR provides several advantages but the increase in the specificity of DNA amplification 
is of utmost relevance, since two sets of primers are used in two successive PCRs. Moreover, it is more 
sensitive than qPCR by 1-log due to the second PCR reaction.393,394 This is important for CML 
diagnosis, mostly for MRD detection. In fact, AML sample 16 was found to be a case of Ph+ AML 
solely after RT-nested PCR analysis. Even though RT-nested PCR is often more successful in 
specifically amplifying long DNA fragments than conventional PCR or qPCR, it requires more detailed 
knowledge of the target sequences. Indeed, a nested-PCR format was also designed to enable BCR-
ABL1 mutations screening (Table 2.2) and the outcome was compiled on table 2.3. The resulting PCR 
products were analyzed by Sanger sequencing, the gold-standard technique for gene variations 
identification and mutational burden quantification, which is highly important in the characterization of 
clonal diseases such as CML.395 
Due to the novelty of clinical cases corresponding to samples 44, 54 and 7 (Table 2.3), the next 
segments of this discussion will describe them in detail. 
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Table 2.3 Clinical samples cytogenetic and molecular characterization. 









BCR-ABL1 or CEBPA point mutations; polymorphisms; 
ACAs (mutational burden*) 
AML at diagnosis 1 BM - - - 
2 BM - - - 
3 BM - - - 
4 BM - - - 
5 BM - - - 
6 BM - - - 
7 BM - - CEBPA: c.1067A>T; p.N356I (50 %) 
8 BM - - - 
9 BM - - - 
10 BM - - - 
11 BM - - - 
12 BM - - - 
13 BM - - - 
14 BM - - - 
15 BM - - - 
16 BM - e14a2 - 
CML at diagnosis 17 BM n/a e14a2 ABL1: c.763G>A; p.E255K (100 %) 
18 BM n/a e13a2 - 
19 BM n/a e14a2 - 
20 BM n/a e14a2 ABL1: c.944C>T; p.T315I (12 %) 
21 BM n/a e13a2 ABL1: c.943A>G; p.T315A (<10 %) 
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22 BM n/a e14a2 - 
23 BM FISH = 98 % e13a2 - 
24 BM FISH = 87 % e14a2 - 
25 BM FISH = 98 % e14a2 - 
26 BM FISH = 97 % e14a2 - 
27 BM FISH = 95 % e13a2 - 
28 BM FISH = 99 % e13a2 - 
29 BM FISH = 77 % e14a2 - 
30 BM FISH = 95 % e14a2 - 
31 BM FISH = 98 % e14a2 - 
32 PB FISH = 90 % e13a2 - 
CML at follow-up 33 PB qPCR = 0.017 % - - 
34 PB qPCR = 0.34 % e14a2 - 
35 PB qPCR = 0.00031 % - - 
36 PB qPCR = 0.11 % e13a2 - 
37 PB qPCR = 1 % - - 
38 PB qPCR = 3.4 % e13a2 - 
39 PB n/a e13a2 - 
40 PB n/a e14a2 / e13a2 - 
41 PB FISH = 33 % e14a2 - 
42 PB FISH = 75 % e14a2 - 
43 PB n/a e14a2 
BCR: c.2700T>C; p.N900N (100 %) 
ABL1: c.749G>A; p.G250E (75 %)            
ABL1: c.1052T>C; p.M351T (50 %) 
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44 PB FISH = 80 % e14a2 / e6a2 
BCR: c.2700T>C; p.N900N (100 %) 
ABL1 (e14a2): c.720G>A; p.T240T (50 %)  
ABL1 (e6a2): c.720G>A; p.T240T (100 %) 
Double Ph; trisomy 8 
45 PB FISH = 6 % e14a2 ABL1: c.875A>G; p.E292G (20 %) 
46 PB n/a e14a2 - 
47 PB n/a e13a2 - 
48 PB n/a e14a2 - 
49 PB FISH = 60 % e14a2 - 
50 PB FISH = 6 % e13a2 - 
51 PB n/a e14a2 - 
52 PB qPCR = 0.34 % e14a2 / e13a2 - 
53 PB qPCR = 1.4 % e14a2 BCR: c.2700T>C; p.N900N (100 %) 
Ph+ ALL at 
diagnosis 
54 BM n/a e1a2 ABL1: c.1319A>G; p.Y440C (20 %) 
*Mutational burden was assessed via sequencing chromatogram peak relative quantification. 
ACA, additional chromosomal aberration; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CML, chronic myeloid leukemia; FISH, 
fluorescence in situ hybridization; IS, international scale; n/a; not available; PB, peripheral blood; Ph, Philadelphia chromosome; qPCR, quantitative polymerase chain reaction 
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Clinical case 44 - Double Ph+ CML patient, co-expressing P210BCR-ABL1 and P195BCR-ABL1 isoforms 
In CML, BCR-ABL1 mutational events and variations on multidrug resistance transporters are 
probably the most frequent resistance mechanism to TKIs.17 ACAs in Ph+ CML are also strongly 
associated with disease progression, however their ultimate impact on prognosis is still unclear due to 
their low frequency.367 
This report is based on a previously healthy 36 years-old man, without any relevant past diseases 
and a one-month history of fever and night sweats. On physical examination, no hepatosplenomegaly 
or lymphadenopathy were found. Hemoglobin was 12.9g/dL, white blood cell count was 58300/pL 
(90.8 % neutrophils, 1.4 % eosinophils, 0 % basophils, 6.5 % lymphocytes, 1.3 % monocytes) and 
platelet count was 507 000/pL. Bone marrow aspiration showed 1% blasts and FISH for BCR-ABL1 
was 98 % positive (Table 2.4). Cytogenetic analysis of 20 mitotic bone marrow cells showed: four 
nuclei with one Ph chromosome; seven nuclei harboring one Ph chromosome and trisomy 8; and nine 
double Ph+ nuclei and trisomy 8 (Figure 2.2).  
A diagnosis of CP-CML was made, with a Sokal score of 0.57, Hasford 58 and EUTOS 0. The 
patient initiated IM at 400 mg/day. Cytogenetic response was not achieved at three months of treatment, 
and not even after increase of the IM dose to 600 mg/day for two weeks (FISH=80 %) and 800 mg/day 
for four and half months (FISH=61 %) (Table 2.4). Due to incomplete cytogenetic response, molecular 
analysis of BCR-ABL1 was performed, which linked Ph+ cells to two different isoforms of the gene: 
P210 (e14a2) and P195 (e6a2) (Figures 2.3 and 2.4; Appendix I - Figures I.1 and I.2). Except for two 
well characterized SNPs,396–398 both transcripts exhibited no point mutations in the ABL1 domain 
(Appendix I - Figures I.3-6; Table I.1).  
Treatment was switched to bosutinib at month eight after diagnosis, with side effects requiring dose 
adjustments (grade I diarrhea, grade III elevation of liver enzymes and grade I rash). CyR was 
accomplished at month 13. Later, DMR was achieved for P210BCR-ABL1, but the patient remained 
positive at cytogenetic level (FISH = 5 %) (Table 2.4). The patient is now referred for alloSCT. 
Ph duplication is usually associated with an overexpression of BCR-ABL1 and therefore associated 
with an aggressive clinical outcome.367,368 This chromosomal aberration allied to the presence of an 
atypical short isoform of BCR-ABL1 might explain the progression of disease in the CML patient, the 
lack of cytogenetic response to IM and the need for a third-generation TKI targeting the BCR-ABL1 
protein. Indeed, shorter BCR-ABL1 transcripts were reported to induce an aggressive clinical 
phenotype due to the lack of important regulatory BCR sequences.31, 361, 365,399 
This is the first report of a patient attaining DMR for P210 and stable cytogenetic response for P195, 
under treatment with bosutinib. We conclude that this CML scenario is associated with an inferior 
outcome to therapy with first generation TKI, and that this subset of patients need to be identified as 
high-risk patients and monitored closely for efficacy during chemotherapy. 
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Table 2.4 Disease progression for clinical case 44, including TKI treatment regimen, hematologic, 
cytogenetic and molecular levels.  
*BCR-ABL1 molecular analysis linked Ph+ cells to two different variants: P210 and P195. 
CHR, complete hematologic response; CyR, cytogenetic response; FISH, fluorescence in situ hybridization; HR, 
hematologic response; IM, imatinib; MR4.5, molecular response with 4.5-log reduction from IRIS baseline (BCR-








  Diagnosis 1 % blasts; FISH t(9;22) = 98 % 
IM 400 [0 - 3] Loss of HR; No CyR 
 600 [3 - 3.5] No HR; FISH = 80 % (11 % atypical pattern) 
 800 [3.5 - 8] CHR; FISH = 61 % * 
Bosutinib 400 [8 – 8.5] CHR; FISH = 68 % 
 400 [8.5 - 11] CHR; FISH = 44 % 
 400 [11 - 13] CyR; Toxicity symptoms 
- - [13 - 15] Toxicity fully solved 
Bosutinib 300 [15 – 20] CyR; FISH = 3.8 % (0.8 % atypical pattern); MR4,5 (P210) 
 400 [20 - 21] MR4,5 (P210) 
  NOW 
FISH = 5 % (2 % atypical pattern);  




Figure 2.2 Cytogenetic analysis for clinical case 44: A) karyotype banding and B) fluorescence in situ 
hybridization (FISH) using LSI BCR/ABL1 Dual Color, Dual Fusion translocation probe (Abbott 
Molecular, Des Plaines, IL, USA). Chromosome G-banding showed: 4 nuclei 
46,XY,t(9;22)(q34.1;q11.2); 7 nuclei 47,XY,+8,t(9;22)(q34.1;q11.2) [A1, with corresponding 
interphase FISH image – B1]; 9 nuclei 48,XY,+8,t(9;22)(q34.1;q11.2), +der(22)t(9;22)(q34.1;q11.2) 
[A2, with corresponding interphase FISH image – B2]. Images were provided by the Hematology 
Department from Hospital dos Capuchos (CHLC, Lisboa).  
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Figure 2.3 ABL1 and BCR-ABL1 molecular analysis. A) Control PCR amplification of ABL1 from K562 
cells, BV173 cells and patient 44 white blood cells. B) Nested-PCR amplification of P210BCR-ABL1 
isoforms from K562 cells, BV173 cells and patient 44 white blood cells. C) Nested-PCR amplification 
of rarer BCR-ABL1 isoforms from patient 44 white blood cells. PCR products (1 µl) were resolved via 
2 % (w/v) agarose gel electrophoresis. Expected PCR amplicon sizes are specified in table 2.1. NTC – 




Figure 2.4 Sequence analysis of BCR-ABL1 from patient sample 44. A) Sanger sequencing of PCR 




Clinical case 54 – Ph+ B-ALL patient with a novel BCR-ABL1 mutation 
The outcome of patients with Ph+ ALL has greatly benefited with TKIs therapy, however the 
sensitivity to each TKI must be considered in individual cases for a successful result. In parallel to what 
is recommended for CML, Ph+ ALL patients that do not respond to IM should undergo mutational 
screening for an assessment of drug resistance mechanisms.373,376 
Here we report a 31-years old leukemia male patient. The diagnosis of B-ALL was confirmed by 
bone marrow morphology with cytochemistry staining and flow cytometry analysis. Further cytogenetic 
and molecular biology characterization was performed concluding that the patient was bearing a Ph+ 
B-ALL (Figure 2.5). The patient started chemotherapy according to the Dana Farber Cancer Institute 
consortium protocol400 with dasatinib 140 mg/day (chosen for better central nervous system 
prophylaxis), which induced clinical and hematological remission. According to protocol, at day 29 
after diagnosis and treatment initiation, bone marrow was collected for MRD evaluation, revealing a 
positive result. MRD positivity was confirmed by a second test performed four weeks later.  
Patient bone marrow at day 29 was further analyzed for TKIs resistance mutations to better 
understand the MRD response. Molecular analysis of patient’s white blood cells revealed the expression 
of P190BCR-ABL1 (Figure 2.6; Appendix II – Figure II.1), the most common isoform in Ph+ ALL. The 
subsequent mutational analysis via Sanger sequencing showed a point mutation in the ABL1 domain of 
the fusion transcript, more precisely in the region that translates for the C-terminal lobe of the kinase 
domain (Figure 2.7). Through quantification of sequencing chromatogram peaks, it is possible to 
conclude that this variation is present in 20 % of BCR-ABL1-expressing cells. This is recurrent in clonal 
hematological diseases due to the selective pressure caused by TKIs administration. In fact, the in-frame 
mutation in leukemic cells is not present in ABL1 from nonleukemic cells, indicating a somatically 
acquired mutation rather than a germline mutation. This was confirmed by the analysis of the genomic 
DNA of patient’s epithelial cells (Figure 2.7). 
The newly described BCR-ABL1 nucleotide substitution, c.1319A>G (codon TAC>TGC), results 
in the amino acid alteration p.Tyr440Cys (Figure 2.7). The substitution of a highly conserved amino 
acid across different species (Appendix II – Table II.1), and a shift between a large amino acid (tyrosine) 
into a small amino acid with a thiol side chain (cysteine), is likely to induce deviations to correct protein 
folding. To understand the possible effect of this mutation in the BCR-ABL1 structure, we probed the 
sequence through MutationTaster that predicts changes in the transcript splice sites, as well as 
alterations to protein features.387 Using Support Vector Machine and sequence information there is a 
predicted decrease in the stability of protein structure, with a confidence score of -0.898, due to the 
p.Tyr440Cys mutation.388 DISOclust software analysis also shows an increase in the disorder 
probability score in the mutated ABL1 domain, particularly in residues located after the Y440C 
mutation (Appendix II – Figure II.2).389 
Point mutations within the C-terminal lobe region of BCR-ABL1 have been described to impair the 
protein´s structure. For example, the well-studied E459K substitution makes the protein inactive 
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conformation unstable even though the amino acid position is not near the ATP/IM binding site. Since 
IM only binds to the inactive conformation of BCR-ABL1, patients harboring this mutation typically 
do not respond to the first-line TKI, but are more sensitive to bosutinib that can bind to the active 
conformation of the protein.401 Considering this information, the patient was proposed for bosutinib 
treatment and, ultimately, for bone marrow alloSCT.   
 
 
Figure 2.5 Interphase fluorescence in situ hybridization (FISH) analysis for clinical case 54, using LSI 
BCR/ABL1 Dual Color, Dual Fusion translocation probe (Abbott Molecular, Des Plaines, IL, USA).  
Image depicting a Ph+ nucleus, 46,XY,t(9;22)(q34.1;q11.2), was provided by the Hematology 
Department from Hospital dos Capuchos (CHLC, Lisboa). 
 
Figure 2.6 ABL1 and BCR-ABL1 molecular analysis of patient 54 white blood cells. A) Control PCR 
amplification of ABL1. Expected amplicon size is 296 bp (Table 2.1). B) Nested-PCR amplification of 
P190BCR-ABL1 isoform. Expected amplicon size is 381 bp (Table 2.1). PCR products (1 µl) were resolved 
via 2 % agarose gel electrophoresis. NTC – non-template control; Ladder - GeneRuler DNA Ladder 




Figure 2.7 P190BCR-ABL1 protein structure indicating the position of the detected BCR-ABL1 point 
mutation. Sequencing chromatograms displaying: A) BCR-ABL1 nucleotide sequence from Ph+ ALL 
patient 54 white blood cells. Chromatogram peak analysis indicates that the variation is present on 20 
% of total Ph+ clones; B) ABL1 nucleotide sequence from Ph+ ALL patient 54 epithelial cells; C) ABL1 
from control individual (wild-type, WT). P-loop: phosphate binding loop; IM binding: ATP/IM 
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Clinical case 7 – AML patient with a novel CEBPA mutation 
The 67-year-old male patient was referred to Hospital dos Capuchos Hematology Department with 
generalized unspecified pain and leucocytes of 100 000/mL. Bone marrow morphology showed 96 % 
blast count and, together with imunophenotyping analysis, the case was classified as AML without 
maturation (WHO 2008). G-band karyotyping was normal. FISH for t(9;22) and molecular analysis for 
NPM1 and FLT3 mutations were negative. In contrast, CEBPA sequencing exposed a new nucleotide 
substitution: c.1067A>T (codon AAC>ATC), at a 50 % mutational burden (Figure 2.8). This CEBPA 
in-frame mutation expressed by leukemic cells was not present in non-leukemic cells, indicating a 
somatically acquired mutation rather than germline (confirmed by genomic DNA analysis) (Figure 2.8).  
The detected variation, which has not been previously reported in the Human Genome Variations 
database,386 corresponds to the following alteration of amino acid in the bZIP region of the protein: 
p.Asn356Ile (Figure 2.8). This mutation alters a conserved amino acid across different species 
(Appendix III – Table III.1) and the variance in hydrophobicity between these two amino acids (N>I) 
might induce deviations to correct protein folding.  
To understand the possible effect of the variation on AML, we probed the sequence through 
MutationTaster387 and DISOclust disorder prediction software389 and both predict that this alteration 
decreases protein’s stability with high scores (0.9/1 and Appendix III – Figure III.1, respectively). Using 
Support Vector Machine and sequence information there is a predicted disruption on the structure of 
the protein with a confidence score of -0.353 due to the p.N356I mutation.388 Moreover, in frame 
mutations within the C-terminal bZIP region have been described to impair DNA binding and/or homo- 
and heterodimerization.402,403 
Despite the range of mutations in CEBPA in AML patients, this is the first report on the variation 
c.1067A>T (p.Asn356Ile). Patients that carry a mutation in the bZIP region have a tendency towards a 
CEBPA double-mutant gene expression profile causing the complete abrogation of the transcription 
factor function. These mutations are associated with decreased relapse risk as well as improved survival 
compared to patients without a mutation.381,384 
The patient started induction chemotherapy but complete response evaluation was not possible due 
to premature death by sepsis during neutropenia phase. Though mutated CEBPA is generally related 
with a favorable prognosis for cytogenetically normal AML, elevated leucocytosis at presentation is 




Figure 2.8 A) C/EBP protein main domains: transactivation domains (TADs) and a leucine zipper 
domain (bZIP) for dimerization and DNA binding. The amplified region of the CEBPA gene is also 
represented, as well as the non-synonymous mutation detected. B) Normal CEBPA nucleotide sequence 
from a control individual (wild-type, WT) showing the normal c.1067A (AAC) allele and below the 
CEBPA mutation in the AML patient (clinical case 7): c.1067A>T [a substitution of AAC (Asn) to ATC 
(Ile)]. Chromatogram peak analysis is indicative of a heterozygous state with a mutant allele burden of 
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2.5 Concluding Remarks 
These findings demonstrate the importance of BCR-ABL1 transcript identification and mutational 
screening in Ph+ leukemia patients at the time of diagnosis and in follow-up samples, particularly in 
individuals that do not respond to treatment or do not achieve complete remission. This is also valid for 
CEBPA mutations analysis in AML, which proved to require further optimization due to some 
drawbacks previously experienced by other groups, namely, difficulty in amplification and sequencing 
of the gene due to the presence of non-specific PCR products.380 Other techniques should be envisaged 
to perform CEBPA analysis, which will be explored in chapter 6 (Future perspectives section). 
Note that chapter 2 pinpoints some of the downsides of the conventional methodology for BCR-
ABL1 screening: time-consuming, complex and expensive. Thus, a complete molecular analysis of 
leukemia samples enables the ensuing part of this study, which aims to develop a new, fast, simple and 
cost-effective method for the detection of BCR-ABL1 on clinical samples. The robustness of the new 
method using Au-nanoprobes will be assessed in chapter 3 and compared to gold-standard procedures 



































CHAPTER 3 – DETECTION OF BCR-ABL1 TRANSCRIPTS IN CLINICAL SAMPLES 
VIA GOLD NANOPROBES 
 
Clinical samples and all information on cytogenetic levels and BCR-ABL1 gene quantification were 
kindly provided by Hospital dos Capuchos (Centro Hospitalar de Lisboa Central, CHLC, Lisbon). R. 
Vinhas performed all experiments related to BCR-ABL1 transcript identification, nanoparticles 
characterization, gold-nanoprobe colorimetric assay optimization and validation, as well as data 
analysis, at the Research Unit on Applied Molecular Biosciences (UCIBIO, Universidade Nova de 
Lisboa), under the supervision of P.V. Baptista and A.R. Fernandes. The author of this thesis opted for 
reproduction of the resulting scientific paper, thus apologizing for any repeated content in different 
contexts of the document. 
 
Vinhas R, Correia C, Ribeiro P, Lourenço A, Sousa AB, Fernandes AR, Baptista PV. 2016. 
Colorimetric assessment of BCR-ABL1 transcripts in clinical samples via gold nanoprobes. Analytical 
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3.1 Abstract 
AuNPs functionalized with thiolated oligonucleotides (Au-nanoprobes) have been used in a range 
of applications for the detection of bioanalytes of interest, from ions to proteins and DNA targets. These 
detection strategies are based on the unique optical properties of AuNPs, in particular, the intense color 
that is subject to modulation by modification of the medium dielectric. Au-nanoprobes have been 
applied for the detection and characterization of specific DNA sequences of interest, namely pathogens 
and disease biomarkers. Nevertheless, despite its relevance, only a few reports exist on the detection of 
RNA targets. Among these strategies, the colorimetric detection of DNA has been proven to work for 
several different targets in controlled samples but demonstration in real clinical bioanalysis has been 
elusive.  
Here, we used a colorimetric method based on Au-nanoprobes for the direct detection of the e14a2 
BCR-ABL1 fusion transcript in myeloid leukemia patient samples without the need for 
retrotranscription. Au-nanoprobes directly assessed total RNA from 38 clinical samples, and results 
were validated against RT-nested PCR and RT-qPCR. The colorimetric Au-nanoprobe assay is a simple 
yet reliable strategy to scrutinize myeloid leukemia patients at diagnosis and evaluate progression, with 
obvious advantages in terms of time and cost, particularly in low- to medium income countries where 
molecular screening is not routinely feasible. 
 
3.2 Introduction 
Au-nanoprobes, due to their unique optical proprieties, have been widely used for nucleic acid 
detection with high sensibility and sensitivity at much lower costs when compared with conventional 
molecular methods. Disperse Au-nanoprobe solutions show a characteristic SPR band at around 525 
nm (red color), which is red-shifted upon salt-induced aggregation (blue color); hybridization to a 
complementary nucleic acid target sequence prevents aggregation and the solution remains red.206 This 
non-cross-linking colorimetric detection method has been efficiently applied to the detection of 
pathogens and other DNA sequences of interest, where hybridization to a specific complementary target 
leads to Au-nanoprobe stabilization and resistance to salt-induced aggregation.123,164 
As mentioned earlier, CML is a clonal bone marrow stem cell disease with an annual incidence of 
1–2 new cases per 100 000 adults and accounting for approximately 15 % of leukemia cases. CML is 
one of the rarest forms of leukemia, which is expected to become the most prevalent hematologic 
malignancy in the world by 2020.37,404,405 For the past decades, management of CML therapy with TKIs 
has been successfully achieved.406–408 The Ph chromosome, a reciprocal translocation of the long arms 
of chromosomes 9 and 22, t(9;22), is found in more than 90 % patients with CML, 15–25 % of patients 
with acute lymphoblastic leukemia (ALL), and 1 % of newly diagnosed adults with acute myeloid 
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leukemia (AML).23,354,355 This translocation transposes the ABL1 oncogene from chromosome 9q34 to 
the BCR gene on chromosome 22q11 (Figure 3.1).28,30 
This reciprocal translocation during hematopoiesis combined with alternative splicing events may 
originate at least eight different reported BCR-ABL1 transcripts, all encoding proteins with high tyrosine 
kinase activity. The vast majority of patients with CML (∼95 %) express either e13a2 or e14a2 mRNAs 
that result from a rearrangement of the major breakpoint cluster regions (M-BCR) generating 210-kDa 
fusion proteins (Figure 3.1C). Several studies suggest that not only qualitative differences in the type 
of BCR-ABL1 proteins expressed but also quantitative variations in their total level within the cells 
may have an important role in determining CML phenotype.33–35, 358,409 The fused BCR-ABL1 gene and 
its gene products provide specific markers for diagnosis and disease monitoring. Currently, CML 
diagnosis is primarily based on clinical symptoms, complete blood count, and bone marrow biopsy. 
Cytogenetic analysis, such as karyotype and fluorescence in situ hybridization (FISH), may be carried 
out to check the presence of the Ph chromosome, and molecular tests, e.g., RT-PCR and RT-qPCR, are 
used for assessing type and levels of fusion transcript on RNA from bone marrow or peripheral blood 
specimen.39,410 Monitoring CML by RT-qPCR and RT-nested PCR depends on local facilities and on 
the degree of molecular standardization of the local laboratory.110,411,412  
Based on their size-dependent SPR absorption and the high surface-to-volume ratio allowing for 
surface functionalization with a variety of molecules, AuNPs are frequently used as probes in biological 
detections.164,206 Baptista and colleagues developed a proof-of-concept colorimetric Au-nanoprobe 
method for direct detection and quantification of a BCR-ABL1 e14a2 fusion suitable for identification 
of BCR-ABL1 targets in lab-controlled conditions.123 Contrary to the existing molecular tools for the 
diagnostics of CML, the Au-nanoprobe methodology requires neither retrotranscription of the sample 
RNA into cDNA nor its amplification in a nested-PCR format with extreme complexity. Despite several 
reports on the use of BCR-ABL1 target as proof-of-concept for nanotechnology-based detection, the use 
of NPs for CML diagnostics in clinical samples has never been performed before.  
Here, we were able to directly screen RNA extracted from blood or bone marrow samples from 
patients admitted to the clinics for CML or AML via the Au-nanoprobe assay and validated results 
against the gold standard, RT-nested PCR and qPCR, without loss of information. 
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Figure 3.1 Genetics of CML. A) Chromosomes reciprocal translocation that originates the BCR-ABL1 
oncogene during hematopoiesis. B) Structure of BCR and ABL1 genes. C) Structure of the two most 
common BCR-ABL1 fusion transcripts (e14a2 and e13a2) and a rare one (e1a2). e14a2 and e13a2 
isoforms encode 210 kDa fusion proteins, and the e1a2 isoform encodes a 190-kDa protein. D) Au-
nanoprobe designed to target e14a2 mRNA. 
 
 
3.3 Material and Methods 
Clinical samples and control cell lines characterization 
Cytogenetic and/or molecular characterization of samples was performed has described in the 
Materials and Methods section of chapter 2, including the following steps: patients informed consent 
and clinical samples; cytogenetic analysis; cell culture of leukemia cell lines; total RNA extraction and 
cDNA synthesis; BCR-ABL1 molecular analysis. 
 
Au-nanoprobe synthesis 
The probe sequence and the complementary target derive from the BCR-ABL1 e14a2 (also known 
as b3a2) chimeric protein mRNA. This target was selected because it represents the most frequent 
breakpoint in CML, accounting for 55 % of cases.17,34 Probe selectivity was assessed against two other 
BCR-ABL1 breakpoint regions: e13a2 and e1a2. Control oligonucleotide target sequences included 
BCR, ABL1, and an unrelated target (Table 3.1). 
Au-nanoprobe design and synthesis were performed as previously described.123 In brief, 14-nm 
AuNPs were prepared by the citrate reduction method and functionalized with the respective thiolated 
80 
 
oligonucleotide in an aqueous solution of AuNPs at a 1:150 (AuNP:oligonucleotide) ratio for 16 h. 
After centrifugation (20 min at 14 500 x g), the oily precipitate was washed with 10 mM phosphate 
buffer (pH 8.0), 0.1 M NaCl, centrifuged, and resuspended in the same buffer. The resulting Au-
nanoprobes were stored in the dark at 4 °C. 
Characterization of AuNPs and Au-nanoprobes was performed through Transmission Electron 
Microscopy (TEM), Dynamic Light Scattering (DLS) and UV-Vis spectroscopy. 
 
 
Table 3.1 Oligonucleotide probe and synthetic oligonucleotide targets 
Oligonucleotides Sequence (5’-3’) 
Target sequence 
GeneBank Acc. No. 
e14a2 probe Thiol-CGCTGAAGGGCTTTTGAACT AJ131466.1 
























NC - Non-complementary target 
 
 
Colorimetric detection with Au-nanoprobes 
The Au-nanoprobe assay was performed in a total volume of 30 μL containing the Au-nanoprobe 
at a final concentration of 2.5 nM and the appropriate targets at a final concentration of 0.33 μM in 10 
mM phosphate buffer (pH 8.0). A blank was made in the same conditions but replacing target or total 
RNA by an equivalent volume of 10 mM phosphate buffer (pH 8.0). Following 5 min of denaturation 
at 95 °C, the mixtures were cooled down to 25 °C and 80 mM MgCl2 added for color revelation. 
Absorption spectra were run in a Tecan Infinite® M200 microplate reader (Männedorf, Switzerland).  




 (Equation 3.1) 
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Au-nanoprobe aggregation is portrayed by the natural logarithm of rAbs: a value of 0 for the ln (rAbs) 
is considered as the threshold for distinction between non-aggregated [ln (rAbs)≥ 0] and aggregated [ln 
(rAbs)<0] Au-nanoprobe, corresponding to a positive and a negative sample, respectively. The accuracy 
of the Au-nanoprobe assay was assessed calculating positive and negative predictive values (PPV and 
NPV, respectively), by comparison to the gold-standard methodology, RT-PCR. These proportions 
determine the positive results that are true positive hits (PPV) and true negatives (NPV): 
PPV = 
Number of positives (gold standard)




Number of negatives (goldstandard)




A one-way analysis of variance (ANOVA) and a post hoc Tukey’s test were carried and mean 
differences (P value <0.001) between groups determined with a confidence interval (CI) of 99 %. 
 
3.4 Results and Discussion 
Au-nanoprobe characterization 
Characterization of the synthesized citrate-capped AuNPs and the Au-nanoprobe was assessed by 
TEM imaging, DLS measurements, and UV-Vis spectroscopy (Table 3.2). Integration of the 
information provided by these three techniques allows for a thorough characterization of NPs, namely 
size, distribution and morphology. This information is required by the Nanotechnology Characterization 
Laboratory for the standardization of nanomaterials intended for diagnostics or therapeutics. 
TEM delivers quantitative measures of AuNPs physical size and morphology but only considers 
the inorganic core of the NP for size determination.413 TEM measurements determined that the citrate-
capped AuNPs used in this study present an average diameter of 14 nm (Table 3.2).  
DLS enables the determination of the overall mean size of the particle considering the NPs 
inorganic core and the organic coating layer. Moreover, DLS is highly influenced by the presence of 
small populations of large particles or groups of smaller particles, which can be translated into a greater 
overall NP size.414 Indeed, hydrodynamic diameter of AuNPs and the Au-nanoprobe was determined to 
be 20.2 nm and 28.8 nm, respectively (Table 3.2).  
UV-Vis spectra can also be used to infer NPs size, by calculating the ratio of the absorbance of 
AuNPs at the surface plasma resonance peak (Aspr) to the absorbance at 450 nm (A450).415 Moreover, a 
characteristic red-shift from 519 (AuNP) to 524 nm (Au-nanoprobe) clearly indicates an increase in the 





Table 3.2 AuNPs and Au-nanoprobe characterization through Transmission Electron Microscopy 
(TEM), Dynamic Light Scattering (DLS) and ultraviolet-visible (UV-Vis) spectroscopy. 
















Molecular diagnostics of CML usually involves the detection of the BCR-ABL1 e14a2 fusion 
transcript. First, we calibrated the Au-nanoprobe to selectively identify this fusion transcript using 
synthetic oligonucleotides as targets for hybridization. Figure 3.2 shows that the Au-nanoprobe was 
able to discriminate between the fully complementary target and two other BCR-ABL1 fusion transcripts 
that share the same ABL1 region as the e14a2 transcript (e13a2 and e1a2) at 100 fmol/μl of ssDNA 
oligonucleotide. One can observe the selectivity of the Au-nanoprobe towards the e14a2 transcript, as 
the values for BCR, ABL1, and non-complementary targets are below the defined threshold. 
Total RNA extracted from K562 (harboring the target e14a2 fusion transcript), BV173 (harboring 
the e13a2 fusion transcript), or HL60 (promyelocytic leukemia cell line without fusion transcript) was 
used to calibrate the assay for complex sample mixtures. The Au-nanoprobe was able to recognize the 
e14a2 sequence present in K562 cells, with identical specificity as that attained for synthetic 
oligonucleotides (Figure 3.3).  
RNA extracted from HL60 and BV173 cell lines was scored as negative despite the presence of 
partially complementary targets: BCR, ABL1, and e13a2 mRNA (Figure 3.3B). The obtained value is 
clearly below the established threshold indicating that the system is capable to selectively detect only 
the correct target sequence even in presence of similar sequences with more than 50 % homology to the 
target. The colorimetric data is in clear agreement with that of the gold standard, RT-PCR.38,44 A limit 
of detection (LOD) of 15 ng/μl is ideal and critical for optimal performance and sequence discrimination 
directly from RNA samples. 
50 nm 
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Figure 3.2 Au-nanoprobe detection of the e14a2 BCR-ABL1 transcript variant. A) Visible spectra 
before salt addition (Probe, red); after the addition of salt in absence of any target (blank, blue), presence 
of the e14a2 (green) or e13a2 (purple) BCR-ABL1 synthetic oligonucleotides. B) Specificity of the Au-
nanoprobe towards different synthetic oligonucleotides. A threshold of 0 for Au-nanoprobe aggregation 
[ln (rAbs)] was considered for discrimination between positive and negative detection. The error bars 
represent the standard error of the mean from three independent assays. *Statistically significant 







Figure 3.3 Au-nanoprobe detection of the e14a2 BCR-ABL1 transcript variant in total RNA samples. 
RNA was extracted from cell lines (HL60, K562, and BV173). A) Agarose (2 %) gel electrophoresis 
showing nested-PCR products using standardized primers for the detection of the e14a2 (360 bp) and 
e13a2 (285 bp) transcripts. First lane is DNA ladder (GeneRuler, Fermentas). B) e14a2 Au-nanoprobe 
detection assay. A threshold of 0 for Au-nanoprobe aggregation [ln (rAbs)] was considered for 
discrimination between positive and negative detection. The error bars represent the standard error of 
the mean from at least three independent assays. *Statistically significant difference with P value 
<0.001, in comparison to HL60 or BV173 samples (post hoc Tukey’s test) 
 
 
Au-nanoprobe assay for CML diagnostics 
Following calibration of the Au-nanoprobe assay, 38 myeloid leukemia samples (16 AML sample 
and 22 CML samples), previously characterized at the cell and molecular levels, were blindly tested via 
the Au-nanoprobe approach and compared to RT-nested PCR. From the attained data, we determined 
the sensitivity, specificity, and positive and negative predictive values (PPV and NPV, respectively) for 
the Au-nanoprobe assay (Figure 3.4; Table 3.3). 
Samples were scored negative for e14a2 based on ln(rAbs)<0. Twelve clinical samples were 
correctly scored as positive for the e14a2 transcript and the remaining scored as negative. Even though 
all AML bone marrow samples were found negative for t(9;22) by FISH analysis, the Au-nanoprobe 
method was sensitive enough to detect one AML sample harboring the e14a2 fusion transcript, 
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confirmed by RT-nested PCR (sample 16). Moreover, the Au-nanoprobe procedure allowed to 
scrutinize peripheral blood follow-up samples expressing the e14a2 transcript. Sample 34, previously 
determined to express BCR-ABL1 levels of 0.34 % IS, was correctly scored as positive. According to 
the 2015 ELN guidelines, these levels define a CCyR.38 
Care should be taken when borderline values are obtained, as seen in samples 28 and 38, to avoid 
the occurrence of false positives. However, results based on ln(rAbs) are in accordance with RT-nested 
PCR results. PPV (12 true positive hits out of 12 positive calls) and NPV (26 true negative hits out of 
26 negative calls) of 100 % indicate that the Au-nanoprobe assay under these conditions is a reliable 










Figure 3.4 Au-nanoprobe detection of the e14a2 BCR-ABL1 transcript variant in total RNA clinical samples. RNA extracted from bone marrow or peripheral 
blood samples from patients previously diagnosed with AML (1–16) or CML (17–38). A) Agarose (2 %) gel electrophoresis showing nested-PCR products 
using standardized primers for the detection of the e14a2 (360 bp) and e13a2 (285 bp) transcripts. Lanes L refer to DNA ladder (GeneRuler, Fermentas - 
ThermoFisher, Waltham, MA, USA): 200, 300, 400, and 500 bp (from bottom to top). B) e14a2 Au-nanoprobe assay. A threshold of 0 for Au-nanoprobe 
aggregation [ln (rAbs)] was considered for discrimination between positive and negative detection. The error bars represent the standard error of the mean from 
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Table 3.3 Performance of Au-nanoprobe diagnostic test. 
 






AML       
at 
diagnostics 
1 BM n/a No amp - 
2 BM n/a No amp - 
3 BM n/a No amp - 
4 BM n/a No amp - 
5 BM n/a No amp - 
6 BM n/a No amp - 
7 BM n/a No amp - 
8 BM n/a No amp - 
9 BM n/a No amp - 
10 BM n/a No amp - 
11 BM n/a No amp - 
12 BM n/a No amp - 
13 BM n/a No amp - 
14 BM n/a No amp - 
15 BM n/a No amp - 




17 BM n/a e14a2 + 
18 BM n/a e13a2 - 
19 BM n/a e14a2 + 
20 BM n/a e14a2 + 
21 BM n/a e13a2 - 
22 BM n/a e14a2 + 
23 BM 98 % e13a2 - 
24 BM 87 % e14a2 + 
25 BM 98 % e14a2 + 
26 BM 97 % e14a2 + 
27 BM 95 % e13a2 - 
28 BM 99 % e13a2 - 
29 BM 77 % e14a2 + 
30 BM 95 % e14a2 + 
31 BM 98 % e14a2 + 




33 PB 0.017 % No amp - 
34 PB 0.34 % e14a2 + 
35 PB 0.00031 % No amp - 
36 PB 0.11 % e13a2 - 
37 PB 1 % No amp - 
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38 PB 3.4 % e13a2 - 
* FISH analysis for diagnostic samples (1-32) and RT-qPCR analysis for follow-up samples (33-38) 
BM, bone marrow; IS, international scale; n/a, not available; No amp, no amplification; PB, peripheral blood 
 
 
3.5 Concluding Remarks 
The rapid and fast molecular characterization of CML patients is of utmost relevance if suitable 
therapy is to be initiated. Routine molecular diagnostics requires cumbersome equipment and 
specialized technicians to evaluate the presence of the characteristic BCR-ABL1 fusion transcripts that 
constitute the hallmark of this disease. Here, we demonstrated for the first time that the Au-nanoprobe 
system based on the NCL mechanism may be used to rapidly identify e14a2-positive patients (Figure 
3.5). Besides being able to detect a clinical sample with a BCR-ABL1 fusion transcript, this approach 
allowed to discriminate between the two most frequent isoforms of this genetic abnormality - e13a2 
and e14a2 - that alone account for more than 95 % of CML cases. The attained PPV and NPV indicate 
that the Au-nanoprobe assay is suitable for the direct screening of patients’ mRNA with obvious 
advantages in terms of time. It should be noted that the Au-nanoprobe assay detects the fusion transcript 
directly from RNA extracted from patient samples and, thus, is free from the stochastic bias introduced 
by the standard methodologies involving enzymatic retrotranscription into cDNA followed by PCR. 
Because it avoids these reaction steps, the Au-nanoprobe approach is much faster and simple, reducing 
the detection time frame from 9 h, required for RT-nested PCR alone, to 1 h and 30 min. 
Diagnostic confirmation of myeloid leukemia patients where the Ph chromosome is undetectable 
by chromosome banding analysis or FISH is a major concern. Results achieved with an e14a2 
expressing AML sample (negative for t(9;22) negative by cytogenetic analysis) and with follow-up 
samples with BCR-ABL1 levels as low as 0.34 % IS indicate the Au-nanoprobe methodology is suitable 
for screening patients that exhibit a CCyR but still did not achieve a MMR. Note that ELN recommends 
the assessment and monitoring of the disease by RT-qPCR on buffy coat blood cells every 3 months, 
not only after a CCyR has been achieved but also from the beginning.38 The Au-nanoprobe methodology 
would be highly advantageous in these consecutive tests due to its simplicity and low cost. The assay 
performance suggests that it might be useful for a combined diagnostics strategy: early screening via 
the Au-nanoprobes for POC to quickly identify CML samples, followed by standard protocol on 
negative samples. 
The possibility of fast and cheap screening technology based on RNA samples at admission is 
clearly advantageous. This is particularly relevant for countries where the economic burden of 
molecular diagnostics of rare diseases is way too high to allow routine testing via proposed guidelines. 
Considerable time would be saved from the time of admission to the start of therapy, which in turn 
would impact on therapy success with advantages for patients. 
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The overall cost of the Au-nanoprobe assay is approximately €0.20-1.00 per sample without the 
need of dedicated instrumentation. This is particularly relevant considering that the percentage of newly 
reported cases of CML occurring in low- to middle-income countries has more than tripled over the 
past 40 years and that only about 5 % of the global resources spent on cancer are deployed in these 
countries.101 CML is one of the commonest adult leukemia in Indian population accounting for 30 to 60 
% of all adult leukemia, yet little is known about the epidemiology of CML in such regions mostly due 
to poor registries, lack of conclusive molecular diagnosis, and the prohibitive cost of CML molecular 
characterization.416,417 Indeed, the first molecular test to measure BCR-ABL1 in sub-Saharan Africa was 
performed in 2011 in Ethiopia.418 The availability of rapid and cost-effective tests should result in 
reducing the rate of misclassifications for leukemia and will likely improve CML incidence and 
mortality rates in low- to medium-income countries. 
Moreover, the Au-nanoprobe colorimetric assay is highly translatable onto POC devices providing 
a novel platform for health diagnostics, as well as low-cost testing based on rapid low-volume sample 
analysis.169, 220,221,419 This possibility will be further explored in the next chapter of this thesis, by 
miniaturizing the assay and integrating microfluidics and NPs to enable CML diagnostics at both 











Figure 3.5 CML colorimetric detection via Au-nanoprobe assay. First, total RNA is extracted from 
bone marrow, or peripheral blood, samples. RNA solution is mixed with the Au-nanoprobe, designed 
to detect only the e14a2 BCR-ABL1 fusion transcript. Hybridization to a complementary nucleic acid 
target sequence prevents salt induced aggregation and the solution remains red (surface plasmon 
resonance (SPR) band at 525 nm). In the absence of the e14a2 transcript, and even in the presence of 
partially complementary targets (BCR and ABL1), Au-nanoprobes salt induced aggregation occurs and 























CHAPTER 4 – MICROFLUIDIC CHIP FOR GOLD NANOPROBE-BASED BCR-ABL1 
RNA DETECTION  
 
All microfluidic fabrication, setups and experiments were performed at the Center of Excellence in 
Microelectronics Optoelectronics and Processes (CEMOP, Universidade Nova de Lisboa). R. Vinhas 
assisted with the experiments, prepared and calibrated the Au-nanoprobe and all biological samples, 
performed the hybridization step before injection into the chip, and helped with data analysis, at the 
Research Unit on Applied Molecular Biosciences (UCIBIO, Universidade Nova de Lisboa), under the 
supervision of P.V. Baptista and A.R. Fernandes. The author of this thesis opted for reproduction of the 
resulting scientific paper, thus apologizing for any repeated content in different contexts of the 
document.  
 
Alves PU, Vinhas R, Fernandes AR, Birol SZ, Trabzon L, Bernacka-Wojcik I, Igreja R, Lopes P, 
Baptista PV, Águas H, Fortunato E, Martins R. 2018. Multifunctional microfluidic chip for optical 
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4.1 Abstract 
Many diseases have their treatment options narrowed and end up being fatal if detected during later 
stages. Therefore, POC devices have an increasing importance for routine screening applications in the 
health sector due to their portability, compactness, fast analyses and decreased costs. A multifunctional 
sensor, which uses Au-nanoprobes to perform RNA optical detection inside a microfluidic chip, was 
developed and tested. To prove the concept, this device was used for CML, a hemato-oncology disease 
that can be better treated in its early stages and is lacking routine fast screening tests. The chip passively 
mixed target RNA from samples, Au-nanoprobes and saline solution to infer a result from their final 
colorimetric properties. An optical fiber network was used to evaluate its transmitted spectra inside the 
chip. Trials provided accurate output results within 3 minutes, yielding signal-to-noise ratios up to 9 
dB. When compared to actual state-of-art screening techniques, these results were, at microscale, at 
least 10 times faster than the reported detection methods for CML. Concerning miniaturized POC 




NP-based bioanalyte detection has been at the forefront of miniaturized systems for molecular 
diagnostics at POC. In particular, AuNPs have been revolutionizing the molecular field of optical 
analysis due to their good stability, visible color change between aggregate and non-aggregate state, 
and affinity with biomolecules.164, 188, 206,420 The first reports on molecular detection of DNA based on 
the cross-linking of AuNPs with color change have paved the way for several different approaches to 
circumvent limitations associated to current PCR based methods.187 Baptista et al developed a NCL 
colorimetric method based on the differential aggregation of oligonucleotide functionalized AuNPs, 
and hence applied it to the detection of DNA (pathogens, human genomic, etc.). More interestingly, this 
system has also been used for the detection of RNA since it enables screening and characterization of 
transcripts, allowing gene expression studies and genetic disease studies.123,421 Several of these systems 
have been further incorporated into microfluidics platforms for enhanced detection capabilities.220, 
419,422–425  
Microfluidic technology provides the means for miniaturization of chemical and biochemical 
analysis that may easily be made portable.426,427 They bring several advantages when compared to 
standard apparatus, such as the significant decrease in volumes of reagents and samples, faster operation 
and reaction times, decreased analysis time and decreased costs.428,429 These characteristics can be 
synergistically and simultaneously combined on microfluidic platforms,430,431 making this type of  
devices promising for research purposes,432 for high value applications in the medical and 
pharmaceutical industries,433 and ideal for POC testing.434 Optics is an effective mean for signal 
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transduction that can be paired with microfluidics to design highly compact and integrated devices.435 
Recent studies, which use different types of NPs to either provide or enhance optical output signals, 
have reported significant progress towards POC applications.436,437 Lately, microfluidics has also 
burgeoned into paper-based biosensors,438 as they provide extremely cheap cellulosic material, 
compatible with many chemical/biochemical/medical applications and allow the transportation of 
liquids without external forces due to capillary forces.439,440 However, this technology still faces some 
limitations,441 such as the sample retention within channels and sample evaporation during transport, 
which result in low efficiency of sample-delivery inside the device (usually less than 50 %). The LOD 
on paper microfluidics is also poorer when compared to conventional microfluidics due to its incapacity 
of analyzing samples at low concentrations.441 Due to these constrains, and despite requiring more 
expensive equipment, conventional microfluidics is chosen regularly for POC applications.442 
This work describes in detail a novel and low-cost conventional PDMS microfluidic chip which 
combines a short-path length micromixer and an optical circuit to perform colorimetric detection 
(Figure 4.1). To demonstrate the impact of this microfluidic chip for molecular diagnostics, the Au-
nanoprobe assay was applied in the detection of BCR-ABL1 fusion transcript (RNA), which is the 
molecular hallmark of CML. 
CML is originated from the Ph chromosome - a reciprocal translocation of the long arms of 
chromosomes 9 and 22, t(9;22). This aberrant chromosome is found in 95 % patients with CML, 15–25 
% of patients with ALL and 1 % of newly diagnosed adults with AML.23,354,355 The Ph chromosome 
results from the fusion of two genes, BCR and ABL1. This fused gene leads to the transcription of the 
fused protein tyrosine kinase, which is constitutively active. Although several transcript isoforms have 
been reported, for the purpose of this study the Au-nanoprobe was designed towards the most frequent 
variant, e14a2, accounting for about 55 % of CML patients.17, 29,30,34 The high treatment success rate of 
the disease relies not only on drug efficacy, but also on fast, accurate and early diagnostic tools.38 Due 
to the scarcity of such tools, intense research has been devoted to the development of new 
methodologies for CML screening and management.  
Following design, fabrication and characterization of the chip, three case studies with increasing 
complexity were performed and analyzed: one, where Au-nanoprobes were used with and without salt, 
for proof of concept; a second, where BCR-ABL1 synthetic oligonucleotides were combined with Au-
nanoprobes to evaluate the mixing and cross-linking behavior under mixing and optical detection inside 
the microchannel; and a third, where the system performance was assessed using total RNA extracted 
from a CML cell line, thus mimicking real clinical sample screening. 
Results obtained this way were faster than the standard laboratory operation process at 
macroscale421 and unprecedented at microscale. They are suitable for the fast screenings required in 
medical care and POC, and key to unlock new and more complex versions of optical based genosensors, 
either to diagnose CML or other similar diseases. 
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Figure 4.1 Concept of this lab-on-chip as a point-of-care application: i) White cells extracted from a 
small blood sample are collected to analyze gene expression; ii) This approach aims to diagnose chronic 
myeloid leukemia using its genetic marker, BCR-ABL1 fusion transcript; iii) Total RNA extracted from 
white blood cells is then mixed with Au-nanoprobes and heated to promote hybridization. Note that Au-
nanoprobes are functionalized with BCR-ABL1 complementary sequences; iv) The resulting solution 
and a salt solution are infused on the two microfluidic chip inlets; v) Thorough mixing and optical 
detection of these components is performed inside the microfluidic chip. If the patient expresses BCR-
ABL1 transcripts complementary to the oligonucleotide sequence of Au-nanoprobes, their hybridization 
will cause the final solution to remain red (positive match) in the presence of salt. Otherwise, the non-
hybridized Au-nanoprobes will aggregate and cause the final solution to turn blue (negative match) in 
the presence of salt. With the appropriate setup, and using LabView software, output results described 




4.3 Material and Methods 
Materials 
All chemicals were of molecular biology grade and purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Ultrapure water used in these processes came from a Millipore water purification system (Merck 
Millipore, Billerica, MA, USA). Oligonucleotides were provided by STABVIDA (Caparica, Portugal). 
SU-8 2050 photoresist, propylene glycolmethyl ether acetate developer (PGMEA) and customized 
masks, used during the lithography process of the microchip fabrication, were obtained from 
Microchem (Westborough, MA, USA) and JDPhoto (Herts, UK), respectively. Epoxy resin ES562, 
used as a master mold for PDMS soft lithography, was ordered from Permabond (Winchester, UK). For 
the PDMS microchips fabrication, a Sylgard 184 Silicone Elastomer Kit was used (DowCorning, 
Barcelona, Spain). To improve separation between the PDMS and SU-8 mold, a silanization step was 
performed onto the SU-8 mold using tridecafluoro-1,1,2,2-tetrahydrooctyl trichlorosilane (Microchem). 
Microfluidic connections between chip and reservoirs were made using an optimized Teflon tubing kit, 
ordered from Elveflow (Paris, France). 
 
Fabrication of the microfluidic chip 
Microfluidic chips here presented followed standard fabrication steps.443 A mask with the chip's 
pattern was designed in AutoCAD 2014. This mask was then printed on sodalime glass using chrome 
as ink for a precise definition. The first mold, on SU-8, was patterned by UV photolithography. SU-8 
was spin-coated on silicon wafers at 1400 rpm (Karl Suss CT62, Suss MicroTec, Munich, Germany) to 
form a layer with approximately 125 μm, soft baked on a levelled hotplate at 65 ºC during 5 min, 
followed by 25 min at 95 ºC, then left for relaxation and cool down for 10 min. Afterwards, they were 
exposed on a mask aligner (MA6, SussMicroTec, Germany) for 18 s with an exposure dose of 310 
mJ/cm2. The designed photolithographic mask was used in this step, together with an i-line filter to 
expose with the recommended wavelength of 365 nm. A post-bake took place for a duration of 5 min 
at 65 ºC, followed by 11 min at 95 ºC. The samples were then submerged to develop in PGMEA for 
approximately 12 min. A magnetic agitation at 500 rpm was used to enhance this process. In the end, 
samples were rinsed with isopropanol, and dried with compressed nitrogen. 
A replica from the SU-8 mold was made using epoxy resin, which presents higher durability without 
losing the definition required to fabricate several chips. The SU-8 mold was first silanized in a vacuum 
desiccator to facilitate the posterior removal of PDMS. PDMS was prepared by mixing base and curing 
agents in a 10:1 weight proportion, stirred, degassed in a vacuum desiccator and poured over the SU-8 
mold for the curing process in a levelled oven for 4 h at 65 ºC. The PDMS slab fabricated in this process, 
with the complementary pattern, was subsequently peeled off from the SU-8 mold and placed on top of 
a Petri dish with features faced up. On top of the PDMS slab, epoxy resin was poured until a layer of 
approximately 2 mm in thickness was formed. Another degassing step took place in the vacuum 
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desiccator to remove bubbles trapped in epoxy. To finish this process, epoxy was cured in the levelled 
oven at 120 ºC for 1 h and peeled from the PDMS. The resulting epoxy mold was then used for soft 
lithography fabrication of the PDMS chips. This procedure took the same steps as those described above 
for the PDMS slab.  
For the inlets and outlet, PDMS chips were punched using a razor sharp stainless-steel biopsy 
puncher with 1.25 mm outer diameter. The chips were irreversibly bonded to glass slides, using oxygen 
plasma for 70 s at 98 mTorr with an applied power of 100 W on a Trion Minilock Phantom III RIE 
(TrionTech, Clearwater, FL, USA). To complete the plasma sealing, PDMS chips already bonded to 
glass were baked at 100 ºC for 5 min to increase the bond strength.  
Samples were characterized by optical microscopy (Leitz Laborlux12MEST, Leica Microsystems, 
Wetzlar, Germany), confocal scanning microscopy (LSM700, Zeiss, Oberkochen, Germany), 
profilometry (XP-200, Ambios Technology, Santa Cruz, USA), UV-3101 PC UV/visible/NIR double 
beam spectrophotometry (Shimadzu, Kyoto, Japan) and scanning electron microscopy (FIB-SEM, 
Zeiss, Oberkochen, Germany). 
 
Optical setup preparation 
Two graded-index multimode optical fibers with 62.5 μm core diameter, 125 μm cladding diameter 
and 0.275 numerical aperture (GIF625, Thorlabs, Dachau, Germany) were stripped and cleaved from 
both sides, and inserted in the input and output optical entrances of the chip. One of the two remaining 
fiber tips was defined as the input fiber and connected to a SMA-ended GIF625 patch cable (Thorlabs). 
This cable was either coupled to a high-power green light-emitting diode (LED, M530F1, dominant 
wavelength: 530 nm, half width: 33 nm, typical output power: 5.1 mW, Thorlabs) or red LED (M625F1, 
dominant wavelength: 625 nm, half width: 18 nm, typical output power: 10.1 mW, Thorlabs). A 
constant current of 0.4 A was applied on both LEDs during the experiments. The other fiber tip was 
defined as the output fiber and was connected to a pigtailed silicon photodiode (FDSP625, Thorlabs). 
Connections with optical fibers were done with bare fiber terminators (BFTU, Thorlabs) and mating 
sleeves. 
A circuit with an operation amplifier (AD549 Operational Amplifier, Analog Devices, Norwood, 
MA, USA) was used to enhance the photodiode output current, and convert it to a voltage signal. The 
photodiode was connected to the operational amplifier’s inverting input (virtual ground), and a feedback 
network that incorporated a capacitor (1.5 nF) and a resistor (20 MΩ). The operational amplifier’s 
noninverting input was grounded, ranging from ±12 V. Data acquisition as well as command sending 
were done via the computer using a LabView program (LabView 2013, National Instruments, Austin, 
TX, USA) with a NI USB 6008 interface (National Instruments). The same LabView program was used 
to operate a Legato 210P syringe pump (KD Scientific, Holliston, MA, USA), to automatically infuse 




Au-nanoprobes and target RNA 
Au-nanoprobe design and synthesis were performed as previously described in Chapter 3 (Material 
and Methods section).421 AuNPs of 14 nm, prepared by the citrate reduction method, were 
functionalized with a thiolated oligonucleotide in 10 mM phosphate buffer pH 8.0, 0.1 M NaCl. The 
resulting Au-nanoprobes were stored in the dark at 4 °C and characterized by UV-Vis spectroscopy, 
TEM and DLS. 
The probe sequence and the complementary target were derived from the BCR-ABL1 e14a2 (also 
known as b3a2) mRNA (GenBank Accession No AJ131466.1), which is the most frequent breakpoint 
in CML.17,34 Au-nanoprobe selectivity was assessed against two non-modified synthetic 
oligonucleotides: a complementary target corresponding to the BCR-ABL1 e14a2 mRNA sequence, and 
an unrelated sequence was used as non-complementary target (as described in Table 3.1). 
Immortalized human cell lines derived from a CML patient in blast crisis, K562 (BCR-ABL1 e14a2 
fusion transcript positive cell line) and from an acute monocytic leukemia patient, THP1 (BCR-ABL1 
negative) were cultured, respectively, in DMEM and RPMI with 10 % FBS, at 37 °C with 5 % (v/v) 
CO2. These cell lines were used as positive and negative controls for the presence and absence of BCR-
ABL1 transcript, respectively. 
Total RNA was extracted from K562 and THP1 cell pellets by the guanidine thiocyanate procedure 
(SV Total RNA Isolation System, Promega) as described in chapter 2 (Material and Methods 
section).421 RNA was resuspended in DEPC-treated water and stored at -80 °C until use. RNA 
concentration and purity (Abs260nm/Abs230nm and Abs260nm/Abs280nm) were determined by UV 
spectrophotometry. 
 
4.4 Results and Discussion 
Microfluidic chip design 
The microfluidic chip layout was conceived by combining 3 distinct sections (Figure 4.2A). The 
first section allowed infused solutions to reach the common channel simultaneously (Figure 4.2A - i). 
This synchronization enables a more efficient utilization since no solution will be left unmixed. 
The second component of the chip had a planar micromixer incorporated to perform mixing 
between solutions (Figure 4.2A - ii). This micromixer was chosen over active and 3D micromixers444,445 
due to its cost efficiency and easy integration with other components of the microchannel, thus allowing 
low cost fabrication since it only requires a single layer of photolithography to yield the full design. 
Among passive planar micromixers, rhombic micromixers with obstacles446 are suitable for this 
application as they fulfill the mixing requirements over a wide range of Reynold numbers and for short 
mixing channels (2.5 mm), thus they were implemented in the described device. The integrated mixer 
has one and a half rhombi, and each edge has a total of nine diamond shaped obstacles to disturb the 
laminar flow and force mixing between solutions (Figure 4.2B). Each rhombus is also separated by 
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throttles that seek to increase mixing efficiency even further by creating pressure gradients with an 
abrupt variation on the channel’s width. These variations tend to generate vortexes, and thus, to enhance 
mixing. 
The third and last section of the chip comprises the optical detection unit, where the nucleic acid 
colorimetric analysis takes place (Figure 4.2A - iii). This screening takes advantage of an extended 
optical path length design inside the chip,220 which uses optical fibers to convey light between source 
and microfluidic chip, and between microfluidic chip and photodiode. Air lenses were incorporated at 
the entrance and exit, between the optical fiber grooves and the detection channel, to minimize signal 
losses;419 the former collimates light coming out of the fiber tip and illuminates the microchannel 
content uniformly, and the latter focuses the outgoing light into the core of the output optical fiber. Two 
optical grooves were also integrated in the chip design to enable approximation and alignment between 
optical fibers and channel (this is where the optical fiber circuit crosses paths with the microfluidic 
channel). Built-in cleaning channels were added to allow easy removal of dust and particles before 
optical fiber insertion (Figure 4.2C). Green (530 nm) and red (625 nm) light emitting diodes, detector 
and electrical setup were kept fixed, while disposable microfluidic chips and attached optical fibers can 
be replaced with ease for a cleaner usage. LED wavelengths were chosen according to the absorption 
spectra of aggregated and non-aggregated Au-nanoprobes.165,447 The low price, biocompatibility and 
optical properties of PDMS made this silicon rubber a common choice to fabricate the microfluidic 







Figure 4.2 A) Microfluidic chip design. i) infusion section; ii) mixing section; iii) optical detection 
section; 1 – Target DNA/RNA and Au-nanoprobes solution inlet; 2 – Salt (MgCl2) inlet; 3 – Optical 
fiber cleaning channels; 4 – Microchannel outlet; 5 – Optical fiber insertion cavity. B) Detailed scanning 
electron microscopy picture of the mixing region. The mixing region takes advantage of 1.5 rhombi, 
each with 36 diamond shaped obstacles and 2 throttles to perform efficient passive mixing. C) Detailed 
scanning electron microscopy picture of the detection region. A collimating lens is used between the 
first optical fiber groove and microchannel to align the incoming light onto the channel. Likewise, two 
focusing lenses are used between microchannel and the second optical fiber groove to focus the 




An optoelectronic setup was assembled to integrate the microfabricated chips and to perform optical 
analysis (Figure 4.3). 
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Figure 4.3 Setup scheme. Input electrical circuit: Light with one of two wavelengths (625nm; 530nm) 
is emitted from a powered LED through an optical fiber, represented by the dashed line. Optical circuit: 
The microfluidic chip is crossed by 2 optical fiber segments. The first allows incoming light to interact 
with solutions present in the region where optical detection occurs. The second carries the transmitted 
light outside the chip. A syringe pump is used to infuse these solutions inside the chip. Output electrical 
circuit: A photodetector transduces outcoming light to a current signal, which is amplified by an 
operation amplifier with a feedback network (capacitor: 1.5 nF; resistance: 20 MΩ), and converted to a 




The detection response (Rs) was defined as the ratio of the digital output acquired by the computer 
of the red LED (dominant wavelength: 625 nm) and green LED (dominant wavelength: 530 nm) on a 
screened sample:  
Rs =  
Sample Vout (625 nm)
Sample Vout (530 nm)
    
Baseline Vout (625 nm)
Baseline Vout (530 nm)
⁄  
 
This ratio was normalized to baseline sample ratio, 10 mM phosphate buffer pH 8 solution, as it 
eliminates the intrinsic optical properties that vary from chip to chip or with time and usage.220,419 
Baseline data were extracted prior to and after each assay in order to confirm the system reliability. 
 
Colorimetric analysis 
AuNPs of 14-nm in diameter were used and functionalized with the ssDNA probe that recognizes 
a unique sequence on the BCR-ABL1 oncogene, the hallmark of CML, and fully characterized by UV-
Vis spectroscopy, TEM and DLS, as described in chapter 3 (Results and Discussion - Au-nanoprobe 




Table 4.1 AuNPs and Au-nanoprobe characterization through Transmission Electron Microscopy 
(TEM), Dynamic Light Scattering (DLS) and ultraviolet-visible (UV-Vis) spectroscopy. 









Au-nanoprobe  26.3 524 
SPR – surface plasmon resonance 
 
Hybridization of Au-nanoprobes to targets was performed in 10 mM phosphate buffer pH 8, 
followed by a 5-minute denaturation at 95 °C. Samples were then cooled down to room temperature 
before injection into the chip.  
The microfluidic chip was rinsed with isopropanol to increase the microchannel hydrophilicity and 
to avoid formation of bubbles that could otherwise affect the optical readings and increase the dead 
volume A syringe pump was used to infuse two different solutions of 5 µL each, one in each inlet 
(flowrate: 5 μL/min), according to each experiment and in a 1:1 proportion (Table 4.2). Data acquisition 
of electrical output signals generated from LED transmitted light started immediately after the 
micromixing of infused solutions, in a no-flow regime. These measurements were acquired with a 
sampling interval of approximately one minute. 
For baseline measurements, 10 mM phosphate buffer pH 8 solution was used as the transparent 
medium inside the chip. It was selected as a reliable baseline source as all the tested samples are diluted 
in this solution. This procedure normalizes the system response for the baseline (Rs = 1). Sample 
screenings with Rs > 1 mean that the output voltage was higher for red light, and correspond to non-
aggregated results. Likewise, sample screenings with Rs  1 mean that the output voltage was similar 
or higher for green light, and correspond to aggregated results.  
Microchip sensitivity (ΔRs) was defined as the difference between the detection responses from 
assays with positive/non-aggregated results (Rs+) and negative/aggregated results (Rs-): 
ΔRs =  Rs
+   Rs- 
 
A one-way ANOVA analysis with Tukey's Multiple Comparison test using Wolfram Mathematica 
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Concentration of salt - MgCl2 
To achieve faster optical results, kinetic aggregation behavior inside the mixer was studied by 
mixing 5 nM of Au-nanoprobes and salt solutions with concentrations ranging from 0 to 1 M (1:1). 
Here, the mixed and final solution was studied for an Au-nanoprobe concentration of 2.5 nM, which is 
the optimum value for RNA detection recommended in literature.159,421 It was optically analyzed as soon 
as the mixing process finished, and 15 minutes thereafter. Data showed that for salt concentrations of 
0.1 M, the complete aggregation state of Au-nanoprobes could only be measured after 15 minutes of 
mixing (Figure 4.4). To cause immediate aggregation, at least 0.2 M of salt were needed. In both cases, 
0.2 M of salt is more than enough to stabilize Rs. 
 
 
Figure 4.4 Salt saturation study for Au-nanoprobes. Ratio measurements performed immediately after 




To calibrate the signal-to-noise ratio (SNR), a cluster of trials with AuNPs with and without the 
predetermined salt concentration were performed, at various concentration levels (1; 3; 5 nM) and LED 
intensities (0.4; 0.5; 0.6 A). The device’s SNR was calculated for each experimental point: 





Where ΔRs and δΔRs are the device’s sensitivity and sensitivity error, respectively. Using the 
Hermite method on Mathematica 10.0, data points were interpolated to find an approximate SNR 
function within the ranges studied (Figure 4.5). Although higher concentrations present greater 




is 2.5 nM.159,421 This concentration was therefore used to read the highest SNR value on Figure 4.5, 




Figure 4.5 Signal-to-noise ratio (SNR) of the device, as a function of light-emitting diode (LED) 
applied current and gold nanoparticles (AuNPs) concentration of infused solution. Citrate capped 




The microfluidic chip was used in conjunction with the Au-nanoprobe assay to detect the specific 
RNA sequence associated with CML in three progressive case studies (Table 4.2). The first case study 
was performed to verify the colorimetric screening and reproducibility of hybridized Au-nanoprobes 
with/without salt (proof-of-concept). For the second case study, synthetic oligonucleotide sequences 
were added to Au-nanoprobes and mixed with salt to evaluate the output screening and reproducibility 
according to the tested sequence (complementary/noncomplementary sequence of CML). This study 
was done as an intermediate step towards clinical trials. The only addition to Au-nanoprobes and salt is 
the synthetic oligonucleotide, either complementary or non-complementary. The complementary 
oligonucleotide sequences have a perfect match with Au-nanoprobes and thus they represent the best-
case scenario of a positive match. To mimic clinical trials, the third case study uses RNA extracted from 
culture cells (K562, positive for BCR-ABL1, or THP1, negative control), instead of synthetic DNA 
sequences, to evaluate the output screening and reproducibility of results. Due to the complexity of 
RNA solutions, positive controls extracted from cells tend to have a lower affinity to Au-nanoprobes 
when compared to complementary synthetic oligonucleotide sequences but constitute a better 
comparison to the real clinical sample. 
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A discriminated response between complementary (positive call) and non-complementary 
(negative call) assays was obtained for all 3 tested cases (Figure 4.6). Performed statistical analysis of 
variance (ANOVA) with Tukey’s comparison test output strongly suggested that positive and negative 
results belong to different populations (p < 0.05), yielding a significant discrimination. 
For the first case study, the Rs values obtained showed the least dependency on time. The absence 
of biological targets and other impurities was a major contributor to this consistency (Figure 4.6). The 
inclusion of synthetic oligonucleotides and RNA, in the second and third case studies respectively, 
increased the final solution density and added more variability, increasing the measurement errors. 
Positive measurements in these studies had Rs decrease over time. The presence of high salt 
concentration values may have promoted Au-nanoprobe aggregation and precipitation onto the 
microchannel over time, causing these losses in the ratio. Negative trials showed aggregation occurred 
sooner than 90 seconds, and thus, all the acquired data in these trials presented a stabilization ratio of 
Rs ≈1.00. The Rs average values increased for the positive trials of the second and third case studies due 
to an increase in absorption of green light and decrease in absorption of red light, mainly caused by the 
non-aggregated Au-nanoprobes and respective targets. 
Experimental results showed that SNR decreases both with time and complexity of experiments, 
i.e. species in solution. The best SNR was attained between 90 and 150 seconds, providing for the 
strongest outputs in the shortest frames of time (Figure 4.7). Presence of target molecules (synthetic 
oligonucleotides and/or total RNA) appeared to induce an increase to the detection sensitivity, even 
though a slight increase to the noise was also perceived.  
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Table 4.2 Experimental conditions used the microfluidic chip assay. Detailed description on the components used for each case study and respective 
concentrations. 
Case study 1st (without target) 2nd (synthetic oligonucleotides) 3rd (total RNA) 








































2.5 nM (+ 0.2 M MgCl2) 2.5 nM + 100 nM + 0.2 M 2.5 nM + 60 ng/µL + 0.2 M 
Hybridization of Au-nanoprobes to targets was performed in 10 mM phosphate buffer pH 8, followed by a 5-min denaturation at 95 °C. Samples were then cooled down to 
room temperature before injection into inlet 1 of the chip. Solutions were infused in each inlet in a 1:1 proportion. 
C, complementary target; NC, non-complementary target
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Figure 4.6 Colorimetric results via proposed microfluidic chip for each case study. Measurements were 
performed in 90-150 seconds (opaque bars) and 150-210 seconds (patterned bars) after filling the 
detection chamber. Flow was at rest during data acquisition. Bars represent the average Rs of 
independent measurements (n ≥ 3) and error bars indicate standard deviations. Statistical analysis was 




Figure 4.7 Sensitivity between positive and negative colorimetric results, within 90-150 seconds 
(opaque bars) and 150-210 seconds (patterned bars), and signal-to-noise ratio (SNR) trend over time 
(orange lines) for each case study. Bars represent the average ΔRs of independent measurements (n ≥ 3) 
and the error bars indicate their standard deviations. 
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The performance of the Au-nanoprobe assay off-chip was thoroughly studied in chapter 3. Au-
nanoprobes could distinguish BCR-ABL1 variants, without RT-PCR amplification, to a 100 % accuracy 
and a LOD of 15 ng/µL. The LOD for BCR-ABL1 detection directly from RNA using the microfluidic 
setup was found at 40 ng/µL, however standard deviation is lower for 60 ng/µL of RNA (Figure 4.8). 
Time to data output using the microfluidic device and Au-nanoprobes is at least 10 times faster, when 
compared to the off-chip Au-nanoprobe assay421 and 27 times faster when compared to conventional 
screening techniques for CML (RT-PCR),38,44 or to the few existent optical screenings with Au-
nanoprobes at microscale.419 The promotion of rapid kinetics of aggregation of Au-nanoprobes is 
enhanced by the proposed device, which greatly improves qualitative data output. 
Upon comparison of LOD values, one could argue there is a loss of sensitivity when using the 
microfluidic device, however results are conveyed faster using lower volumes in the latter. Though both 
tests need further optimization/validation, these two methodologies should be considered depending on 




Figure 4.8 Limit of detection of BCR-ABL1 using the corresponding Au-nanoprobes in the designed 
optical setup with the microfluidic chip, and same limit of detection for the off-chip version of the Au-
nanoprobe assay, using a commercial microplate reader (Tecan Infinite® M200 microplate reader - 
Männedorf, Switzerland). The on-chip setup consumed 10 µL of total solution in a microfluidic chip, 
used 0.2 M of MgCl2 and performed the screenings at real time. The off-chip setup consumed 30 µL of 
total solution in a microtube, used 80 mM of MgCl2 and provided the results 15 minutes after the 
screening. Bars represent the average Rs of independent measurements (n ≥ 3) and error bars indicate 
standard deviations. 
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4.5 Concluding Remarks 
A novel multifunctional microchip was developed and used to detect BCR-ABL1, the fusion 
transcript responsible for CML, directly from total RNA extracted from cells, via colorimetric Au-
nanoprobe NCL assay. The overall design and assembly was implemented taking into account ease of 
scale up production and maintaining low cost fabrication. These characteristics make the device suitable 
for a disposable POC platform with a non-disposable host device integrating the two LED light sources, 
photodetector and electronic circuit with signal amplification, analogue to digital conversion and PC 
connectivity. Optimization of the mixing device made possible the detection of target RNA in a small 
sample volume (10 µL), thus reducing the amount of sample required (3× less than conventional 
setups).419  
Volume might be further reduced via addition of a non-miscible buffer (mineral oil) with the sole 
purpose of pushing the sample solution through the mixing and optical stages, as the colorimetric 
detection step requires only 50 nL (volume of the filled detection channel).452,453 The setup itself can 
also be optimized towards POC by miniaturizing its components, such as designing and incorporating 
a mechanical pump to the microfluidic chip454 and shortening its optical path length. 
The gold standard for CML detection and follow-up is RT-qPCR, with a cost of €20 per sample. 
Based on current costs for Au-nanoprobe colorimetric assay, the estimated cost is €0.20-1.00 per 
assay.421 A microfluidic chip, integrating all steps for diagnostics, will depend on production setup that 
would bring costs of standalone chip operation to €10, but offering unique advantages: the microfluidic 
chip presented good sensitivity and was able to yield accurate results in a remarkably short period of 
time, due to the fast transition between mixing and detection stages provided by the chip’s design, and 
the process becomes available anywhere due to the possibility of portability. Moreover, the total cost 
of each assay can be further decreased with mass production of such devices.  
Since the colorimetric method for CML screening has been fully validated in mimicked clinical 
samples, future work shall focus on the integration of this microfluidic platform into a stand-alone 
device that will open the possibility to more complex, automatized and cost-effective generic 
DNA/RNA tests suitable for POC screening. In this specific case, it will improve the early diagnosis of 
CML and provide an easy to use platform for patients’ follow-up. 
 
Chapters 3 and 4 focused on the development of a new fast, simple and reliable method for CML 
diagnostics. As mentioned earlier, AuNPs are excellent tools for biomarker detection due to their size 
and remarkable optical features. However, these same properties can be applied on a nanotherapeutics 
approach, namely in specific gene silencing. The Au-nanoprobe-based assay provided valuable insights 
regarding hybridization, sequence specificity and selectivity, which were paramount for the 
development of an Au-nanoconstruct that effectively silences BCR-ABL1. This strategy is described in 






































CHAPTER 5 – GENE SILENCING USING GOLD-NANOPROBES: TOWARDS A 
NANOTHERANOSTICS APPROACH FOR CML 
 
M. Cordeiro, from the Research Unit on Applied Molecular Biosciences (UCIBIO, Universidade Nova 
de Lisboa), designed, synthesized and characterized the Au-nanobeacon approach described at the end 
of this chapter. R. Vinhas performed all remaining experiments, data analysis and drafted the following 
manuscript, at UCIBIO (Universidade Nova de Lisboa), under the supervision of P.V. Baptista and A.R. 
Fernandes. The author of this thesis opted for reproduction of the resulting scientific paper, thus 
apologizing for any repeated content in different contexts of the document. 
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5.1 Abstract 
Introduction of TKI for CML treatment is associated with a 63 % probability of maintaining a 
CCyR, meaning that over 30 % patients require an alternative methodology to overcome resistance, 
tolerance, or side effects. Considering the potential of nanotechnology in cancer treatment and the 
benefits of a combined therapy with IM, a nanoconjugate was designed to achieve BCR-ABL1 gene 
silencing. AuNPs were functionalized with a ssDNA oligonucleotide that selectively targets the e14a2 
BCR-ABL1 transcript expressed by K562 cells. This gold (Au)-nanoconjugate showed great efficacy in 
gene silencing that induced a significant increase of K562 cell death. Variation of Bcl-2 and Bax protein 
expression, an increase of caspase-3/7 activity, and apoptotic bodies in cells treated with the 
nanoconjugate demonstrate its aptitude for inducing apoptosis on K562 BCR-ABL1-expressing cells. 
Moreover, the combination of the silencing Au-nanoconjugate with IM prompted a decrease of IM IC50. 
This Au-nanoconjugate was also capable of inducing the loss of viability of IM-resistant K562 cells. 
This strategy shows that combination of the nanoconstruct and IM make K562 cells more vulnerable to 
chemotherapy and that the Au-nanoconjugate alone may overcome IM-resistance mechanisms, thus 
providing an effective treatment for CML patients who exhibit drug tolerance. 
 
5.2 Introduction 
CML affects approximately 1.5 million people worldwide and is characterized by the uncontrolled 
proliferation of myeloid cells in the bone marrow and blood.455 The disease hallmark results from a 
genetic abnormality: a reciprocal chromosomal translocation between the long arms of chromosomes 9 
and 22, designated as t(9;22)(q34;q11), creating a derivative 9q+ and a shortened 22q-, the Ph 
chromosome. Due to different possible breakpoints on chromosome 22 and alternative splicing events, 
several transcripts can originate from this translocation.17,34 However, the e14a2 and e13a2 are present 
in most CML patients, with the e14a2 transcript representing 55 % of Ph+ cases.17,34 CML was the first 
malignancy in which a unique chromosomal abnormality was identified in approximately 95 % of  
cases.23,455 All BCR-ABL1 gene fusions described thus far encode for a constitutively active tyrosine 
kinase that plays a central role on leukemogenesis, since it disturbs downstream signaling pathways, 
causing enhanced proliferation, differentiation arrest, and resistance to cell death.24 Hence, targeted 
TKIs are the standard treatment for CML, which works best on early stages of the disease, with IM 
being the first-line treatment. Based on the Sokal risk score at the time of diagnosis, patient age, drug 
cost, comorbidities, drug toxicity, and gene mutation profile, other TKIs can be administered: dasatinib, 
nilotinib, bosutinib, or ponatinib.17 Although more effective than IM, these TKIs are associated with 
different safety profiles, and their impact on long-term overall survival remains undetermined.456 
Despite the efficacy of TKI treatment, early relapse and TKI resistance, which have been associated 
with BCR/ABL1-dependent or -independent mechanisms, are still major concerns.106, 141,457 
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Antisense DNA therapy is a powerful instrument for regulating the expression of genes associated 
with disease, with the potential to be used as an adjuvant to conventional chemotherapy.458,459 ssDNA 
oligonucleotides may be delivered into cells and target specific mRNA molecules, inhibiting expression 
of the encoded protein.460 AuNPs protect the antisense oligonucleotide against degradation by RNases, 
thus increasing circulation half-life and, therefore, the payload of therapeutic agent that is delivered to 
cells. The potential of AuNPs to vectorize actuators for gene silencing via simple assembly onto the NP 
core has been demonstrated in vitro and in vivo for a range of different nucleic acid moieties, including 
small interfering RNA (siRNA)304,461–464 and antisense ssDNA.241, 305, 307,465,466 The latter has been proven 
to be very specific, particularly when using stem-looped oligonucleotides, making it suitable for the 
real-time monitoring of gene silencing via Au-nanobeacons.241, 305,307 
In this study, we silenced the BCR-ABL1 chimeric gene in vitro, using AuNPs functionalized with 
an antisense oligonucleotide (Figure 5.1). The effects of the construct on BCR-ABL1 signaling 
pathways were further assessed through the evaluation of the changes in the expression levels of key 
players of cell proliferation and apoptosis/survival. Besides gene silencing evaluation, a combined 
therapy assay was performed to understand the role of the Au-nanoconjugate as an adjuvant to the 
conventional treatment for CML (IM), even in K562 cells resistant to the drug. The effect of this Au-
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Figure 5.1 In vitro BCR-ABL1 gene silencing via gold nanoconjugates. Gold nanoparticles (AuNPs) 
functionalized with a ssDNA oligonucleotide (AuNP@PEG@e14a2) selectively target the e14a2 BCR-
ABL1 transcript expressed by K562 cells. Moreover, the silencing Au-nanoconjugate improves imatinib 
(IM) effect on cell proliferation and apoptosis.  
 
 
5.3 Material and Methods 
Au-nanoconjugate synthesis and characterization 
AuNPs of 14 nm were synthesized by the citrate reduction method.172 AuNPs were first 
functionalized with PEG modified with a 5’-thiol group (C15H32O7S, 356.48 Da) (AuNP@PEG), 
corresponding to 30 % saturation of AuNPs’ surface. AuNP@PEGs were subsequently functionalized 
with the thiolated oligonucleotide: 5’-TTTCGGCGCTGAAGGGCTTTTGAACTCCGAAA-3’ 
(palindromic sequence underlined; sequence targeting the fusion e14a2 BCR-ABL1 transcript was 
derived from GenBank: AJ131466.1) (AuNP@PEG@e14a2 - Au-nanoconjugate).421 A palindromic 
sequence was added to allow the stem-loop structure. The final ssDNA sequence was designed and 
analyzed using the Nucleic Acid Package (NUPACK) software.467,468 Au-nanoconjugates were prepared 
at a 1:100 (AuNP:oligonucleotide) ratio and centrifuged for 40 min at 14 000 x g, and the precipitate 
was washed three times with diethylpyrocarbonate-treated water. The number of oligonucleotides 
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bonded to the AuNP surface was determined using Quant-iT OliGreen ssDNA Reagent (ThermoFisher, 
Waltham, MA, USA). The resulting Au-nanoconjugates were stored at 4 °C in the dark and 
characterized by UV-Vis spectroscopy, TEM, and DLS. 
A control scrambled oligonucleotide 5’-TTTCGGGTTGACGTTAGCCGGATCTACCGAAA-3’ 
was also prepared and characterized under the same conditions: AuNP@PEG@scramble. 
To target c-MYC, AuNPs were also functionalized with 30 % PEG and the following thiolated 
ssDNA oligonucleotide: 5’GCGCCCATTTCTTCCAGATATCCTCGCTGGGCGC (palindromic 
sequence underlined; sequence targeting c-MYC mRNA was derived from GenBank NM_002467.5). 
All protocols used for AuNP@PEG@e14a2 were strictly followed for AuNP@PEG@MYC. 
 
Cell culture and Au-nanoconjugate challenge 
The immortalized cell line K562 (cell line positive for BCR-ABL1 e14a2 fusion transcript) derived 
from a CML patient in blast crisis was cultured in DMEM supplemented with 10 % FBS at 37°C with 
5 % CO2 and 99 % relative humidity. 
For these in vitro assays, cells were seeded at a density of 1 x 105 cells per well (24-well plates) or 
5 x 103 cells per well (96-well plates) and challenged with 0.6 nM AuNP@PEG@e14a2, corresponding 
to 30 nM oligonucleotide (Au:oligonucleotide ratio = 1:50). As control, cells were exposed to 0.6 nM 
AuNP@PEG (control vehicle); to 0.7 nM AuNP@PEG@scramble (corresponding to 30 nM 
oligonucleotide; Au:oligonucleotide ratio = 1:44); or to 0.1 µM IM, and 0.01 % DMSO as control for 
IM. For experiments targeting c-MYC, cells were challenged with 0.6 nM AuNP@PEG@MYC 
(corresponding to 45 nM oligonucleotide; Au:oligonucleotide ratio = 1:75). 
Sequence specificity was also tested using two different cell lines: an acute monocytic leukemia 
cell line negative for BCR-ABL1 (THP1) and a CML cell line positive for the BCR-ABL1 e13a2 
transcript (BV173), cultured as described earlier. Incubation of cells with nanoconjugates or IM was 
performed at a density of 2.5 x 104 cells per well (96-well plate).  
IM-resistant K562 cells were generated via incubation of K562-sensitive cells with increasing 
concentrations of IM (starting with a concentration of 0.01 µM up to 1 µM) for more the 50 passages 
(K562-IM). BCR-ABL1 gene expression on K562-IM cells was evaluated via qPCR as described in the 
following section (Gene expression analysis). Data were analyzed by the comparative threshold cycle 
(Ct) method (2-ΔΔCt),469 where relative gene expression is given by quantification of BCR-ABL1 relative 
to the internal control gene (18S), normalized to the control condition (parental K562 cells):  
ΔCt = CtBCRABL1  Ct18S 
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To assess BCR-ABL1 mutational status on K562-IM cells, a nested-PCR amplification was 
performed as described in chapter 2, under the BCR-ABL1 molecular analysis – Mutational screening 
section, using primers for the P210BCR-ABL1 variant, depicted in Table 2.2. PCR products were sequenced 
at STABVIDA (Caparica, Portugal). 
 
Gene expression analysis 
Cells exposed to the different conditions (AuNP@PEG and Au-nanoconjugates) in 24-well plates 
were collected at different time points between 3 and 72 hr. Cells were centrifuged at 200 x g for 5 min 
at room temperature, and total RNA was extracted from cell pellets using TRIsure (Bioline, Taunton, 
MA, USA) according to the manufacturer’s instructions. Total RNA (100 ng) was reverse transcribed 
using the NZY M-MuLV First-Strand cDNA Synthesis kit (NZYTech, Lisbon, Portugal). 
qPCR amplification of cDNA was performed on a Corbett Rotor-Gene 6000 thermal cycler 
(Qiagen, Hilden, Germany) using the HOT FIREpol EvaGreen qPCR Mix which includes HOT 
FIREPol DNA polymerase and corresponding buffer, 2.5 mM MgCl2, dNTPs and EvaGreen dye 
(Solis BioDyne, Tartu, Estonia). The reaction mixture was prepared in a final volume of 20 µL with 1 
µL of cDNA and the following primers, at a concentration of 100 nM each: BCR forward (5’-
GAAGTGTTTCAGAAGCTTCTCC) and ABL1 reverse (5’-GTTTGGGCTTCACACCATTCC); c-
MYC forward (5’-GCTCATTTCTGAAGAGGACTTGT) and c-MYC reverse (5’-
AGGCAGTTTACATTATGGCTAAATC); BCL2 forward (5’-CTTCGCCGAGATGTCCAGCCA) 
and BCL2 reverse (5’-CGCTCTCCACACACATGACCC); 18S forward (5’-
GTAACCCGTTGAACCCCATT) and 18S reverse (5’-CCATCCAATCGGTAGTAGCG). qPCR 
conditions included an initial denaturation at 95 °C for 15 min and 40 cycles of 95 °C for 20 s, 55 °C 
(BCR-ABL1, c-MYC and 18S) or 65 °C (BCL-2) for 20 s, and 72 °C for 30 s. qPCR data were analyzed 
by the Ct method (2-ΔΔCt),469 where relative gene expression is given by quantification of the gene of 
interest (BCR-ABL1, c-MYC or BCL-2) relative to internal control gene (18S), normalized to the control 
condition (cells exposed to AuNP@PEG): 
ΔCt = CtBCRABL1 or c-MYC or BCL-2  Ct18S 
 
ΔΔCt = ΔCtAu-nanoconjugate  ΔCtAuNP@PEG 
 
Flow cytometry 
Cells were exposed to AuNP@PEG@e14a2 in 24-well plates, recovered by centrifugation at 400 x 
g for 5 min at 4 °C, and washed with cold PBS. Cells were resuspended in PBS and analyzed by 
measuring side scatter peak area (SSC-A) of 10 000 events per reading in an Attune Acoustic Focusing 





Cell proliferation assays  
K562 cells were plated in 24-well plates, and growth rate was determined by counting the number 
of viable cells after challenge with AuNP@PEG or AuNP@PEG@e14a2 nanoconjugates using the 
trypan blue (0.2 %) exclusion assay (ThermoFisher, Waltham, MA, USA), where viable cells possess 
intact cell membranes that exclude the dye, whereas dead cells do not and appear blue.470 Cell-doubling 
time was calculated as: 
Doubling time = 
time x log 2
log (final conc.)  log (initial conc.)
 
 
Additionally, K562, THP1, and BV173 cells exposed to IM, AuNP@PEG and Au-nanoconjugates 
were assessed in 96-well plates using the CellTiter 96 AQueous Non-Radioactive Cell Proliferation 
Assay (MTS, Promega, Madison, WI, USA).471 Absorbance at 490 nm was measured in a Tecan Infinite 
M200 microplate reader (Männedorf, Switzerland), and values were corrected to the respective control 
conditions (without cells). The IC50 for IM at 48 h was also determined via MTS assay by exposing 
K562 cells to growing IM concentrations ranging from 0.01 to 10 µM. 
 
Apoptosis assay 
K562 cells cultured in a 24-well plate were fixed with 4 % (w/v) paraformaldehyde, washed with 
PBS, and stained using 10 µg/mL Hoechst 33258 (ThermoFisher, Waltham, MA, USA).472,473 At least 
six images per condition were collected using an AxioImager D2 fluorescence microscope (Zeiss, 
Oberkochen, Germany) with a 40x objective or a 100x immersion objective, a 365-nm excitation filter, 
and a 445/50-nm emission filter. 
 
Western blot 
Cells were washed with PBS and resuspended in lysis buffer [150 mM NaCl, 50 mM Tris (pH 8.0), 
5 mM EDTA, 2 % (v/v) NP-40, 1x phosphatase inhibitor (PhosStop, Roche, Basel, Switzerland), 1x 
protease inhibitor (cOmplete Mini, Roche), 1 mM PMSF, and 0.1 % (w/v) DTT]. Whole-cell extracts 
were sonicated and centrifuged at 5000 x g for 10 min. The supernatant was recovered, and protein 
concentration was determined using the Pierce 660nm Protein Assay Reagent (ThermoFisher, Waltham, 
MA, USA) per manufacturer’s specifications. Then, 25 mg total protein extracts were separated by 
SDS-PAGE in a 10 % (37.5:1) acrylamide-bisacrylamide gel (Merck Millipore, Billerica, MA USA). 
Following electrophoretic transfer onto a 0.45-mm nitrocellulose membrane (GE Healthcare, Little 
Chalfont, UK) and blocking with 5 % (w/v) milk solution in tris-buffered saline with 0.1 % (v/v) tween 
20 (TBST), blots were incubated per manufacturer’s instructions for 1 h at room temperature with 
primary antibodies against Bcl-2 (reference no. B3170, Sigma-Aldrich, St. Louis, MI, USA), Bax 
(reference no. 32503, Abcam, Cambridge, UK), and ß-actin (reference no. A5441, Sigma-Aldrich). 
(Equation 5.5) 
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Membranes were washed with TBST and incubated with the appropriate secondary antibody conjugated 
with horseradish peroxidase (reference no. 7074 or 7076, Cell Signaling Technology, Danvers, MA, 
USA). WesternBright ECL (Advansta, Menlo Park, CA, USA) was applied to the membranes, and 
signal was acquired in a Gel Doc imager (Bio-Rad, Hercules, CA, USA). 
 
Caspase-3/7 activity 
Caspase-3/7 activity was assessed using the Caspase-3 Apoptosis Detection Kit from Santa Cruz 
Biotechnology (Dallas, TX, USA), as described by Luis et al.474 Briefly, 50 mL cell lysates were diluted 
in 200 mL reaction buffer containing 10 mM DTT and 5 mL fluorometric substrate DEVD-AFC (7-
amino-4-trifluoromethyl coumarin) and incubated at 37 °C for 1 h. Caspase-3/7 activity was quantified 
by fluorescent detection of free AFC after cleavage from DEVD peptide. The free AFC level was 
measured using a Varian Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies, Santa 
Clara, CA, USA) with a 400-nm excitation filter and a 505-nm emission filter. 
 
Au-nanobeacon in vitro challenge and imaging 
In vitro imaging of BCR-ABL1 silencing was performed using a Au-nanobeacon combined with 
Förster resonance energy transfer (FRET) based spectral codification, in a strategy designed by 
Cordeiro et al, 2016.122 Briefly, 14nm-AuNPs were first functionalized with thiolated PEG 
corresponding to 45 % saturation of AuNPs’ surface, and subsequently with the thiolated nanobeacon. 
The nanobeacon hairpin was optimized to specifically detect the BCR-ABL1 fusion region of the e14a2 
isoform sequence: 5’-CACCTCGAAATCTGAAGGGCTTTTGAACTCTGTTTTCGAGGTG 
(palindrome sequence underlined; sequence targeting the fusion e14a2 BCR-ABL1 transcript was 
derived from GenBank: AJ131466.1). The 3’ end of this sequence was coupled to sulfoindocyanine 
Cy3 (donor fluorophore). The sequence complementary to the palindrome sequence of the 
nanobeacon’s hairpin (5’-CACCTCGAAA) was coupled to Dy-520XL (acceptor fluorophore). 
Cells were cultured in phenol-free medium (DMEM or RPMI, depending on the cell line) on 24-
well plates (1 x 105 cells per well) and challenged with 0.5 nM Au-nanobeacon (corresponding to 30 
nM oligonucleotide; Au:oligonucleotide ratio = 1:64) and/or 25 nM acceptor (1 Au : 50 acceptor). After 
the stimulus, cells were transferred onto a microtube, centrifuged at 300 x g for 5 min, washed with 
PBS, and immediately examined by fluorescence microscopy. At least six images per condition, were 
collected using AxioImager D2 fluorescence microscope (Zeiss, Oberkochen, Germany) with a 40x-
objective and a filter with excitation at 540-552 nm, emission at 590-4095 nm and splitter at 580 nm, 
with the same exposure settings. Fluorescence intensity quantification per cell, per condition, was 
performed after background correction, using Image J software (National Institutes of Health, 






All data are expressed as mean ± standard error from at least three independent experiments. 
Statistical significance was evaluated through one-way ANOVA followed by Tukey’s multiple 
comparison test. Mean differences between groups were determined with a 95 % confidence interval. 
Statistical significance of data from Table 5.2, Figures 5.7 and 5.10, was evaluated through two-way 
ANOVA followed by Bonferroni’s test. 
 
5.4 Results and Discussion 
Standard chemotherapy may be combined with gene silencing approaches to assist cancer cell 
death. For instance, ssDNA silencing oligonucleotides can recognize a specific gene product to shut 
down the production of a protein associated to disease, by activating RNase H that cleaves DNA/RNA 
hybrids; via steric blockage of translation; or by modulating alternative splicing.460 This way, those cells 
harboring the selected gene marker will be selectively targeted for enhanced destruction, allowing for 
improvement of efficacy. In CML, the molecular hallmark of disease - BCR-ABL1 fusion transcript - 
may be used to selectively target malignant cells in combination with a particular TKI, thus potentiating 
cell death. Gene silencing has profited from nanovectorization strategies that extend circulation half-
life of therapeutic nucleic acids while improving cell uptake.301,475 Here, we used AuNPs to deliver a 
specific oligonucleotide targeting the BCR-ABL1 mRNA sequence in CML cells, where the silencing 
moiety was in a stem-loop configuration to improve selectivity and specificity toward target 
sequence.307,476 AuNPs with 14 nm in diameter were synthesized and further functionalized with 
polyethylene glycol (AuNP@PEG) and with a ssDNA targeting the BCR-ABL1 mRNA sequence (50 
oligonucleotide density per NP). 
PEG functionalization is crucial to: i) increase nanoconjugate solubility both in vivo and in vitro, 
ii) reduce their uptake by the reticuloendothelial system, thus increasing AuNPs circulation time, and 
iii) decrease serum and tissue protein association.477 
The ssDNA sequence targeting BCR-ABL1 was designed based on several factors. The core 
sequence, targeting the fusion region of the e14a2 transcript, matches the one used to detect the same 
transcript on ex vivo RNA samples via the Au-nanoprobe assay (described in chapters 3 and 4). All the 
information concerning sequence specificity and selectivity on the previous stages of the work was 
paramount to potentiate the effect of the designed nanoformulation on BCR-ABL1 gene silencing. 
Moreover, a palindromic sequence was added to both ends of the ssDNA oligonucleotide to induce the 
hairpin conformation and increase its selectivity, by ensuring that the hairpin will only open in the 
presence of a fully complementary target. In silico experiments, using NUPACK software which is 
ideal for the thermodynamic analysis of dilute solutions of interacting nucleic acid strands,468 allowed 
to infer the best palindrome sequence for this purpose. This precise sequence was chosen to promote 
the formation of a perfect stem-loop structure by avoiding complementarity of the palindrome to the 
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BCR-ABL1 targeting sequence (internal hybridization) and evade the hybridization of the overall 
sequence to BCR or ABL1 transcripts. Gibbs free energy variation, ΔG, also indicates that this secondary 
structure will likely open in the presence of a complementary target (ΔGopen/hybridized oligonucleotide = -45.4 
kcal/mol) as opposed to a non-complementary target (ΔGclosed hairpin oligonucleotide = -2.9 kcal/mol).  
The resulting nanoconjugates were characterized by UV-Vis spectroscopy, TEM and DLS (Table 
5.1). Data related to Z-average and SPR peak shift show an increase of NPs size upon PEG 
functionalization and, even more, after oligonucleotide (e14a2 or scramble) loading. Although the 
polydispersity index (PI) slightly increases subsequently to replacement of the citrate capping (AuNPs) 
for thiolated ligands (PEG or oligonucleotides), all measured PI values are indicative of a monodisperse 
population.478 Z-potential measures the magnitude of the electrostatic or charge repulsion/attraction 
between particles, which affects their stability and dispersion/aggregation status. PEG binding to the 
surface of AuNPs is known to induce a shift from negative to more neutral Z-potential values, as 
demonstrated in table 5.1. On the contrary, since ssDNA molecules have negative charge, 
functionalization with oligonucleotides induced a shift from -41 mV (AuNPs@PEG) to -103 mV 
(AuNP@PEG@scramble) or -93 mV (AuNP@PEG@e14a2). 
 
 
Table 5.1 AuNPs, AuNP@PEG and AuNP@PEG@e14a2 characterization through Transmission 














14 nm 17 0.211 -74 519 
AuNP@PEG 27 0.380 -41 520 
AuNP@PEG@scramble 54 0.346 -103 522 
AuNP@PEG@e14a2 51 0.312 -93 524-525 








BCR-ABL1 gene silencing and cell fate 
Real-time qPCR analysis of BCR-ABL1 gene expression shows that, after 12 h of exposure of K562 
cells to 0.6 nM AuNP@PEG@e14a2, expression of the fusion transcript decreases till it reaches a 
minimum at 24 h (Figure 5.2). After 72 h, BCR-ABL1 expression is completely restored, possibly due 
to oligonucleotide degradation and/or cell expansion over time, which increases the number of cells per 
NP applied in cell medium, but in line with what has been previously observed for other targets.301,479 
Together, these data show efficient gene silencing by the designed nanoconjugates. 
Once effective gene silencing of BCR-ABL1 was achieved, we investigated downstream control 
points for apoptosis/survival. A comparable transient effect was observed for BCL-2, a downstream 
target gene of BCR-ABL1, which followed a similar reduction profile (Figure 5.2). This result further 
corroborates the overall cell effect of silencing BCR-ABL1, since Bcl-2 expression levels are strongly 
regulated by BCR-ABL1 in cancer cells. In fact, in the signaling pathway that ultimately culminates in 
increased survival and unregulated proliferation of Ph+ cells, BCR-ABL1 prevents apoptosis by 





Figure 5.2 Au-nanoconjugate AuNP@PEG@e14a2 effectively silence BCR-ABL1. BCR-ABL1 (blue 
full circle) and BCL-2 (black full triangle) mRNA relative expression after treatment of K562 cells with 
AuNP@PEG and AuNP@PEG@e14a2. Data were normalized to the 18S gene and then to cells exposed 
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Flow cytometry data also corroborate these trends for K562 cells treated with AuNP@PEG@e14a2 
(Figure 5.3). Measurement of side scatter intensity (SSC) in flow cytometry is an efficient way to study 
cell interaction with AuNPs associated with their strong scattering.481 SSC values increased for cells 




Figure 5.3 Side scattering analysis of K562 cells after exposure to AuNP@PEG@e14a2. Side 
scattering peak area (SSC-A) was measured via flow cytometry and raw values were normalized against 
















In CML, BCR-ABL1 induces the deregulation of cell proliferation with the inhibition of apoptosis 
and an increased survival rate. Exposure of K562 cells to the Au-nanoconjugate significantly delayed 
cell growth, particularly for the 24-48 h period (Figure 5.4A). In that period, cell-doubling time was 
circa 116 h, which is much slower than control (PBS) or control vehicle (AuNP@PEG): 17 h and 20 h, 
respectively. These data are in accordance with gene expression studies discussed earlier, where the 
window of silencing effectiveness was between 24 h and 48 h. Cell-viability studies by the MTS assay 
also show a decrease of cell viability of 25 % at 48 h (Figure 5.4B). The short-term effect induced by 
the construct might be associated with the increase in cell numbers after 48 h, skewing the most efficient 
cell:Au-nanoconjugate ratio. The Au-nanoconjugate functionalized with a scrambled oligonucleotide 
showed no effect on cell viability. As such, the previously observed reduction in cell viability (25 %; 
Figure 5.4B) was due to the oligonucleotide effect by targeting the fusion e14a2 BCR-ABL1 transcript. 
The Au-nanoconjugate specificity toward cells expressing the e14a2 BCR-ABL1 transcript was 
confirmed by assessing cell viability on THP1 (BCR-ABL1-negative cell line derived from an acute 
monocytic leukemia patient) and BV173 (CML cell line derived from an e13a2-positive patient). The 
silencing nanoconjugate, specific for the e14a2 BCR-ABL1 isoform, solely promoted cell-viability 
reduction on K562 cells, indicating that the construct is highly specific, since the e14a2 and e13a2 
transcripts share the ABL1 part of the sequence (Figure 5.4C). This high-sequence specificity had been 
previously demonstrated for in vitro CML diagnostics in clinical samples using AuNPs.421 Because the 
sequence only targets the isoform of interest, it acts as a molecular marker for targeted therapy. As 
expected, IM had no effect on THP1 but decreased cell viability on BV173 and K562, since it was 
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Figure 5.4 Cell proliferation assays upon exposure to AuNP@PEG@e14a2. A) Cell viability count via 
trypan blue exclusion assay on untreated K562 cells (black circles), cells exposed to AuNP@PEG (red 
triangles), and silencing nanoconjugate (blue squares). Cells’ doubling time was also calculated 
(embedded table). conc., concentration. B) Cell viability over time on K562 cells challenged with 
AuNP@PEG@e14a2 (silencing nanoconjugate) and AuNP@PEG@scramble. C) Sequence specificity 
of AuNP@PEG@e14a2 toward BCR-ABL1 measured by impact on cell viability on THP1, BV173, and 
K562 cells; cells were also challenged with 0.1 µM imatinib (IM), which is specific for BCR-ABL1. 
Data on plots (B) and (C) were normalized to AuNP@PEG. **p < 0.01; ***p < 0.001, Tukey’s test 







The IM mechanism of action involves blocking the active site of BCR-ABL1 tyrosine kinase, that 
subsequently induces cancer cell death via apoptosis.482,483 We investigated the triggering of apoptotic 
pathways by cells challenged with our silencing nanoconjugate, AuNP@PEG@e14a2. Cells nuclei 
undergo several morphological changes even at early apoptosis, including chromatin condensation, 
nuclear fragmentation, and the presence of apoptotic bodies, which can be visualized using a fluorescent 
DNA dye (Hoechst) (Figure 5.5).484 The silencing nanoconjugates were shown to induce an increase on 
the number of apoptotic cells at 48 h, when compared to normal cells, cells exposed to 
AuNP@PEG@scramble, or cells exposed to AuNP@PEG, which does not induce apoptosis (Appendix 
V – Figure V.1). 
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Figure 5.5 Silencing nanoconjugate AuNP@PEG@e14a2 induces apoptosis. A) Hoechst staining on 
non-treated (control) cells (a and a1) or cells treated for 48 h with 0.1 µM IM (b and b1), 0.6 nM 
AuNP@PEG (c and c1), 0.7 nM AuNP@PEG@scramble (d and d1), or 0.6 nM AuNP@PEG@e14a2 
(corresponding to 30 nM of oligonucleotide) (e and e1). Representative fluorescence microscopy 
images are shown in (a)–(e); scale bars, 50 µm. Zoomed images for each condition are shown at right, 
in (a1)–(e1), for better visualization between apoptotic (red arrows) or mitotic (green arrow) cell 
morphology; scale bars, 20 µm. B) Apoptotic events count based on nucleus morphology and formation 
of apoptotic bodies after Hoechst staining. ***p < 0.001, Tukey’s test statistical significance when 
compared to control and AuNP@PEG. 
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The anti-apoptotic protein Bcl-2 and pro-apoptotic protein Bax are important regulators in the 
mitochondrial apoptotic pathway, particularly in BCR-ABL1-expressing cells. Inhibition of apoptosis 
is thought to result from activation of the phosphoinositide 3-kinase and Ras pathways, with induction 
through Akt of c-Myc and Bcl-2, and variation of their expression levels is of great importance for 
regulating apoptosis.485 Many chemotherapeutic agents, including TKIs, trigger apoptotic cell death by 
activating caspases. Upon an apoptotic stimulus, initiator caspases (e.g., caspase-8 and caspase-9) 
cleave and activate executioner caspases (e.g., caspase-3), inducing proteolytic cleavage of specific 
apoptotic substrates that culminate in cell death.486 To further confirm the downstream events triggered 
by direct silencing of BCR-ABL1 that ultimately induce apoptosis, we evaluated the actual expression 
of these two canonical apoptotic pathways: the Bcl-2/Bax and caspase activation (Figure 5.6). 
The observed pro-apoptotic effect of our silencing nanoconjugate corroborated data attained from 
the gene silencing experiments (Figure 5.2), where BCL-2 gene expression was downregulated. 
Silencing of BCR-ABL1 using AuNP@PEG@e14a2 not only downregulated Bcl-2 but also upregulated 
Bax expression, shifting K562 cells from the anti-apoptotic setting characteristic of BCR-ABL1-
expressing cells to pro-apoptotic (Figures 5.6A and 5.6B). A 2-fold change on the Bax/Bcl-2 ratio was 
obtained for AuNP@PEG@e14a2, higher than that of IM, the gold standard of CML chemotherapeutics 
(Figure 5.6C). Caspase-3/7 activity was then measured at 24 and 48 h and, although no effect was 
observed at the shorter time point, there was an increase in caspase activity at 48 h, mimicking the effect 
induced by IM (Figure 5.6D). The time-dependent profile observed with this assay also highlights the 
delay observed between gene silencing (higher effect at 24 h) and protein expression/activation (higher 
effect at 48 h). 
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Figure 5.6 Triggering of apoptotic cascade via AuNP@PEG@e14a2. A) Expression of K562 cells Bcl-
2 and Bax after exposure to the Au-nanoconjugate. Bcl-2 (26 kDa) and Bax (21 kDa) protein 
quantification was performed via western blotting on cell extracts after a 48 h exposure to 0.1 µM 
imatinib (IM) or 0.6 nM AuNP@PEG@e14a2. Band quantification was first normalized against ß-actin 
(42 kDa) and, subsequently, to the control condition: cells without treatment or cells exposed to 0.6 nM 
AuNP@PEG. B) Bcl-2 protein expression (control as 100 %). C) Apoptotic index of K562 cells, based 
on Bax/Bcl-2 ratio. D) Caspase-3/7 activity on K562 cells after exposure to 0.1 µM IM or 0.6 nM 
AuNP@PEG@e14a2. Values were normalized against cells without treatment (value represented by 
the threshold). *p < 0.05; **p < 0.01; ***p < 0.001, Tukey’s test statistical significance. 
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Improving CML cell death by a combination of IM and silencing nanoconjugates 
Recently, the use of combinatory strategies for effective therapy has been the focus of numerous 
studies to overcome the consequences of TKI resistance and long-term treatments in CML. In fact, TKI 
resistance affects nearly 30 % of CML patients and is related to the overexpression of BCR-ABL1, 
mutational events, drug metabolism, transport and intracellular influx, and patient non-compliance.456 
The efficacy of the Au-nanoconjugate as an adjuvant to conventional therapy was assessed by 
measuring cell viability after a combined 48 h-challenge with the silencing nanoconjugate and 
increasing concentrations of IM (0.01–10 µM). AuNP@PEG@e14a2 combined with IM increased 
efficacy by 23 % when compared to the drug alone, demonstrating the ability of the nanoconjugate to 
enhance the effect of IM on cell proliferation. It should be mentioned that challenging cells with 
AuNP@PEG seem to slightly increase cell viability. When compared to IM + AuNP@PEG, the 
combinatory approach of IM + silencing nanoconjugate was 30 % more effective (Table 5.2). 
 
 
Table 5.2 Imatinib’s (IM) IC50 when combined with silencing nanoconjugate AuNP@PEG@e14a2. 
IC50 were calculated for the 48 h-stimuli. 
* Bonferroni’s test statistical significance, compared to IM or IM+AuNP@PEG: p < 0.001 (***). 




The effect of the Au-nanoconjugate on IM-resistant cells was also analyzed (Figure 5.7). To obtain 
this in vitro model, K562 cells were exposed to increasing concentrations of IM up to 1 µM. Several 
studies show potential resistance mechanisms that arise from this exposure and correlate to CML 
disease progression in vivo: incidence of point mutations in BCR-ABL1 that impair TKIs binding to the 
encoded protein; overexpression of BCR-ABL1; and/or overexpression of genes involved in drug 
transport or redistribution.97,487,488 Although it was not possible to analyze the expression of efflux 
pumps at mRNA or protein level in these cells (e.g. MDR1), their tolerance to IM was associated to an 
increase of BCR-ABL1 expression rather than mutations to ABL1 (Appendix V – Figure V.3). 
Figure 5.7 demonstrates that IM-resistant K562 cells do not respond to the concentration of the drug 
corresponding to the half maximal inhibitory concentration (IC50) of sensitive parental K562 cells (as 
shown in Figure 5.4C). Remarkably, AuNP@PEG@e14a2 induced a significant reduction (30 %) of 
viability in K562-IM-resistant cells. 
 
 IM IM + AuNP@PEG IM + AuNP@PEG@e14a2 
Imatinib IC50 
(nM) 
220 240 170*** 
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Figure 5.7 Viability via MTS assay of K562 cells resistant to imatinib (IM). Cells were challenged with 
0.1 µM imatinib or 0.6 nM AuNP@PEG@e14a2 for 24 or 48 h. *p < 0.05, Bonferroni’s test statistical 
significance, compared to the control condition AuNP@PEG. 
 
 
5.5 Concluding Remarks 
Here, we show that using a sequence-selective silencing nanoconjugate, AuNP@PEG@e14a2, may 
be used to regulate CML cell proliferation and apoptosis (Figure 5.8). Such silencing potential is exerted 
with great sequence selectivity that may be used to selectively target those cells harboring a particular 
gene/gene isoform. This strategy may provide an additional wave of destruction to current TKIs, 
particularly in patients that display TKI toxicity and/or resistance and frequently relapse. It is clearly 
aligned with the recent recommendations of the ELN, due to the high cost to CML patients and public 
institutions of long-term treatment and the occurrence of adverse effects.38,489 Our procedure might open 
the way for the development of specific and selective molecular targeting approaches that should impact 
how we perceive chemotherapy and provide for enhanced precision for a range of drugs that have 




Figure 5.8 Gold nanoparticle (AuNP)-based BCR-ABL1 gene silencing. (1–6) In (1), AuNPs 
functionalized with the e14a2 antisense hairpin ssDNA oligonucleotide (AuNP@PEG@e14a2) are 
internalized by K562 cells, a CML in vitro model. (2) The Au-nanoconjugate recognizes BCR-ABL1 
mRNA expressed by these cells. The hairpin opens in the presence of the complementary BCR-ABL1 
sequence, silencing gene expression and triggering mRNA degradation and (3) leading to the translation 
inhibition of the encoded tyrosine kinase and to (4) the downregulation of Bcl-2 and the upregulation 
of Bax and caspase-3/7 activity. (5) The apoptotic pathway increases CML cell apoptosis and decreases 
proliferation and survival, ultimately killing BCR-ABL1 leukemic cells. (6) Conjugation of tyrosine 
kinase inhibitors (IM) with the gene-silencing Au-nanoconjugate should be an effective way to 
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After effective BCR-ABL1 silencing using gold nanoformulations, a few other lines of research 
were pursued to potentiate leukemia cells elimination. CML treatment relies mostly on its central player, 
BCR-ABL1, however this oncogenic pathway offers other targets to fight the deregulated proliferation, 
differentiation and apoptosis characteristic of Ph+ cells. For instance, the well-studied protooncogene 
c-MYC is one of the targets of BCR-ABL1 and is expressed at high level in CML cells.490 Indeed, in 
vitro inhibition of c-MYC with antisense oligonucleotides can inhibit BCR-ABL1 transformation or 
leukemogenesis.491 Our preliminary results show stable c-MYC inhibition after 24 h of exposure of 
K562 cells to AuNPs functionalized with 30 % PEG and an hairpin-shaped ssDNA oligonucleotide that 
targets c-MYC mRNA (AuNP@PEG@MYC). In vitro cells viability was also decreased to 
approximately 75 % after a 48 h-stimulus with the Au-nanoconjugate (Figure 5.9). The next stages of 
this project should include combination of c-MYC silencing with BCR-ABL1 silencing and/or inhibition 
with TKIs therapy. This collective strategy should be extremely advantageous since these agents will 
act on distinct molecules of the same pathway therefore increasing the chances of regulating CML cells 




Figure 5.9 In vitro c-MYC gene silencing on K562 cells using AuNP@PEG@MYC. A) Au-
nanoconjugate targeting c-MYC effectively silences the gene expressed by K562 cells. Plot represents 
mRNA relative expression after treatment of K562 cells with 0.6 nM AuNP@PEG@MYC 
(corresponding to 40 nM oligonucleotide). Data were normalized to the 18S gene and then to cells 
exposed to AuNP@PEG. Ct, threshold cycle. B) Cell viability over time on K562 cells challenged with 
the silencing nanoconjugate (MTS assay). Data were normalized to cells exposed to AuNP@PEG. Error 
bars represent the standard error of the mean of at least three independent experiments. **p < 0.01, 

























































Although AuNPs can act as imaging agents on their own, which could be used to locate them in 
vivo, several imaging components/strategies can be loaded onto the NP to monitor its effect on cells, 
e.g., gene silencing. Thus, we tested a nanotheranostics approach based on AuNPs functionalized with 
beacons.122,240,304,306 Our strategy coupled a fluorescent molecule to the distal end (3’) of the hairpin-
shaped silencing oligonucleotide (Au-nanobeacons) combined with FRET based spectral codification 
for the detection of BCR-ABL1 fusion sequence (e14a2 isoform). In the absence of a complementary 
sequence, the hairpin should be in closed conformation and the AuNP acts as a fluorescence quencher 
due to its proximity to the fluorophore. Presence of a complementary target (e14a2 mRNA) opens the 
hairpin structure and enables fluorescence recovery. Additionally, this fluorophore acts as a donor for 
FRET to an acceptor fluorophore on a second oligonucleotide sequence that will hybridize in the 
vicinity of the donor upon target recognition.122 The existing array of available fluorescent molecules 
makes it possible to develop a range of Au-nanoconjugates suitable for monitoring each BCR-ABL1 
isoform silencing. The specific spectral signature of donor and acceptor pairs formed provides an 
additional level of information of the hybridization events occurring in solution.  
The described approach has been previously tested for BCR-ABL1 detection using synthetic 
oligonucleotide solutions as a platform for CML diagnostics.122 We have now tested it on K562 cells 
for the real-time monitoring of BCR-ABL1 silencing, using fluorescence microscopy (Figure 5.10). 
These preliminary data show that the strategy is highly specific for cells that express the e14a2 
transcript, even when using the Au-nanobeacon alone. Several other experiments should be envisaged 
to understand the FRET phenomenon, and its advantages, under these conditions. Since fluorescence 
microscopy filters are very broad and generic, these same in vitro tests should be performed on a 
fluorescence spectrophotometer for a more fine control over excitation/emission wavelengths, and 
better distinction between fluorophores (donor vs acceptor) and their separate contributions to the 
detected signal. Because cells were examined over discrete periods of time (6, 12 and 24 h), one could 
perform a live cell imaging experiment to better control this Au-nanobeacon-based methodology over 
time.  
While the described results using AuNPs are very promising for CML theranostics, numerous 
parameters should be optimized, which will be discussed in more detail in the next chapter of this thesis 












Figure 5.10 In vitro real-time imaging of BCR-ABL1 silencing. A) Fluorescence microscopy of K562 
cells challenged with e14a2 targeting Au-nanobeacon (donor molecule, sulfoindocyanine Cy3) and/or 
acceptor (Dy-520XL). Representative fluorescence microscopy images are shown with corresponding 
scale bars (50 µm). B) Fluorescence intensity quantification per cell, per condition, after background 
correction. Three different cell lines (HL60, BV173 and K562) were used to evaluate the specificity of 
the Au-nanobeacon/acceptor (48 h-stimulus). Error bars represent the standard error of the mean of at 
least three independent experiments. For additional information on this strategy design, please refer to 
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6.1 Final considerations 
Cancer nanomedicine has been deeply focused on two main vectors: solutions for accurate 
molecular characterization of tumors and new approaches for improved chemotherapy. However, most 
of these advances are still in the pre-clinical stage of research and far from substituting or assisting 
traditional cancer management procedures. Moreover, the vast majority of these nanoformulations have 
been designed and directed at solid tumors, due to their well-studied architecture, invasiveness and 
distinctive confined localization, in detriment of liquid tumors.  
Nevertheless, several factors inherent to hematological malignancies, particularly leukemia, show 
their potential as targets of smart nanomaterials and how much these diseases would benefit from a 
more personalized approach than current diagnostics and treatment regimens. First and foremost, 
leukemia requires less invasive techniques to obtain hematological, cytogenetic and molecular 
information on the tumor, since a simple blood withdraw is enough to collect these data and correlates 
perfectly with bone marrow levels. Although leukemia is a very diverse disease, all subgroups hallmarks 
are well-defined, which is essential for biomarker detection and specific abnormal cells ablation. 
Attention was given to CML, since it is associated to a unique chromosomal abnormality that results in 
the fusion of BCR and ABL1 genes, present in virtually all patients; also, molecular characterization of 
this genetic alteration is essential for treatment success. Moreover, the disease has got a local 
environment to target (e.g. bone marrow) but most of its malignant cells are circulating through the 
body, thus requiring smarter approaches for tackling these cancer cells with increased efficacy. Many 
features of NPs have been described in this thesis that make them entirely suitable candidates towards 
CML nanotheranostics, a central approach in precision oncology as it allows the integration of 
diagnostics and therapeutics in a single material through NPs engineering. 
 
Cytogenetic and molecular monitoring plays an essential role in the management of leukemia 
patients at diagnosis and during disease progression. Indeed, chapter 2 of this thesis was paramount for 
medical decision making in cases harboring known genetic variations, but also disclosed new clinical 
cases and provided an integrated analysis between patient’s molecular profile, disease treatment and 
progression. This was particularly relevant for the three cases described in more detail in that chapter 
(clinical cases 44, 54 and 7). Although further bioinformatic studies are still needed, for instance on 
mutation modelling, protein mutagenesis, structure and function, these reports are likely to improve the 
knowledge on leukemia pathogenesis and, in the future, aid patients harboring similar genetic 
aberrations.  
Several issues related to cytogenetic and molecular characterization of leukemia samples were 
encountered. Cytogenetic testing lacks sensitivity for CML follow-up, since BCR-ABL1 transcripts 
remain detectable far beyond samples testing negative for t(9;22) via FISH. Molecular monitorization 
using RT-PCR overcomes this limitation, due to its well-known sensitivity and specificity, however it 
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is time-consuming, complex, error-prone and expensive. Thus, new solutions should be envisaged to 
mitigate these issues. 
Another issue relates to BCR-ABL1 transcript identification which is highly important, not only for 
suitable disease monitoring since transcript levels should be compared to the correct standard, but also 
for prognosis evaluation given that different transcripts are associated to distinct disease progression 
and treatment responses. Indeed, recent recommendations from ELN state that transcript variant 
identification should be performed at diagnosis. However, most routine tests done in hospital settings 
only quantify the most frequent BCR-ABL1 isoforms (e14a2 or e13a2), and these distinct molecular 
entities are usually regarded as the same phenotypical group.  
For all these reasons, samples described on chapter 2 were used for proof-of-concept of emerging 
molecular technologies to advance monitoring in CML. Note that the process of implementing a 
molecular genetic test for diagnostic use is complex and involves many levels of assessment, and most 
methodologies do not leave pre-clinical stages due to lack of appropriate samples for clinical validation. 
 
Numerous biosensing platforms have been proposed relying on the optical properties of AuNPs. 
Thus, chapter 3 focused on CML diagnosis and enabled the optimization of a new methodology for 
CML detection, based on Au-nanoprobes. This colorimetric approach was previously optimized using 
total RNA from leukemia cell lines,123,124 however, we present for the first time the validation of NCL 
method using samples derived from leukemia patients, and compare its sensitivity and specificity to 
standardized clinical procedures for CML detection and characterization. Though the test was 
performed on a small sample size, one must considerer the incidence of Ph+ diseases and the time frame 
of this project.  
The results obtained using Au-nanoprobes and total RNA from clinical samples show the robustness 
of the test, namely PPV and NPV values (100 %). The assay, not only detected BCR-ABL1-positive 
samples, but also enabled distinction between the most frequent isoforms (e14a2 vs e13a2). The 
outcome is particularly attractive taking into consideration that the extracted RNA was mixed directly 
with Au-nanoprobes, without amplification via RT-PCR or other methodology, thus reducing time and 
complexity when compared to routine molecular diagnostics. 
The features of the Au-nanoprobe assay are ideal for CML molecular diagnostics, since according 
to the ELN and NCCN guidelines, BCR-ABL1 molecular monitoring is required every 3 months after 
disease diagnosis and until DMR is achieved. Although RT-PCR has been highly optimized in terms of 
transcript quantification and international harmonization of results, the procedural aspects of the 
technique are still complex and time-consuming. Due to the inherent simplicity of the Au-nanoprobe 
assay at a very small scale, the test is suitable for a fast an accurate preliminary screening of CML, thus 
assisting routine methodologies such as RT-qPCR. Sensitivity levels of the assay are also promising 
since it was able to detect the e14a2 transcript in a sample that exhibited levels as low as 0.34 % BCR-
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ABL1 IS. However, additional optimization is needed to achieve the sensitivity values required by ELN 
or NCCN guidelines for CML molecular tests (0.01 % BCR-ABL1 IS; corresponding to DMR).38 After 
complete cytogenetic response is attained, patient molecular stratification is the cornerstone of CML 
monitoring due to the advent of highly effective TKIs, sophisticated molecular tools and automated 
analytical solutions. Moreover, the Au-nanoprobe assay seems to be highly dependent on total RNA 
quantity, since samples with RNA concentration below 15 ng/µL constantly scored as negative, 
independently of their transcript type. These issues, and potential solutions, will be further explored in 
the Future perspectives section. 
 
Au-nanoprobe assays offer the additional possibility of incorporation into chip-based detection 
devices. Indeed, the previous CML diagnostic method, optimized to detect BCR-ABL1 directly from 
total RNA extracted from cells, was successfully translated onto a microfluidic platform, integrating 
the mixing of the system components and optic detection (chapter 4). This new design allowed to 
achieve faster and accurate results using lower volumes than its off-chip version, mostly due to the scale 
of the device and the fast transition between injection of samples, mixing and photodetection.  
Both versions of the Au-nanoprobe assay described in this thesis (off-chip or on-chip) can offer 
solutions for different clinical settings. The microfluidics chip may be a suitable solution for CML 
healthcare worldwide, since it is made of a disposable cheap POC platform with a non-disposable 
component integrating the light sources and photodetector, for a fast low-volume screening. However, 
its cost, though lower than conventional methodologies, might still be unaffordable for some countries. 
In these cases, the simple off-chip version of the assay can be an appropriate solution, since it requires 
fewer resources. AuNP-based diagnostics may bring molecular diagnostics to remote and impoverished 
countries where monitoring strategies are strict and limited, enabling worldwide efforts to diagnose and 
control CML. Many patients and clinicians still do not have access to reproducible and standardized 
BCR-ABL1 testing. Shipping reference samples to smaller facilities located in isolated regions, or even 
perform any kind of molecular testing, may not always be feasible or cost-effective.  
Nevertheless, proper comparison between these methodologies can only occur after completion of 
the microfluidic device to include the hybridization step of the Au-nanoprobe colorimetric assay and, 
possibly, an upstream module for automatized RNA extraction in a closed system, as way to decrease 
the differences in performance between sites, operators, days, and prevent contaminations. Differences 
between methodologies (Off-chip Au-nanoprobe assay vs microfluidic device vs RT-PCR) should then 
be assessed using clinical samples and IS standards.  
 
On the last part of this thesis, focus was given to CML therapeutics and its challenges (chapter 5). 
All the information gathered and optimized for the design of a specific Au-nanoprobe, targeting the 
most frequent BCR-ABL1 transcript, was used to develop a Au-nanoconjugate intended to silence the 
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e14a2 isoform of the gene. The sequence-selective silencing nanoconjugate, AuNP@PEG@e14a2, 
regulated CML cells proliferation and apoptotic pathways in vitro. Even though this was a transient 
effect, the nanoformulation enabled a decrease on imatinib’s IC50, meaning a lower dose was required 
to achieve the same result, and induced a viability decrease on IM-resistant cells. This NP-based 
treatment strategy is particularly relevant for patients that exhibit aggressive side effects and/or do not 
respond to TKIs. ELN guidelines show the importance of discontinuing TKI therapy, achieving DMR 
and maintaining the operational cure, due to the associated cost of CML management and the burden 
caused to patients.489 Novel therapy options should be researched in order to enhance TKI precision in 
the clinics, but also to avoid allogeneic transplantation (salvage therapy) in case of complete 
unresponsiveness to chemotherapy. 
Other studies have shown that silencing of c-MYC in various BCR-ABL1 positive cell lines causes 
significant downregulation of BCR-ABL1, decreases proliferation rate and induces cell death in CML 
cells. Hence, based on the same strategy applied for BCR-ABL1 gene silencing using AuNPs, a second 
Au-nanoconjugate was designed targeting c-MYC, as to achieve a higher effect on K562 cells viability. 
Though more stable over time, the effect obtained using this nanoconstruct was very similar to the one 
obtained when using the one targeting BCR-ABL1, which might be due to the close interplay of these 
two oncogenes. However, several other conditions should be tested, namely, a combined stimulus with 
both agents. One should also keep in mind c-MYC primary oncogenic role across several tumors, 
meaning the designed construct (AuNP@PEG@MYC) may be used against other malignancies thus 
attaining a more versatile function than that of AuNP@PEG@e14a2.  
After accomplishing effective Au-nanotherapeutics based on gene silencing, a nanotheranostics 
strategy for CML was considered. Gold nanotheranostics opens a new venue for complex differential 
diagnostics, and therapy of the disease. The ability of AuNPs to specifically target and probe tumor 
cells makes them a useful delivery system for anticancer agents. The type of formulation additives used 
can also improve visualization and control over the effects of these agents in vitro and in vivo. The 
tested approach enabled the real-time monitoring of specific gene-silencing events on K562 cells, 
however it requires a deeper analysis and further experiments to understand all underlying mechanisms: 
route of AuNPs internalization; cellular localization and distribution; antisense oligonucleotide/target 
hybridization dynamics; and fluorescence/FRET events. Besides, a more complete version of this 
nanoconstruct should be envisaged to enhance its efficacy and specificity, which will be discussed on 
the Future perspectives section.  
 
This work allowed a better understanding on the molecular basis of leukemia and the way it defines 
prognosis and treatments options. However, it mostly contributed to the development of new tools for 
CML management, at both point-of-care diagnostics and early development of a nanotheranostics 
approach to selectively eliminate malignant cells, and help conventional therapies.  
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6.2 Future perspectives 
Although the line of research of this thesis answered several questions regarding leukemogenesis 
and provided novel solutions for biomarker detection and therapeutics, much remains to be done for 
these nanomedicines to be more effective, standardized, certified and reach clinical settings. Hence, 
potential future stages on this project will be discussed in this section. 
 
Leukemia molecular monitoring 
The way several biomarkers influence leukemia prognosis is of utmost importance. For instance, 
mutations on CEBPA, NPM1, and FLT3 genes are among the most common and bear important 
prognostic significance for AML. However, diagnostic testing for CEBPA mutations in cytogenetically 
normal AML is hindered by technical challenges associated with the GC content of the gene, the 
complex nature of the mutations, including frequent expansions or contractions of homopolymer 
sequences and the large number of different insertions and deletions, and the complexity of the sequence 
analysis and variant interpretation. Suitable alternatives for detection of all CEBPA mutations should 
be designed: iPLEX-MassArray, next generation sequencing or high-resolution melting.  
On the contrary, molecular monitoring of Ph+ diseases, namely transcript identification, 
quantification and mutational screening, is highly standardized in clinical laboratories. Nevertheless, 
there is still room for improvement in terms of methodologies complexity, time required to obtain 
results, increase the amount of information provided by fewer tests and the invasiveness of sample 
collection (e.g., bone marrow biopsy vs peripheral blood withdraw). 
Alternate approaches for molecular response assessment are currently being explored to investigate 
whether enhanced sensitivity may help achieving treatment-free remission and TKI discontinuation in 
a greater proportion of CML patients, and to widen the access to reliable and standardized monitoring, 
namely by probing different key players of the disease (e.g., BCR-ABL1 gDNA, mRNA, protein or 
different molecules on the BCR-ABL1 signaling pathway).492 NPs are excellent tools to probe the 
disease at different stages: early-phase, chronic-phase, accelerated phase, or remission. Indeed, the same 
Au-nanoprobe used to monitor BCR-ABL1 transcripts is suitable to detect the same sequence in gDNA, 
after DMR is achieved. Furthermore, these nanostructures can be functionalized with specific antibodies 
to probe for disease biomarkers at protein level in more complex fluids, such as serum, in a similar 
strategy designed by Weerkamp et al (2009).30 By using AuNPs functionalized with antibodies that 
recognize BCR epitopes in the most upstream part of the BCR protein and another set that recognizes 
the ABL1 epitope located downstream of exon 3, the assay enables the detection of all BCR-ABL1 
isoforms. A crosslinking approach should be the most appropriate solution for this assay, since only the 
presence of a complementary target to both antibodies (BCR-ABL1 fusion protein) will decrease 




BCR-ABL1 isoforms complete screening 
Although the e14a2 BCR-ABL1 isoform accounts for more than half of CML cases, the optimized 
Au-nanoprobe assay should target other transcripts: the common isoform e13a2 and rare variants. All 
the information collected for the e14a2 isoform biosensing using Au-nanoprobes, namely sequence 
design and test conditions, should aid on the development of an array test for additional BCR-ABL1 
isoforms. This would enable a high throughput molecular screening of all Ph+ patients. 
The method can be further adapted to allow BCR-ABL1 mutational screening and the associated 
TKIs resistance mechanisms (at least for the most common TKI resistance mutations). In fact, the Au-
nanoprobe assay has been successfully optimized to detect single nucleotide variations for other 
diseases.193, 199, 207, 419,493  
  
BCR-ABL1 transcript quantification 
The optimized Au-nanoprobe assay was proven to be very effective as a qualitative method for 
CML biosensing. Transcript identification at the time of diagnosis is in accordance to recent ELN and 
NCCN guidelines, since it is imperative for correct follow-up and can help choosing a suitable 
therapeutic regimen. Nevertheless, BCR-ABL1 quantification is required for disease monitoring 
throughout the course of the disease. The AuNPs colorimetric method can in fact be adapted for gene 
quantification. This was demonstrated by Conde et al, where the Au-nanoprobe assay showed a linear 
correlation for BCR-ABL1 detection within the range of 10-60 ng/μl of total RNA.123,124 
Nevertheless, if BCR-ABL1 quantification using Au-nanoprobes is to be pursued, several 
parameters should be considered. The novel methodology for measuring BCR-ABL1 transcript levels in 
patients with CML should be compared to IS values to allow comparison to RT-qPCR sensitivity and 
accuracy, as well as results harmonization between individual laboratories. Moreover, the method 
robustness and sensitivity can be improved by using an isothermal amplification technique, such as 
rolling circle amplification (RCA). Indeed, a recent study using RCA on K562 RNA samples allowed 
for the direct quantification of BCR-ABL1 genes at room temperature, eliminating the requirement for 
external temperature controllers and overall complexity of the molecular diagnostic approach, thus 
making it more suitable for integration on a biomolecular recognition device for POC.494 
 
On-chip BCR-ABL1 detection 
The microfluid version of the colorimetric method has been fully validated using RNA samples 
from leukemia cell lines, however results should be corroborated using patient-derived samples as 
previously done for the off-chip setting. Future work shall also focus on the integration of a 
hybridization module on the microfluidic platform, upstream the mixing and photodetection 
components. Although the inclusion of a temperature-controlled chamber in the device raises several 
technical issues, it unlocks the possibility for a more complex, automatized and cost-effective CML 
detection assay, thus enabling a fast screening of diagnostic and follow-up samples. 
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The final version of the lab-on-chip is envisaged to include a complete setup for blood analysis, 
from RNA extraction to biomarker detection.  The micro-scale of the complete device should provide 
an output faster than existing automatized equipment (Genexpert) using smaller sample volumes.220, 
419,422 
  
CML gene silencing 
By targeting BCR-ABL1, our designed Au-nanoconjugate provided for an effective solution to 
overcome TKI resistance in CML. Yet, these resistance mechanisms can also be BCR-ABL1 
independent. Overexpression of MDR1, the gene encoding for a drug efflux pump, has been identified 
as a mechanism of resistance to IM.33,94 CML resistance reversal can be achieved by silencing the MDR1 
gene therefore increasing IM intracellular levels. 
A different strategy might be related to miRNAs. miRNA expression profiles can clearly distinguish 
CML patients from healthy individuals, CML phases, and between patients either responding or not 
responding to TKI therapy.495,496 Identification of miRNAs that directly target the expression of BCR-
ABL1 may play a role in the miRNA-based therapy in CML. In effect, miR-17/92 cluster has been well 
characterized in the context of CML, with specific molecular mechanisms. Upregulation of this 
miRNAs cluster has been described as the result of a transactivation by the BCR-ABL1-MYC pathway 
in early chronic phase.  
Note that AuNPs provide an appropriate vector to convey all the mentioned alternatives to tackle 
CML, as it was demonstrated with AuNP@PEG@e14a2. Furthermore, they can be functionalized with 
distinct silencing oligonucleotides in a multifunctional strategy, targeting different key players on CML 
pathogenesis: BCR-ABL1, MDR1, miRNAs or anti-apoptotic genes. Yet, other nanoscale vehicles can 
be used to achieve effective gene therapy: liposomes, cationic polymers, dendrimers and 
exosomes.462,497,498 These vectors protect nucleic acids from rapid degradation in plasma and cellular 
cytoplasm, thus increasing their short half-life. However, all of them seem to possess the same 
drawback, as they are only able to induce a transient gene-silencing effect, most likely due to the dilution 
of the effector molecule upon cell division and its degradation upon intracellular release. To achieve 
prolonged gene silencing, a controlled release approach should be considered. One can also combine 
the advantages of the mentioned vehicles in a single system. For instance, the unique physicochemical 
and optical properties of AuNPs can be encapsulated onto a cationic liposomes or dendrimers to enhance 
the stability of negatively charged nucleic acids in the bloodstream and improve their cellular 
delivery.499,500 
Although I have demonstrated the efficacy of in vitro gene silencing using AuNPs towards CML 
therapeutics, a few parameters remain to be tested, namely, a complete comparison between the effect 
of the nanoformulation (AuNP@PEG@e14a2) against the effect of the silencing moiety alone or in 
combination to other vehicles. Moreover, one can apply the same strategy but using siRNA technology. 
Antisense ssDNA oligonucleotides and siRNAs share important similarities as gene expression 
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modulators. However, their design and mechanism are quite different: an antisense ssDNA 
oligonucleotide must function as a single strand; on the contrary, siRNA duplexes cooperate with the 
RNA-induced silencing complex (RISC) to bind complementary RNA. This basic difference may lower 
cost and simplify delivery, in favor of the antisense ssDNA technology. Still, siRNAs have been more 
thoroughly studied in cell culture, however it is not clear whether this efficacy translates to in vivo trials. 
Different gene therapy technologies have different strengths and weaknesses, nevertheless the main 
problem is that most have not crossed the pre-clinical stages of research.  
 
Nanotheranostics for CML 
Even though the results shown in chapter 5 of this thesis are very promising for the development of 
a nanotheranostics platforms towards personalized management of CML, other components need to be 
added to the silencing Au-nanoconjugate/Au-nanobeacon for it to be exceedingly effective. 
In what concerns leukemia, passive targeting via EPR might be an aspect to consider when treating 
the core of the disease (bone marrow),501 however the bulk of malignant cells is spread through 
peripheral blood. Hence, active targeting is particularly important when treating blood-borne diseases 
to enhance the effect on circulating abnormal cells without damaging healthy ones. Adding folic acid 
to the Au-nanoconjugate will likely improve tumor cell selectivity and the uptake efficiency of the 
nanoformulation, since folate receptors are highly overexpressed on the surface of many tumor types, 
including CML. Folate and folate conjugates can bind to its receptor with high affinity and be 
internalized by cells via receptor-mediated endocytosis, while avoiding normal cells that express low 
levels of these surface proteins.502 Interleukin-3 receptor is also overexpressed in CML blasts compared 
to normal hematopoietic cells and thus is able to act as a receptor target in a cancer drug delivery 
system.503 
Finally, one can take advantage of the nanocarrier to deliver IM to CML cells. Combining the TKI 
and the BCR-ABL1 silencing moiety in the same particle should enhance their separate effects for two 
main reasons: it ensures a higher payload of the drug into cells, when compared to the free drug, and 
that both therapeutic functions would be synchronized in time and space. This approach would be highly 
beneficial from a clinical point of view, since it would decrease the off-target effects of IM, by using a 
controlled release mechanism and active targeting, and it would avoid a repeated challenge to the 
patient’s bloodstream. Though this new strategy is foreseen to mitigate the well-studied TKIs resistance 
mechanisms, one should contemplate the occurrence of new tolerance mechanisms against the proposed 
nanoconjugates. Further focus on pharmacokinetic, pharmacodynamic and toxicology status of 
nanoformulations needs to be clarified, as well as the economic viability of the end use product. 
Considering that these additional changes will improve the Au-nanoconjugate/Au-nanobeacon 
efficacy, a more complete version of the nanoformulation should be tested in pre-clinical models of 
CML.  
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 Leukemia in vitro and in vivo models 
We have developed an in vitro model for IM resistance CML. The results we obtained suggest that 
cells respond to IM increasing concentrations by overexpressing BCR-ABL1, but after prolonged 
exposure and for higher doses of TKI, other mechanisms may take place.97 Further studies are needed 
to assess this model: BCR-ABL1 protein and drug transporters expression profile, and whether 
resistance to IM is stable or can in fact be overturned. Note that the problem of drug resistance cannot 
be solved solely by circumventing BCR-ABL1 expression, but also the expression of drug transporters 
or anti-apoptotic proteins involved in the complex CML network. This model is relevant to establish 
the possible mechanisms of resistance in CML and open the way for more effective pharmacological 
intervention. 
The success of nanomedicines development at a pre-clinical stage depends greatly on the 
availability of in vivo tumor models that can mimic the real human tumor environment. Leukemia 
models show several obstacles, namely related to the fact that the pathogenesis of the disease in murine 
models is not relevant to most human cases; also, they fail to replicate the complex microenvironment 
from which these human cancers arise, and do not embody their genetic and molecular 
heterogeneity.504,505 Xenografts mitigate some of these issues, but because they are usually conducted 
on immunocompromised mice to avoid immune rejection of the human cells, they eliminate the effects 
of the immune system on tumor expansion and on NPs efficacy and targeting.505 The variability of 
experimental conditions between the different pre-clinical studies using NPs to tackle leukemia also 
contribute to their reduced clinical impact. Protocols for standardization of experiments should be 
implemented to mitigate this issue. 
 
Clinical translation 
Though the potential of nanomedicines is huge, much remains to be done to translate 
nanoformulations into clinical practice. Numerous parameters must be studied: pharmacokinetics 
(including internalization, biodistribution, clearance and toxicity), efficacy, classification, 
standardization, scalability and safety guidelines. FDA, EMA and the Nanotechnology Characterization 
Laboratory are gathering relevant information to mitigate some of these issues. However, theranostics 
still exists in a grey area since most information refers exclusively to therapeutics or to diagnostics. The 
mentioned issues should be urgently tackled since nanomedicines are now entering a decisive phase of 
clinical trials. Being cancer the main target when designing nanotheranostics approaches, one can 
speculate that nanomedicines clinical research is ahead of regulatory protocols establishment because 
most clinical trials are conducted in late-stage cancer patients, when cutting edge treatments might be 
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APPENDICES 
Appendix I – Clinical case 44 BCR-ABL1 transcript identification and mutational 
analysis 
 
Seq 1    1    TTCCGCTGACCATCAACAAGGAAGATGATGAGTCTCCGGGGCTCTATGGGTTTCTGAATG  60 
              ||||||||||||||||*||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    275  TTCCGCTGACCATCAATAAGGAAGATGATGAGTCTCCGGGGCTCTATGGGTTTCTGAATG  334 
 
Seq 1    61   TCATCGTCCACTCAGCCACTGGATTTAAGCAGAGTTCAAAAGCCCTTCAGCGGCCAGTAG  120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    335  TCATCGTCCACTCAGCCACTGGATTTAAGCAGAGTTCAAAAGCCCTTCAGCGGCCAGTAG  394 
 
Seq 1    121  CATCTGACTTTGAGCCTCAGGGTCTGAGTGAAGCCGCTCGTTGGAACTCCAAGGAAAACC  180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    395  CATCTGACTTTGAGCCTCAGGGTCTGAGTGAAGCCGCTCGTTGGAACTCCAAGGAAAACC  454 
 
Seq 1    181  TTCTCGCTGGACCCAGTGAAAATGACCCCAACCTTTTCGTTGCACTGTATGATTTTGTGG  240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    455  TTCTCGCTGGACCCAGTGAAAATGACCCCAACCTTTTCGTTGCACTGTATGATTTTGTGG  514 
 
Seq 1    241  CCAGTGGAGATAACACTCTAAGCATAACTAAAGGTGAAAAGCTCCGGGTCTTAGGCTATA  300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    515  CCAGTGGAGATAACACTCTAAGCATAACTAAAGGTGAAAAGCTCCGGGTCTTAGGCTATA  574 
 
Seq 1    301  ATC  303 
              ||| 
Seq 2    575  ATC  577 
 
Figure I.1 Alignment of CML patient (sample 44) e14a2 nucleotide sequence [Seq 1] with BCR-ABL1 
e14a2 reference sequence from GenBank AJ131466.1 [Seq 2]. *Detected SNP on BCR exon 13, 





Seq 1    1    CGCCGCAGTGCCATAAGCGGCACCGGCACTGCCCGGTTGTCGTGTCCGAGGCCACCATCG  60 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    330  CGCCGCAGTGCCATAAGCGGCACCGGCACTGCCCGGTTGTCGTGTCCGAGGCCACCATCG  389 
 
Seq 1    61   TGGGCGTCCGCAAGACCGGGCAGATCTGGCCCAACGATGGCGAGGGCGCCTTCCATGGAG  120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    390  TGGGCGTCCGCAAGACCGGGCAGATCTGGCCCAACGATGGCGAGGGCGCCTTCCATGGAG  449 
 
Seq 1    121  ACGCAGATGGCTCGTTCGGAACACCACCTGGATACGGCTGCGCTGCAGACCGGGCAGAGG  180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    450  ACGCAGATGGCTCGTTCGGAACACCACCTGGATACGGCTGCGCTGCAGACCGGGCAGAGG  509 
 
Seq 1    181  AGCAGCGCCGGCACCAAGATGGGCTGCCCTACATTGATGACTCGCCCTCCTCATCGCCCC  240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    510  AGCAGCGCCGGCACCAAGATGGGCTGCCCTACATTGATGACTCGCCCTCCTCATCGCCCC  569 
 
Seq 1    241  ACCTCAGCAGCAAGGGCAGGGGCAGCCGGGATGCGCTGGTCTCGGGAGCCCTGGAGTCCA  300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    570  ACCTCAGCAGCAAGGGCAGGGGCAGCCGGGATGCGCTGGTCTCGGGAGCCCTGGAGTCCA  629 
 
Seq 1    301  CTAAAGCGAGTGAGCTGGACTTGGAAAAGGGCTTGGAGATGAGAAAATGGGTCCTGTCGG  360 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




Seq 1    361  GAATCCTGGCTAGCGAGGAGACTTACCTGAGCCACCTGGAGGCACTGCTGCTGCCCATGA  420 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    690  GAATCCTGGCTAGCGAGGAGACTTACCTGAGCCACCTGGAGGCACTGCTGCTGCCCATGA  749 
 
Seq 1    421  AGCCTTTGAAAGCCGCTGCCACCACCTCTCAGCCGGTGCTGACGAGTCAGCAGATCGAGA  480 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    750  AGCCTTTGAAAGCCGCTGCCACCACCTCTCAGCCGGTGCTGACGAGTCAGCAGATCGAGA  809 
 
Seq 1    481  CCATCTTCTTCAAAGTGCCTGAGCTCTACGAGATCCACAAGGAGTTCTATGATGGGCTCT  540 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    810  CCATCTTCTTCAAAGTGCCTGAGCTCTACGAGATCCACAAGGAGTTCTATGATGGGCTCT  869 
 
Seq 1    541  TCCCCCGCGTGCAGCAGTGGAGCCACCAGCAGCGGGTGGGCGACCTCTTCCAGAAGCTGG  600 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    870  TCCCCCGCGTGCAGCAGTGGAGCCACCAGCAGCGGGTGGGCGACCTCTTCCAGAAGCTGG  929 
 
Seq 1    601  CCAGCCAGCTGGGTGTGTACCGGGCCTTCGTGGACAACTACGGAGTTGCCATGGAAATGG  660 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    930  CCAGCCAGCTGGGTGTGTACCGGGCCTTCGTGGACAACTACGGAGTTGCCATGGAAATGG  989 
 
Seq 1    661  CTGAGAAGTGCTGTCAGGCCAATGCTCAGTTTGCAGAAATCTCCGAGAACCTGAGAGCCA  720 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    990  CTGAGAAGTGCTGTCAGGCCAATGCTCAGTTTGCAGAAATCTCCGAGAACCTGAGAGCCA  1049 
 
Seq 1    721  GAAGCAACAAAGATGCCAAGGATCCAACGACCAAGAACTCTCTGGAAAAAGCCCTTCAGC  780 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1050 GAAGCAACAAAGATGCCAAGGATCCAACGACCAAGAACTCTCTGGAAAAAGCCCTTCAGC  1109 
 
Seq 1    781  GGCCAGTAGCATCTGACTTTGAGCCTCAGGGTCTGAGTGAAGCCGCTCGTTGGAACTCCA  840 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1110 GGCCAGTAGCATCTGACTTTGAGCCTCAGGGTCTGAGTGAAGCCGCTCGTTGGAACTCCA  1169 
 
Seq 1    841  AGGAAAACCTTCTCGCTGGACCCAGTGAAAATGACCCCAACCTTTTCGTTGCACTGTATG  900 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1170 AGGAAAACCTTCTCGCTGGACCCAGTGAAAATGACCCCAACCTTTTCGTTGCACTGTATG  1229 
 
Seq 1    901  ATTTTGTGGCCAGTGGAGATAACACTCTAAGCATAACTAAAGGTGAAAAGCTCCGGGTCT  960 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1230 ATTTTGTGGCCAGTGGAGATAACACTCTAAGCATAACTAAAGGTGAAAAGCTCCGGGTCT  1289 
 
Figure I.2 Alignment of CML patient (sample 44) e6a2 nucleotide sequence [Seq 1] with BCR-ABL1 
e6a2 (GenBank AM491362.1), BCR (GenBank NM_004327.3) and ABL1 (GenBank NM_005157.5) 




Seq 1    1    GCAACAAGCCCACTGTCTATGGTGTGTCCCCCAACTACGACAAGTGGGAGATGGAACGCA  60 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    851  GCAACAAGCCCACTGTCTATGGTGTGTCCCCCAACTACGACAAGTGGGAGATGGAACGCA  910 
 
Seq 1    61   CGGACATCACCATGAAGCACAAGCTGGGCGGGGGCCAGTACGGGGAGGTGTACGAGGGCG  120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    911  CGGACATCACCATGAAGCACAAGCTGGGCGGGGGCCAGTACGGGGAGGTGTACGAGGGCG  970 
 
Seq 1    121  TGTGGAAGAAATACAGCCTGACGGTGGCCGTGAAGACCTTGAAGGAGGACACCATGGAGG  180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    971  TGTGGAAGAAATACAGCCTGACGGTGGCCGTGAAGACCTTGAAGGAGGACACCATGGAGG  1030 
 
Seq 1    181  TGGAAGAGTTCTTGAAAGAAGCTGCAGTCATGAAAGAGATCAAACACCCTAACCTGGTGC  240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1031 TGGAAGAGTTCTTGAAAGAAGCTGCAGTCATGAAAGAGATCAAACACCCTAACCTGGTGC  1090 
 
Seq 1    241  AGCTCCTTGGGGTCTGCACCCGGGAGCCCCCGTTCTATATCATCACTGAGTTCATGACCT  300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1091 AGCTCCTTGGGGTCTGCACCCGGGAGCCCCCGTTCTATATCATCACTGAGTTCATGACCT  1150 
 
Seq 1    301  ACGGGAACCTCCTGGACTACCTGAGGGAGTGCAACCGGCAGGAGGTGAACGCCGTGGTGC  360 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1151 ACGGGAACCTCCTGGACTACCTGAGGGAGTGCAACCGGCAGGAGGTGAACGCCGTGGTGC  1210 
  187 
 
 
Seq 1    361  TGCTGTACATGGCCACTCAGATCTCGTCAGCCATGGAGTACCTGGAGAAGAAAAACTTCA  420 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1211 TGCTGTACATGGCCACTCAGATCTCGTCAGCCATGGAGTACCTGGAGAAGAAAAACTTCA  1270 
 
Seq 1    421  TCCACAGAGATCTTGCTGCCCGAAACTGCCTGGTAGGGGAGAACCACTTGGTGAAGGTAG  480 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1271 TCCACAGAGATCTTGCTGCCCGAAACTGCCTGGTAGGGGAGAACCACTTGGTGAAGGTAG  1330 
 
Seq 1    481  CTGATTTTGGCCTGAGCAGGTTGATGACAGGGGACACCTACACAGCCCATGC  532 
              |||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1331 CTGATTTTGGCCTGAGCAGGTTGATGACAGGGGACACCTACACAGCCCATGC  1382 
 
Figure I.3 Alignment of CML patient (sample 44) ABL1 nucleotide sequence (exons 4-7), from the 




Seq 1    1    TGAGCAGGTTGATGACAGGGGACACCTACACAGCCCATGCTGGAGCCAAGTTCCCCATCA  60 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1343 TGAGCAGGTTGATGACAGGGGACACCTACACAGCCCATGCTGGAGCCAAGTTCCCCATCA  1402 
 
Seq 1    61   AATGGACTGCACCCGAGAGCCTGGCCTACAACAAGTTCTCCATCAAGTCCGACGTCTGGG  120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1403 AATGGACTGCACCCGAGAGCCTGGCCTACAACAAGTTCTCCATCAAGTCCGACGTCTGGG  1462 
 
Seq 1    121  CATTTGGAGTATTGCTTTGGGAAATTGCTACCTATGGCATGTCCCCTTACCCGGGAATTG  180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1463 CATTTGGAGTATTGCTTTGGGAAATTGCTACCTATGGCATGTCCCCTTACCCGGGAATTG  1522 
 
Seq 1    181  ACCTGTCCCAGGTGTATGAGCTGCTAGAGAAGGACTACCGCATGGAGCGCCCAGAAGGCT  240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1523 ACCTGTCCCAGGTGTATGAGCTGCTAGAGAAGGACTACCGCATGGAGCGCCCAGAAGGCT  1582 
 
Seq 1    241  GCCCAGAGAAGGTCTATGAACTCATGCGAGCATGTTGGCAGTGGAATCCCTCTGACCGGC  300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1583 GCCCAGAGAAGGTCTATGAACTCATGCGAGCATGTTGGCAGTGGAATCCCTCTGACCGGC  1642 
 
Seq 1    301  CCTCCTT  307 
              ||||||| 
Seq 2    1643 CCTCCTT  1649 
 
Figure I.4 Alignment of CML patient (sample 44) ABL1 nucleotide sequence (exons 7-9), from the 





Seq 1    1    GTGGGAGATGGAACGCACAGACATCACCATGAAGCACAAGCTGGGCGGGGGCCAGTACGG  60 
              ||||||||||||||||||*||||||||||||||||||||||||||||||||||||||||| 
Seq 2    894  GTGGGAGATGGAACGCACGGACATCACCATGAAGCACAAGCTGGGCGGGGGCCAGTACGG  953 
 
Seq 1    61   GGAGGTGTACGAGGGCGTGTGGAAGAAATACAGCCTGACGGTGGCCGTGAAGACCTTGAA  120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    954  GGAGGTGTACGAGGGCGTGTGGAAGAAATACAGCCTGACGGTGGCCGTGAAGACCTTGAA  1013 
 
Seq 1    121  GGAGGACACCATGGAGGTGGAAGAGTTCTTGAAAGAAGCTGCAGTCATGAAAGAGATCAA  180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




Seq 1    181  ACACCCTAACCTGGTGCAGCTCCTTGGGGTCTGCACCCGGGAGCCCCCGTTCTATATCAT  240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1074 ACACCCTAACCTGGTGCAGCTCCTTGGGGTCTGCACCCGGGAGCCCCCGTTCTATATCAT  1133 
 
Seq 1    241  CACTGAGTTCATGACCTACGGGAACCTCCTGGACTACCTGAGGGAGTGCAACCGGCAGGA  300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1134 CACTGAGTTCATGACCTACGGGAACCTCCTGGACTACCTGAGGGAGTGCAACCGGCAGGA  1193 
 
Seq 1    301  GGTGAACGCCGTGGTGCTGCTGTACATGGCCACTCAGATCTCGTCAGCCATGGAGTACCT  360 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1194 GGTGAACGCCGTGGTGCTGCTGTACATGGCCACTCAGATCTCGTCAGCCATGGAGTACCT  1253 
 
Seq 1    361  GGAGAAGAAAAACTTCATCCACAGAGATCTTGCTGCCCGAAACTGCCTGGTAGGGGAGAA  420 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1254 GGAGAAGAAAAACTTCATCCACAGAGATCTTGCTGCCCGAAACTGCCTGGTAGGGGAGAA  1313 
 
Seq 1    421  CCACTTGGTGAAGGTAGCTGATTTTGGCCTGAGCAGGTTGATGACAGGGGACACCTACAC  480 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1314 CCACTTGGTGAAGGTAGCTGATTTTGGCCTGAGCAGGTTGATGACAGGGGACACCTACAC  1373 
 
Seq 1    481  AGCCCATGCTGGAGCCAAGTTCCCCATCAAATGGACTGCACCCGAGAGCCTGGCCTACAA  540 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1374 AGCCCATGCTGGAGCCAAGTTCCCCATCAAATGGACTGCACCCGAGAGCCTGGCCTACAA  1433 
 
Figure I.5 Alignment of CML patient (sample 44) ABL1 nucleotide sequence (exons 4-7), from the 
e6a2 isoform [Seq 1], with ABL1 reference sequence from GenBank NM_005157.5 [Seq 2]. *Detected 




Seq 1    1    AGTTCCCCATCAAATGGACTGCACCCGAGAGCCTGGCCTACAACAAGTTCTCCATCAAGT  60 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1391 AGTTCCCCATCAAATGGACTGCACCCGAGAGCCTGGCCTACAACAAGTTCTCCATCAAGT  1450 
 
Seq 1    61   CCGACGTCTGGGCATTTGGAGTATTGCTTTGGGAAATTGCTACCTATGGCATGTCCCCTT  120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1451 CCGACGTCTGGGCATTTGGAGTATTGCTTTGGGAAATTGCTACCTATGGCATGTCCCCTT  1510 
 
Seq 1    121  ACCCGGGAATTGACCTGTCCCAGGTGTATGAGCTGCTAGAGAAGGACTACCGCATGGAGC  180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1511 ACCCGGGAATTGACCTGTCCCAGGTGTATGAGCTGCTAGAGAAGGACTACCGCATGGAGC  1570 
 
Seq 1    181  GCCCAGAAGGCTGCCCAGAGAAGGTCTATGAACTCATGCGAGCATGTTGGCAGTGGAATC  240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1571 GCCCAGAAGGCTGCCCAGAGAAGGTCTATGAACTCATGCGAGCATGTTGGCAGTGGAATC  1630 
 
Seq 1    241  CCTCTGACCGGCCCTCCTTTGCTGAAATCCACCAAGCCTTTGAAACAATGTTCCAGGAAT  300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    1631 CCTCTGACCGGCCCTCCTTTGCTGAAATCCACCAAGCCTTTGAAACAATGTTCCAGGAAT  1690 
 
Seq 1    301  CCAGTATCTCA  311 
              ||||||||||| 
Seq 2    1691 CCAGTATCTCA  1701 
 
Figure I.6 Alignment of CML patient (sample 44) ABL1 nucleotide sequence (exons 7-9), from the 
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Table I.1 Single nucleotide polymorphisms detected by Sanger sequencing on patient P210 and P195 






































Appendix II – Clinical case 54 BCR-ABL1 transcript identification and protein structure 
analysis 
 
Seq 1    1    CGCCGCAGTGCCATAAGCGGCACCGGCACTGCCCGGTTGTCGTGTCCGAGGCCACCATCG  60 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    330  CGCCGCAGTGCCATAAGCGGCACCGGCACTGCCCGGTTGTCGTGTCCGAGGCCACCATCG  389 
 
Seq 1    61   TGGGCGTCCGCAAGACCGGGCAGATCTGGCCCAACGATGGCGAGGGCGCCTTCCATGGAG  120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    390  TGGGCGTCCGCAAGACCGGGCAGATCTGGCCCAACGATGGCGAGGGCGCCTTCCATGGAG  449 
 
Seq 1    121  ACGCAGAAGCCCTTCAGCGGCCAGTAGCATCTGACTTTGAGCCTCAGGGTCTGAGTGAAG  180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    450  ACGCAGAAGCCCTTCAGCGGCCAGTAGCATCTGACTTTGAGCCTCAGGGTCTGAGTGAAG  509 
 
Seq 1    181  CCGCTCGTTGGAACTCCAAGGAAAACCTTCTCGCTGGACCCAGTGAAAATGACCCCAACC  240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    510  CCGCTCGTTGGAACTCCAAGGAAAACCTTCTCGCTGGACCCAGTGAAAATGACCCCAACC  569 
 
Seq 1    241  TTTTCGTTGCACTGTATGATTTTGTGGCCAGTGGAGATAACACTCTAAGCATAACTAAAG  300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq 2    570  TTTTCGTTGCACTGTATGATTTTGTGGCCAGTGGAGATAACACTCTAAGCATAACTAAAG  629 
 
Seq 1    301  GTGAAAAGCTCCGGGTCTTAGGCTATAATC  330 
              |||||||||||||||||||||||||||||| 
Seq 2    630  GTGAAAAGCTCCGGGTCTTAGGCTATAATC  659 
 
Figure II.1 Alignment of CML patient (sample 54) e1a2 nucleotide sequence [Seq 1] with BCR-ABL1 





Figure II.2 DISOclust disorder prediction results. Disorder probability score by residue number in 
BCR-ABL1 protein harboring the Y440C on the ABL1 domain. 
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Table II.1 ABL1 protein alignment between different species demonstrates the conservation of the 
affected amino acid. 
Species AA position Alignment 
H. sapiens mutated  
(Ph+ LLA patient) 
440 LWEIATYGMSPCPGIDLSQVYEL 
H. sapiens wild-type 440 LWEIATYGMSPYPGIDLSQVYEL 
P. troglodytes 459 LWEIATYGMSPYPGIDLS 
M. mulatta 168 LWEIATYGMSPYPGIDLSQVYEL 
F. catus 459 LWEIATYGMSPYPGIDLS 
M. musculus 459 LWEIATYGMSPYPGIDLS 
G. gallus 440 LWEIATYGMSPYPGIDLSQVYEL 
T. rubripes   801 LWEIATYGMSPYPGIDL 
D. rerio 459 LWEIATYGMSPYPGIDLSQ 
D. melanogaster 587 LWEIATYGMSPYPAIDLTDVYHK  























Figure III.1 DISOclust disorder prediction results. Disorder probability score by residue number in 
C/EBP protein harboring the N356I mutation. 
 
 
Table III.1 C/EBP protein alignment between different species demonstrates the conservation of the 
affected amino acid. 
Species AA position Alignment 
H. sapiens mutated  
(AML patient) 
356 LDTLRGIFRQLPESSLVKAMGICA 
H. sapiens wild-type 356 LDTLRGIFRQLPESSLVKAMGNCA 
C. sabaeus 354 LDTLRGIFRQLPESSLVKAMGNCA 
P. alecto 354 LDTLRGIFRQLPESSLVKAMGNCA 
M. auratus 367 LDTLRGIFRQLPESSLVKAMGNCA 
C. jacchus 356 LDTLRGIFRQLPESSLVKAMGNCA 
S. scrofa 352 LDTLRGIFRQLPESSLVKAMGNCA 
R. norvegicus 356 LDTLRGIFRQLPESSLVKAMGNCA 
M. musculus 357 LDTLRGIFRQLPESSLVKAMGNCA 
C. porcellus 314 IFRQLPESSLVKAMSNCA 
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Figure IV.1 Microfluidic chip – Mixing and detection design. 
A) Mixing microchannel - detailed view. 6- distance between diamond shaped obstacles: 128μm; 7-
distance between diamond shaped obstacles and wall: 40μm; 8- diamond shaped obstacle width: 
100μm; 9- throttle width: 100μm; 10- Rhombi angle: 120º; 11- Gap between throttle and channel: 12-
180μm; mixer channel width: 260μm. 
B) Optical detection microchannel – detailed view. 13- 3rd lens curvature radius/width: 180μm/110μm; 
14- 2nd lens curvature radius/width: 210μm/110μm; 15- minimum (min.) distance between 2nd lens 
and channel: 42.5μm; 16- min. distance between 1st lens and channel: 41μm; 17- 1st lens curvature 
radius/width: 175μm/110μm; 18- min. distance between 1st lens and optical fiber: 91μm; 19- 1st lens 
maximum (max.) thickness: 98μm; 20- Optical path length inside the channel: 2mm; 21- 2nd lens max. 
thickness: 65μm; 22- min. distance between 2nd and 3rd lenses: 173μm; 23-3rd lens max. thickness: 
50μm; 24- distance between 3rd lens and optical fiber: 100μm. iv) and v) mark the spot of input and 










Appendix V – Supplemental information on BCR-ABL1 gene silencing using AuNP@PEG@e14a2 
 
 
Figure V.1 Effect of AuNP@PEG (0.6 nM) on K562 apoptotic index (Bax/Bcl-2 ratio) (A) and on 
caspase-3/7 activity (B). Threshold represents control condition (untreated cells). Error bars represent 




Figure V.2 Concentration-response plots obtained after a 48 h-exposure of K562 cells to IM alone 
(0.01-10 µM) or combined with nanoconjugates (0.6 nM). Cell viability was measured via MTS assay. 
Error bars represent the standard error of the mean of three independent experiments. 





Figure V.3 Assessment of BCR-ABL1 gene expression and mutational status of K562 cells exposed to 
increasing concentrations of IM (K562-IM). A) BCR-ABL1 gene expression on K562-IM cells was 
evaluated via qPCR. Data was analyzed by the comparative threshold cycle (Ct) method (2−ΔΔCt), where 
relative gene expression is given by quantification of BCR-ABL1 relative to internal control gene (18S), 
normalized to control condition (parental K562 cells). Error bars represent the standard error of the 
mean of three independent experiments. B) Sequencing chromatogram of ABL1 of K562-IM cells: 
exons 4-7. B1) Exons 4-7 query sequence alignment against ABL1 reference mRNA sequence 
(GenBank NM_005157.5) C) Sequencing chromatogram of ABL1 of K562-IM cells: exons 7-9. C1) 
Exons 7-9 query sequence alignment against ABL1 reference mRNA sequence (GenBank 
NM_005157.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
